[
    {
        "path": [
            601160000,
            101000002,
            601410000,
            1008030000,
            800000000
        ],
        "contexts": [
            "\"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery;",
            "(2) The purpose of the label on a medicine is to provide information about the medicine such as its identity, potency, content, storage, expiry date, dose, directions for use, sponsor details and registration\/listing status. Labels on medicines can also include other information not required by this Order but which may be required by other legislation or for commercial purposes such as the sponsor\u2019s logo.",
            "\"name of an excipient\" means the name of the excipient that is accepted for inclusion in the Australian Approved Names List;",
            " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " 8 Information to be included on the label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine consists of dry herbs in individual bags contained in a primary pack whose label complies with all requirements, and the bags are kept around the herbs during preparation, does each individual bag also need to include the information specified in sections 8 and 9 on its label?",
                    "Answer": "No",
                    "Answer Explanation": "Section (c) states that if (i) a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and (ii) the bags are in a primary pack with a label that complies with the requirements of this Order, then the individual bags do not need to be labelled with the information from sections 8 and 9."
                },
                {
                    "Question": "Assuming no other legislation or commercial purposes require it, and the label already provides the required information under this Order about the medicine's identity, potency, content, storage, expiry, dose, directions, sponsor details and registration status, is the sponsor's logo mandatory to include on the label?",
                    "Answer": "No",
                    "Answer Explanation": "Section (2) states that the purpose of the medicine label is to provide required information such as identity, potency, content, storage, expiry date, dose, directions, sponsor details and registration\/listing status. It also states labels can include other information not required by this Order that may be required by other legislation or for commercial purposes, such as the sponsor's logo. Therefore, if no other legislation or commercial purpose requires it, the sponsor's logo is not mandatory on the label that already has the required information under this Order."
                },
                {
                    "Question": "For a metered dose preparation, does the 'delivered dose' refer to the dose delivered to the patient in a single actuation or delivery? For a powder for inhalation, does 'delivered dose' refer to the dose delivered from the inhaler in a single delivery?",
                    "Answer": "Yes to both",
                    "Answer Explanation": "The 'delivered dose' definition states that for (a) metered dose preparations, it means the dose delivered to the patient in a single actuation or delivery, and for (b) powders for inhalation, it means the dose delivered from the inhaler in a single delivery. This definition clarifies the meaning of 'delivered dose' for both metered dose preparations and powders for inhalation as asked in the question."
                },
                {
                    "Question": "When an excipient name is required on a medicine label under section 8, should the name used be the excipient name that is accepted for inclusion in the Australian Approved Names List?",
                    "Answer": "Yes",
                    "Answer Explanation": "The 'name of an excipient' definition states it means the name of the excipient that is accepted for inclusion in the Australian Approved Names List. Section 8 lists the information that must be included on a medicine label. Therefore, when an excipient name is required on the label under section 8, the name used should be the one accepted in the Australian Approved Names List, as per the provided definition."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine consists of dry herbs in individual bags contained in a primary pack whose label complies with all requirements, and the bags are kept around the herbs during preparation, does each individual bag also need to include the information specified in sections 8 and 9 on its label?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section (c) states that if (i) a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and (ii) the bags are in a primary pack with a label that complies with the requirements of this Order, then the individual bags do not need to be labelled with the information from sections 8 and 9.\"\n  },\n  {\n    \"Question\": \"Assuming no other legislation or commercial purposes require it, and the label already provides the required information under this Order about the medicine's identity, potency, content, storage, expiry, dose, directions, sponsor details and registration status, is the sponsor's logo mandatory to include on the label?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section (2) states that the purpose of the medicine label is to provide required information such as identity, potency, content, storage, expiry date, dose, directions, sponsor details and registration\/listing status. It also states labels can include other information not required by this Order that may be required by other legislation or for commercial purposes, such as the sponsor's logo. Therefore, if no other legislation or commercial purpose requires it, the sponsor's logo is not mandatory on the label that already has the required information under this Order.\"\n  },\n  {\n    \"Question\": \"For a metered dose preparation, does the 'delivered dose' refer to the dose delivered to the patient in a single actuation or delivery? For a powder for inhalation, does 'delivered dose' refer to the dose delivered from the inhaler in a single delivery?\", \n    \"Answer\": \"Yes to both\",\n    \"Answer Explanation\": \"The 'delivered dose' definition states that for (a) metered dose preparations, it means the dose delivered to the patient in a single actuation or delivery, and for (b) powders for inhalation, it means the dose delivered from the inhaler in a single delivery. This definition clarifies the meaning of 'delivered dose' for both metered dose preparations and powders for inhalation as asked in the question.\"\n  },\n  {\n    \"Question\": \"When an excipient name is required on a medicine label under section 8, should the name used be the excipient name that is accepted for inclusion in the Australian Approved Names List?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"The 'name of an excipient' definition states it means the name of the excipient that is accepted for inclusion in the Australian Approved Names List. Section 8 lists the information that must be included on a medicine label. Therefore, when an excipient name is required on the label under section 8, the name used should be the one accepted in the Australian Approved Names List, as per the provided definition.\"\n  }\n]}"
    },
    {
        "path": [
            801000000,
            302000000,
            1003000000,
            903030000,
            903010000
        ],
        "contexts": [
            " (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:",
            "(2) To avoid doubt, this Order will apply to the following medicines:",
            " (3) Homoeopathic medicines Where all the active ingredients in a medicine are homoeopathic preparations, the main label on the container and the main label on the primary pack (if any) must, in addition to the requirements referred to in sections 8 and 9 above, include a statement to the effect that the medicine is a homoeopathic medicine in text size that is not less than 50% of the text size of the name of the medicine and (in any event) not less than 2 millimetres.",
            " (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
            " (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine with multiple homoeopathic active ingredients is supplied in a small container, what are the label requirements for the container and primary pack (if any)?",
                    "Answer": "The medicine label must include the names and quantities of the active ingredients, and a statement that it is a homoeopathic medicine in text at least 50% the size of the medicine name and not less than 2mm.",
                    "Answer Explanation": "Section 8(1) states the general label requirements. Section 8(3) specifies additional label requirements for homoeopathic medicines, including a statement that it is a homoeopathic medicine with a minimum text size. Section 9(3)(c) allows presenting the names and quantities of multiple active ingredients together on the same line(s) for small or medium containers."
                },
                {
                    "Question": "Assuming a medicine is supplied in a small container and has multiple active ingredients, what options are permitted for presenting the names and quantities of the active ingredients on the label to comply with paragraph 9(3)(a)?",
                    "Answer": "The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text, since the medicine is supplied in a small container.",
                    "Answer Explanation": "Section 9(3)(c) states that for a medicine supplied in a small or medium container that contains multiple active ingredients, the names and quantities of the ingredients may be presented together on a continuous line or lines of text, in relation to complying with paragraph 9(3)(a). Paragraph 9(3)(a) requires the name and quantity of each active ingredient to appear as a cohesive unit, either below or adjacent to the medicine name."
                },
                {
                    "Question": "Assuming a medicine is not homoeopathic and is not covered by the specific cases in sections 8(2), 8(3), 9 or 10, what are the minimum label requirements that apply?",
                    "Answer": "The minimum label requirements are the general requirements specified in section 8(1).",
                    "Answer Explanation": "Section 8(1) states the label requirements are 'Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below'. Therefore, if a medicine does not meet the criteria in 8(2), 8(3), 9 or 10, only the general label requirements in 8(1) apply as a minimum."
                },
                {
                    "Question": "This regulation order applies to which types of medicines?",
                    "Answer": "The regulation order applies to the medicines specified in section 8(2).",
                    "Answer Explanation": "Section 8(2) states 'To avoid doubt, this Order will apply to the following medicines:'. The specific medicines the order applies to would be listed after this, but are not provided in the given context. Sections 8(1), 8(3), 9 and 10 provide label requirements for medicines the order applies to, but do not themselves specify which medicines are in scope."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine with multiple homoeopathic active ingredients is supplied in a small container, what are the label requirements for the container and primary pack (if any)?\", \"Answer\": \"The medicine label must include the names and quantities of the active ingredients, and a statement that it is a homoeopathic medicine in text at least 50% the size of the medicine name and not less than 2mm.\", \"Answer Explanation\": \"Section 8(1) states the general label requirements. Section 8(3) specifies additional label requirements for homoeopathic medicines, including a statement that it is a homoeopathic medicine with a minimum text size. Section 9(3)(c) allows presenting the names and quantities of multiple active ingredients together on the same line(s) for small or medium containers.\"}, {\"Question\": \"Assuming a medicine is supplied in a small container and has multiple active ingredients, what options are permitted for presenting the names and quantities of the active ingredients on the label to comply with paragraph 9(3)(a)?\", \"Answer\": \"The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text, since the medicine is supplied in a small container.\", \"Answer Explanation\": \"Section 9(3)(c) states that for a medicine supplied in a small or medium container that contains multiple active ingredients, the names and quantities of the ingredients may be presented together on a continuous line or lines of text, in relation to complying with paragraph 9(3)(a). Paragraph 9(3)(a) requires the name and quantity of each active ingredient to appear as a cohesive unit, either below or adjacent to the medicine name.\"}, {\"Question\": \"Assuming a medicine is not homoeopathic and is not covered by the specific cases in sections 8(2), 8(3), 9 or 10, what are the minimum label requirements that apply?\", \"Answer\": \"The minimum label requirements are the general requirements specified in section 8(1).\", \"Answer Explanation\": \"Section 8(1) states the label requirements are 'Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below'. Therefore, if a medicine does not meet the criteria in 8(2), 8(3), 9 or 10, only the general label requirements in 8(1) apply as a minimum.\"}, {\"Question\": \"This regulation order applies to which types of medicines?\", \"Answer\": \"The regulation order applies to the medicines specified in section 8(2).\", \"Answer Explanation\": \"Section 8(2) states 'To avoid doubt, this Order will apply to the following medicines:'. The specific medicines the order applies to would be listed after this, but are not provided in the given context. Sections 8(1), 8(3), 9 and 10 provide label requirements for medicines the order applies to, but do not themselves specify which medicines are in scope.\"}]}"
    },
    {
        "path": [
            804020000,
            910000000,
            101000006,
            1001000000,
            1007000000
        ],
        "contexts": [
            " (b) the name(s) of all active ingredients in the medicine; and",
            " (10) Subsection 9(9) does not apply:",
            "(6) Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au).",
            " (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:",
            " (7) Small containers If:"
        ],
        "result_dict": {},
        "result_str": "Here is my attempt at generating 4 question and answer pairs that require multi-hop reasoning using the provided regulation sections:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming the medicine is for ophthalmic use and its container is too small to fit all the required label information, what information must still be included on the label of the container?\",\n      \"Answer\": \"The name of all active ingredients in the medicine must still be included on the label of the container.\",\n      \"Answer Explanation\": \"Section 10(1) states additional labeling requirements for ophthalmic medicines. Section 10(7) provides an exception for small containers to not include all the information required by sections 8 and 9. However, section 9(10)(b) states that the exception in 9(9) does not apply to the requirement to include the names of all active ingredients on the label. Therefore, even for a small ophthalmic medicine container, the active ingredient names must appear on the container label.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine label follows all the requirements and guidance provided, where can one find additional guidelines to further assist in designing compliant and effective medicine labels?\",\n      \"Answer\": \"Additional medicine label design guidelines are available on the Therapeutic Goods Administration website at http:\/\/www.tga.gov.au.\",\n      \"Answer Explanation\": \"Section 8(6) states that additional guidelines to assist in the design of medicine labels are available on the TGA website. This is in addition to the specific requirements laid out in sections 8-10 of the regulation. So after following the regulation requirements, one can refer to the TGA website for further guidance on effective label design.\"\n    },\n    {\n      \"Question\": \"If a medicine is for ophthalmic use and comes in a small container that is too small to fit all the required information, is the small container exempted from including the names of the active ingredients on the label?\",\n      \"Answer\": \"No, the small container is not exempt from including the names of the active ingredients on the label, even if it is too small to include all the other required information.\",\n      \"Answer Explanation\": \"Section 10(1) specifies additional labeling requirements for ophthalmic medicines. Section 10(7) provides an exemption for small containers from the full labeling requirements in sections 8 and 9. However, section 9(10)(b) explicitly states that the small container exemption in 9(9) does not apply to the requirement to list the active ingredient names. Therefore, an ophthalmic medicine in a small container must still list the active ingredients on the label per 9(10)(b), even if exempt from other labeling requirements per 10(7).\"\n    },\n    {\n      \"Question\": \"For an ophthalmic medicine in a small container that qualifies for the labeling exemption, which specific labeling requirement still applies despite the small container exemption?\",\n      \"Answer\": \"The requirement to include the names of all active ingredients on the label still applies to a small container of an ophthalmic medicine, despite the small container labeling exemption.\",\n      \"Answer Explanation\": \"Section 10(1) states additional requirements for ophthalmic medicine labels. Section 10(7) allows small containers an exemption from the full requirements in sections 8 and 9. However, 9(10)(b) specifies that the exemption in 9(9) for small containers does not apply to the requirement to list active ingredients. So while a small ophthalmic medicine container is exempt from many labeling requirements per 10(7), it must still list active ingredients per 9(10)(b).\"\n    }\n  ]\n}"
    },
    {
        "path": [
            905010000,
            901020000,
            501170000,
            910020000,
            911000000
        ],
        "contexts": [
            " (a) two or more active ingredients; and",
            " (b) the name(s) of all active ingredients in the medicine; and",
            "(q) blood products under Item 13 that are described under paragraphs (a) and (b) under the heading \u2018HUMAN BLOOD PRODUCTS\u2019 in Appendix A to the Poisons Standard.",
            " (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
            " (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is not supplied in a small container and contains an active ingredient specified in Part 1 of Schedule 2, what is the latest date it can be labelled in accordance with subsection 9(11) and Part 1 of Schedule 2?",
                    "Answer": "30 April 2026",
                    "Answer Explanation": "According to context (b), if a medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, it can be labelled as such until after 30 April 2026. Subsection 9(11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label for medicine released for supply before 1 May 2026."
                },
                {
                    "Question": "Assuming a medicine contains two active ingredients, what information must be included on the label according to the contexts provided?",
                    "Answer": "The names of all active ingredients in the medicine must be included on the label.",
                    "Answer Explanation": "Context (a) states that the regulation applies to medicines with two or more active ingredients. Context (b) then specifies that the name(s) of all active ingredients in the medicine must be included on the label."
                },
                {
                    "Question": "Based on the contexts provided, are blood products under Item 13 that are described under paragraphs (a) and (b) under the heading 'HUMAN BLOOD PRODUCTS' in Appendix A to the Poisons Standard covered by this regulation?",
                    "Answer": "Yes, blood products under Item 13 that are described under paragraphs (a) and (b) under the heading 'HUMAN BLOOD PRODUCTS' in Appendix A to the Poisons Standard are covered by this regulation.",
                    "Answer Explanation": "Context (q) directly states that blood products under Item 13 that are described under paragraphs (a) and (b) under the heading 'HUMAN BLOOD PRODUCTS' in Appendix A to the Poisons Standard are included in the scope of this regulation."
                },
                {
                    "Question": "Assuming a medicine contains only one active ingredient specified in Part 1 of Schedule 2 and is not supplied in a small container, what is the latest release date for the medicine to still be able to include the active ingredient on the main label according to subsection 9(11)?",
                    "Answer": "30 April 2026",
                    "Answer Explanation": "Context (11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026. Context (b) further specifies that for medicine not supplied in a small container and labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, this applies until after 30 April 2026. Therefore, the latest release date for a medicine with one Part 1 Schedule 2 ingredient not in a small container to include the ingredient on the main label per 9(11) is 30 April 2026."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is not supplied in a small container and contains an active ingredient specified in Part 1 of Schedule 2, what is the latest date it can be labelled in accordance with subsection 9(11) and Part 1 of Schedule 2?\", \"Answer\": \"30 April 2026\", \"Answer Explanation\": \"According to context (b), if a medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, it can be labelled as such until after 30 April 2026. Subsection 9(11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label for medicine released for supply before 1 May 2026.\"}, {\"Question\": \"Assuming a medicine contains two active ingredients, what information must be included on the label according to the contexts provided?\", \"Answer\": \"The names of all active ingredients in the medicine must be included on the label.\", \"Answer Explanation\": \"Context (a) states that the regulation applies to medicines with two or more active ingredients. Context (b) then specifies that the name(s) of all active ingredients in the medicine must be included on the label.\"}, {\"Question\": \"Based on the contexts provided, are blood products under Item 13 that are described under paragraphs (a) and (b) under the heading 'HUMAN BLOOD PRODUCTS' in Appendix A to the Poisons Standard covered by this regulation?\", \"Answer\": \"Yes, blood products under Item 13 that are described under paragraphs (a) and (b) under the heading 'HUMAN BLOOD PRODUCTS' in Appendix A to the Poisons Standard are covered by this regulation.\", \"Answer Explanation\": \"Context (q) directly states that blood products under Item 13 that are described under paragraphs (a) and (b) under the heading 'HUMAN BLOOD PRODUCTS' in Appendix A to the Poisons Standard are included in the scope of this regulation.\"}, {\"Question\": \"Assuming a medicine contains only one active ingredient specified in Part 1 of Schedule 2 and is not supplied in a small container, what is the latest release date for the medicine to still be able to include the active ingredient on the main label according to subsection 9(11)?\", \"Answer\": \"30 April 2026\", \"Answer Explanation\": \"Context (11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026. Context (b) further specifies that for medicine not supplied in a small container and labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, this applies until after 30 April 2026. Therefore, the latest release date for a medicine with one Part 1 Schedule 2 ingredient not in a small container to include the ingredient on the main label per 9(11) is 30 April 2026.\"}]}"
    },
    {
        "path": [
            802010000,
            601130000,
            804060000,
            1005000000,
            900000000
        ],
        "contexts": [
            " (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.",
            "\"composite pack\" has the same meaning as in the Act;",
            " (f) the name of the sponsor or distributor, or a registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " (5) Sunscreen preparations If:",
            " 9 Information to be included on the main label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is registered goods and is not a composite pack, sunscreen preparation, or covered by any other exceptions in the regulation, what form must the critical health information be displayed in on the label of the primary pack?",
                    "Answer": "Tabulated form",
                    "Answer Explanation": "According to section (a), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form, subject to exceptions in paragraphs (b), (c) and (d). The question assumes the medicine does not fall under any of those exceptions."
                },
                {
                    "Question": "If a non-prescription medicine label includes the name of a registered trademark that readily identifies the medicine's sponsor, does the label still need to explicitly include the name of the sponsor or distributor to meet the regulation requirements?",
                    "Answer": "No",
                    "Answer Explanation": "Section (f) states that the name of the sponsor or distributor, or a registered trademark if it readily identifies the sponsor or distributor of the medicine, must be included. So including just the registered trademark is sufficient if it identifies the sponsor, and explicitly naming the sponsor or distributor is not required in that case."
                },
                {
                    "Question": "What is the definition of 'composite pack' as used in this regulation?",
                    "Answer": "The same as defined in the Act",
                    "Answer Explanation": "The context states that 'composite pack' has the same meaning as in the Act. So to determine the definition, one would need to reference the relevant Act. No definition is provided in the excerpted sections of the regulation itself."
                },
                {
                    "Question": "Which section of the regulation specifies the information that must be included on the main label of non-prescription medicines?",
                    "Answer": "Section 9",
                    "Answer Explanation": "Section 9 is titled 'Information to be included on the main label', indicating that this section covers the required contents of the main medicine label. The other provided sections do not appear to address this topic directly."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\":[{\"Question\":\"Assuming a non-prescription medicine is registered goods and is not a composite pack, sunscreen preparation, or covered by any other exceptions in the regulation, what form must the critical health information be displayed in on the label of the primary pack?\",\"Answer\":\"Tabulated form\",\"Answer Explanation\":\"According to section (a), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form, subject to exceptions in paragraphs (b), (c) and (d). The question assumes the medicine does not fall under any of those exceptions.\"},{\"Question\":\"If a non-prescription medicine label includes the name of a registered trademark that readily identifies the medicine's sponsor, does the label still need to explicitly include the name of the sponsor or distributor to meet the regulation requirements?\",\"Answer\":\"No\",\"Answer Explanation\":\"Section (f) states that the name of the sponsor or distributor, or a registered trademark if it readily identifies the sponsor or distributor of the medicine, must be included. So including just the registered trademark is sufficient if it identifies the sponsor, and explicitly naming the sponsor or distributor is not required in that case.\"},{\"Question\":\"What is the definition of 'composite pack' as used in this regulation?\",\"Answer\":\"The same as defined in the Act\",\"Answer Explanation\":\"The context states that 'composite pack' has the same meaning as in the Act. So to determine the definition, one would need to reference the relevant Act. No definition is provided in the excerpted sections of the regulation itself.\"},{\"Question\":\"Which section of the regulation specifies the information that must be included on the main label of non-prescription medicines?\",\"Answer\":\"Section 9\",\"Answer Explanation\":\"Section 9 is titled 'Information to be included on the main label', indicating that this section covers the required contents of the main medicine label. The other provided sections do not appear to address this topic directly.\"}]}"
    },
    {
        "path": [
            601260000,
            601210000,
            802060000,
            908030000,
            906020000
        ],
        "contexts": [
            "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
            "\"excipient\", in relation to a medicine, means an ingredient of the medicine other than the active ingredient;",
            " (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
            " (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
            " (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is composed of 5 active ingredients of equal quantities, and also contains some inactive excipient ingredients, is it required that all active ingredient names and quantities be listed on the main label of the medicine?",
                    "Answer": "No",
                    "Answer Explanation": "According to context (b), if there are four or more active ingredients in the medicine, the name and quantity of every active ingredient may appear on a side panel, side label, rear panel, or rear label, rather than being required on the main label."
                },
                {
                    "Question": "Consider a composite medicine pack that contains 3 different formulations. Two of the formulations contain the same active ingredient, while the third contains a different active ingredient. Assuming the critical health information for this medicine is printed in red text on a white background, does this comply with the labeling requirements?",
                    "Answer": "No",
                    "Answer Explanation": "Context (c)(i) states that the same active ingredient in multiple formulations is counted separately for determining the number of active ingredients. So this composite pack is considered to have 4 total active ingredients. Context (f) requires that the critical health information must be presented in black or other dark colored text on a white or contrasting background. Red text on white does not meet this requirement."
                },
                {
                    "Question": "Suppose an herbal medicine lists 'Mentha piperita leaf' as an ingredient. Assuming no other information is provided, is this considered sufficient naming of the herbal material?",
                    "Answer": "No",
                    "Answer Explanation": "Based on the definition in the provided context, 'herbal material' must be defined by its full botanical binomial scientific name, including the author citation. Just providing 'Mentha piperita leaf' without the author does not fully meet the naming requirement for herbal materials."
                },
                {
                    "Question": "Consider a medicine kit that contains 3 formulations. Formulation A has 2 unique active ingredients, formulation B has 1 active ingredient that is the same as one in A, and formulation C has 1 unique active ingredient. Assuming the excipients are clearly listed separately from the active ingredients, how many total active ingredients should be counted for labeling purposes?",
                    "Answer": "4",
                    "Answer Explanation": "Context (c)(i) states that the total number of active ingredients across the different formulations are counted. Context (c)(ii) further clarifies that the same active ingredient present in multiple formulations is counted separately for each instance. Therefore, even though there are only 3 unique active ingredients, the duplicate one is counted twice, leading to a total count of 4 active ingredients for the purposes of the labeling requirements."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is composed of 5 active ingredients of equal quantities, and also contains some inactive excipient ingredients, is it required that all active ingredient names and quantities be listed on the main label of the medicine?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to context (b), if there are four or more active ingredients in the medicine, the name and quantity of every active ingredient may appear on a side panel, side label, rear panel, or rear label, rather than being required on the main label.\"}, {\"Question\": \"Consider a composite medicine pack that contains 3 different formulations. Two of the formulations contain the same active ingredient, while the third contains a different active ingredient. Assuming the critical health information for this medicine is printed in red text on a white background, does this comply with the labeling requirements?\", \"Answer\": \"No\", \"Answer Explanation\": \"Context (c)(i) states that the same active ingredient in multiple formulations is counted separately for determining the number of active ingredients. So this composite pack is considered to have 4 total active ingredients. Context (f) requires that the critical health information must be presented in black or other dark colored text on a white or contrasting background. Red text on white does not meet this requirement.\"}, {\"Question\": \"Suppose an herbal medicine lists 'Mentha piperita leaf' as an ingredient. Assuming no other information is provided, is this considered sufficient naming of the herbal material?\", \"Answer\": \"No\", \"Answer Explanation\": \"Based on the definition in the provided context, 'herbal material' must be defined by its full botanical binomial scientific name, including the author citation. Just providing 'Mentha piperita leaf' without the author does not fully meet the naming requirement for herbal materials.\"}, {\"Question\": \"Consider a medicine kit that contains 3 formulations. Formulation A has 2 unique active ingredients, formulation B has 1 active ingredient that is the same as one in A, and formulation C has 1 unique active ingredient. Assuming the excipients are clearly listed separately from the active ingredients, how many total active ingredients should be counted for labeling purposes?\", \"Answer\": \"4\", \"Answer Explanation\": \"Context (c)(i) states that the total number of active ingredients across the different formulations are counted. Context (c)(ii) further clarifies that the same active ingredient present in multiple formulations is counted separately for each instance. Therefore, even though there are only 3 unique active ingredients, the duplicate one is counted twice, leading to a total count of 4 active ingredients for the purposes of the labeling requirements.\"}]}"
    },
    {
        "path": [
            601490000,
            1100000000,
            702000000,
            910030000,
            913000000
        ],
        "contexts": [
            "\"registration number\" means the combination of numbers and letters that is required to be included on the label of medicines in a manner described in regulation 15 of the Regulations;",
            " 11 How information is to be expressed",
            " (2) The information required by this Order to be included on a label or labels must:",
            " (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.",
            " (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Given the following assumptions: 1) A medicine's label is being designed for the first time, 2) The medicine contains an active ingredient listed in Part 2 of Schedule 2, 3) The medicine will be supplied in a container that is not small, and 4) The medicine will be released for supply after 30 April 2028. What is the minimum text size required for the active ingredients on the medicine's label according to the provided regulations?",
                    "Answer": "2.5 millimetres",
                    "Answer Explanation": "According to regulation 11(2)(c), for medicines not supplied in a small container and labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, the minimum text size for active ingredients on the label must be at least 2.5 millimetres after 30 April 2028. Since the given assumptions state the medicine will be in a non-small container, contains an active ingredient from Part 2 of Schedule 2, and will be released after 30 April 2028, the 2.5 millimetre minimum text size requirement applies."
                },
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is being labelled for the first time and will be released for supply before 1 May 2028, which parts of the label are permitted to include the active ingredient according to the given regulations?",
                    "Answer": "The main label",
                    "Answer Explanation": "Subsection 9(13) states that an active ingredient specified in Part 2 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part, if the medicine is released for supply before 1 May 2028. No other label locations are mentioned as permitted in the provided regulations for this scenario."
                },
                {
                    "Question": "Based on the provided regulations, if a medicine label includes a registration number, what must the registration number consist of?",
                    "Answer": "A combination of numbers and letters",
                    "Answer Explanation": "The definition provided states that 'registration number' means the combination of numbers and letters that is required to be included on the label of medicines in a manner described in regulation 15 of the Regulations. Therefore, a registration number must include both numbers and letters according to this definition."
                },
                {
                    "Question": "Consider a medicine with a label designed according to subsection 9(13) and Part 2 of Schedule 2. Assuming the medicine is not in a small container and will be released for supply on 1 June 2028, what is the latest date by which the information on the label must meet the minimum 2.5 millimetre text size for active ingredients required by regulation 11(2)(c)?",
                    "Answer": "30 April 2028",
                    "Answer Explanation": "Regulation 11(2)(c) specifies that for medicines not supplied in a small container and labelled according to subsection 9(13) and Part 2 of Schedule 2, the information on the label must meet the 2.5 millimetre minimum text size for active ingredients after 30 April 2028. This applies regardless of the medicine's actual release date, so 30 April 2028 is the latest date by which the label must comply, even for a medicine released on 1 June 2028."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Given the following assumptions: 1) A medicine's label is being designed for the first time, 2) The medicine contains an active ingredient listed in Part 2 of Schedule 2, 3) The medicine will be supplied in a container that is not small, and 4) The medicine will be released for supply after 30 April 2028. What is the minimum text size required for the active ingredients on the medicine's label according to the provided regulations?\", \"Answer\": \"2.5 millimetres\", \"Answer Explanation\": \"According to regulation 11(2)(c), for medicines not supplied in a small container and labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, the minimum text size for active ingredients on the label must be at least 2.5 millimetres after 30 April 2028. Since the given assumptions state the medicine will be in a non-small container, contains an active ingredient from Part 2 of Schedule 2, and will be released after 30 April 2028, the 2.5 millimetre minimum text size requirement applies.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is being labelled for the first time and will be released for supply before 1 May 2028, which parts of the label are permitted to include the active ingredient according to the given regulations?\", \"Answer\": \"The main label\", \"Answer Explanation\": \"Subsection 9(13) states that an active ingredient specified in Part 2 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part, if the medicine is released for supply before 1 May 2028. No other label locations are mentioned as permitted in the provided regulations for this scenario.\"}, {\"Question\": \"Based on the provided regulations, if a medicine label includes a registration number, what must the registration number consist of?\", \"Answer\": \"A combination of numbers and letters\", \"Answer Explanation\": \"The definition provided states that 'registration number' means the combination of numbers and letters that is required to be included on the label of medicines in a manner described in regulation 15 of the Regulations. Therefore, a registration number must include both numbers and letters according to this definition.\"}, {\"Question\": \"Consider a medicine with a label designed according to subsection 9(13) and Part 2 of Schedule 2. Assuming the medicine is not in a small container and will be released for supply on 1 June 2028, what is the latest date by which the information on the label must meet the minimum 2.5 millimetre text size for active ingredients required by regulation 11(2)(c)?\", \"Answer\": \"30 April 2028\", \"Answer Explanation\": \"Regulation 11(2)(c) specifies that for medicines not supplied in a small container and labelled according to subsection 9(13) and Part 2 of Schedule 2, the information on the label must meet the 2.5 millimetre minimum text size for active ingredients after 30 April 2028. This applies regardless of the medicine's actual release date, so 30 April 2028 is the latest date by which the label must comply, even for a medicine released on 1 June 2028.\"}]}"
    },
    {
        "path": [
            1103000000,
            601460002,
            802030000,
            905030000,
            901030000
        ],
        "contexts": [
            " (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include:",
            "(b) where the medicine is: (i) a solid or semi-solid - the stated weight in the container; (ii) a liquid - the stated volume of fill in the container; (iii) a pressurised metered-dose preparation or dry powder inhaler - the stated number of deliverable doses in the container; (iv) a non-pressurised metered dose preparation - the minimum number of deliverable doses in the container;",
            " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
            " (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
            " (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming the medicine is a liquid and is not intended to be registered goods, what is the required information to be displayed on the label regarding the quantity or proportion of active ingredients?",
                    "Answer": "The stated volume of fill in the container and the quantity or proportion of all active ingredients in the medicine must be displayed on the label.",
                    "Answer Explanation": "According to context (b)(ii), if the medicine is a liquid, the stated volume of fill in the container must be included on the label. Additionally, context (c) requires that the quantity or proportion of all active ingredients in the medicine must be displayed on the label."
                },
                {
                    "Question": "For a medicine that is a solid and contains a homoeopathic preparation, and assuming subsection 8(2) does not apply and the medicine is intended to be registered goods, what information about the active ingredients must be displayed on the label and where should it be placed?",
                    "Answer": "The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.",
                    "Answer Explanation": "Context (3) states that for a medicine containing a homoeopathic preparation, the label must include the quantity or proportion of active ingredients. Context (b)(i) specifies that for a solid medicine, the stated weight in the container must be included. Context (c)(i) indicates that if the medicine is intended to be registered goods and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres."
                },
                {
                    "Question": "Assuming a medicine is a pressurised metered-dose preparation and subsection 8(2) applies, what information about the quantity of the medicine and the active ingredients must be provided on the label?",
                    "Answer": "The label must include the stated number of deliverable doses in the container and the quantity or proportion of all active ingredients in the medicine.",
                    "Answer Explanation": "According to context (b)(iii), for a pressurised metered-dose preparation, the stated number of deliverable doses in the container must be included on the label. Context (c) requires that the quantity or proportion of all active ingredients in the medicine must be displayed on the label. Context (c)(ii) states that if subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required, implying that the information required by context (c) must still be provided."
                },
                {
                    "Question": "For a non-pressurised metered dose preparation containing a homoeopathic preparation, and assuming the information provided under paragraph 8(2)(b)(i) includes words describing the purpose of the active ingredients, what quantity-related information must be displayed on the label?",
                    "Answer": "The label must include the minimum number of deliverable doses in the container and the quantity or proportion of active ingredients for the homoeopathic preparation.",
                    "Answer Explanation": "Context (b)(iv) states that for a non-pressurised metered dose preparation, the minimum number of deliverable doses in the container must be included on the label. Context (3) requires that for a medicine containing a homoeopathic preparation, the label must include the quantity or proportion of active ingredients. Context (c) allows the information provided under paragraph 8(2)(b)(i) to include words describing the purpose of the active ingredients, but this does not replace the requirement to display the quantity or proportion of active ingredients as per context (3)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming the medicine is a liquid and is not intended to be registered goods, what is the required information to be displayed on the label regarding the quantity or proportion of active ingredients?\", \"Answer\": \"The stated volume of fill in the container and the quantity or proportion of all active ingredients in the medicine must be displayed on the label.\", \"Answer Explanation\": \"According to context (b)(ii), if the medicine is a liquid, the stated volume of fill in the container must be included on the label. Additionally, context (c) requires that the quantity or proportion of all active ingredients in the medicine must be displayed on the label.\"}, {\"Question\": \"For a medicine that is a solid and contains a homoeopathic preparation, and assuming subsection 8(2) does not apply and the medicine is intended to be registered goods, what information about the active ingredients must be displayed on the label and where should it be placed?\", \"Answer\": \"The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\", \"Answer Explanation\": \"Context (3) states that for a medicine containing a homoeopathic preparation, the label must include the quantity or proportion of active ingredients. Context (b)(i) specifies that for a solid medicine, the stated weight in the container must be included. Context (c)(i) indicates that if the medicine is intended to be registered goods and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\"}, {\"Question\": \"Assuming a medicine is a pressurised metered-dose preparation and subsection 8(2) applies, what information about the quantity of the medicine and the active ingredients must be provided on the label?\", \"Answer\": \"The label must include the stated number of deliverable doses in the container and the quantity or proportion of all active ingredients in the medicine.\", \"Answer Explanation\": \"According to context (b)(iii), for a pressurised metered-dose preparation, the stated number of deliverable doses in the container must be included on the label. Context (c) requires that the quantity or proportion of all active ingredients in the medicine must be displayed on the label. Context (c)(ii) states that if subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required, implying that the information required by context (c) must still be provided.\"}, {\"Question\": \"For a non-pressurised metered dose preparation containing a homoeopathic preparation, and assuming the information provided under paragraph 8(2)(b)(i) includes words describing the purpose of the active ingredients, what quantity-related information must be displayed on the label?\", \"Answer\": \"The label must include the minimum number of deliverable doses in the container and the quantity or proportion of active ingredients for the homoeopathic preparation.\", \"Answer Explanation\": \"Context (b)(iv) states that for a non-pressurised metered dose preparation, the minimum number of deliverable doses in the container must be included on the label. Context (3) requires that for a medicine containing a homoeopathic preparation, the label must include the quantity or proportion of active ingredients. Context (c) allows the information provided under paragraph 8(2)(b)(i) to include words describing the purpose of the active ingredients, but this does not replace the requirement to display the quantity or proportion of active ingredients as per context (3).\"}]}"
    },
    {
        "path": [
            401020020,
            1007080000,
            901010000,
            805000000,
            801000000
        ],
        "contexts": [
            "(ii) Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)), on or after 1 July 2017.",
            " (h) the quantity of the medicine in the container; and",
            " (a) the name of the medicine; and",
            " (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.",
            " (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine container is enclosed in a delivery device such that it cannot be removed, and the delivery device does not have a label stating the name and quantity of the medicine, does this violate the labeling requirements according to the given regulation sections?",
                    "Answer": "Yes, this violates the labeling requirements.",
                    "Answer Explanation": "According to section 8(1)(a) and (h), the label of a medicine must include the name and quantity of the medicine. Section 8(5) states that if the container is enclosed in a delivery device such that it cannot be removed, the required label information must be applied on the delivery device. Therefore, if the delivery device lacks the name and quantity, it violates sections 8(1)(a), 8(1)(h), and 8(5) of the regulation."
                },
                {
                    "Question": "Suppose a medicine container can be removed from its delivery device. The container label includes the name of the medicine but not the quantity. Assuming no other labeling, does this satisfy the requirements of the given regulation sections?",
                    "Answer": "No, this does not satisfy the labeling requirements.",
                    "Answer Explanation": "Section 8(1) states that, subject to certain qualifications, medicine labels must include both the name of the medicine (8(1)(a)) and the quantity of medicine in the container (8(1)(h)). Since the quantity is missing from the label in this scenario, it fails to meet the requirements outlined in section 8(1), specifically 8(1)(h)."
                },
                {
                    "Question": "Consider a medicine with labeling that fully complies with the requirements in section 8(1) of the given regulation. Assuming this medicine was released on August 1, 2017, which Therapeutic Goods Order is applicable based on the provided regulation section?",
                    "Answer": "Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)) is applicable.",
                    "Answer Explanation": "The given regulation section states that Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)) applies to medicines on or after July 1, 2017. Since the medicine in question was released on August 1, 2017, which is after the July 1, 2017 effective date, TGO 69 (2017) is the applicable order."
                },
                {
                    "Question": "Suppose a medicine container is labeled with the name and quantity of the medicine, meeting the requirements of sections 8(1)(a) and 8(1)(h). However, the container is enclosed in a delivery device, from which it cannot be removed, and the delivery device has no labeling. Does this scenario comply with the labeling requirements in the provided regulation sections?",
                    "Answer": "No, this scenario does not comply with the labeling requirements.",
                    "Answer Explanation": "While the container label itself meets the requirements of sections 8(1)(a) and 8(1)(h) by including the name and quantity of the medicine, section 8(5) states that if the container is enclosed in a delivery device and cannot be removed, the required label information must be applied on the delivery device, not the container. Since the delivery device has no labeling in this scenario, it violates section 8(5), making the overall labeling non-compliant with the given regulation sections."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine container is enclosed in a delivery device such that it cannot be removed, and the delivery device does not have a label stating the name and quantity of the medicine, does this violate the labeling requirements according to the given regulation sections?\", \"Answer\": \"Yes, this violates the labeling requirements.\", \"Answer Explanation\": \"According to section 8(1)(a) and (h), the label of a medicine must include the name and quantity of the medicine. Section 8(5) states that if the container is enclosed in a delivery device such that it cannot be removed, the required label information must be applied on the delivery device. Therefore, if the delivery device lacks the name and quantity, it violates sections 8(1)(a), 8(1)(h), and 8(5) of the regulation.\"}, {\"Question\": \"Suppose a medicine container can be removed from its delivery device. The container label includes the name of the medicine but not the quantity. Assuming no other labeling, does this satisfy the requirements of the given regulation sections?\", \"Answer\": \"No, this does not satisfy the labeling requirements.\", \"Answer Explanation\": \"Section 8(1) states that, subject to certain qualifications, medicine labels must include both the name of the medicine (8(1)(a)) and the quantity of medicine in the container (8(1)(h)). Since the quantity is missing from the label in this scenario, it fails to meet the requirements outlined in section 8(1), specifically 8(1)(h).\"}, {\"Question\": \"Consider a medicine with labeling that fully complies with the requirements in section 8(1) of the given regulation. Assuming this medicine was released on August 1, 2017, which Therapeutic Goods Order is applicable based on the provided regulation section?\", \"Answer\": \"Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)) is applicable.\", \"Answer Explanation\": \"The given regulation section states that Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)) applies to medicines on or after July 1, 2017. Since the medicine in question was released on August 1, 2017, which is after the July 1, 2017 effective date, TGO 69 (2017) is the applicable order.\"}, {\"Question\": \"Suppose a medicine container is labeled with the name and quantity of the medicine, meeting the requirements of sections 8(1)(a) and 8(1)(h). However, the container is enclosed in a delivery device, from which it cannot be removed, and the delivery device has no labeling. Does this scenario comply with the labeling requirements in the provided regulation sections?\", \"Answer\": \"No, this scenario does not comply with the labeling requirements.\", \"Answer Explanation\": \"While the container label itself meets the requirements of sections 8(1)(a) and 8(1)(h) by including the name and quantity of the medicine, section 8(5) states that if the container is enclosed in a delivery device and cannot be removed, the required label information must be applied on the delivery device, not the container. Since the delivery device has no labeling in this scenario, it violates section 8(5), making the overall labeling non-compliant with the given regulation sections.\"}]}"
    },
    {
        "path": [
            601260000,
            804040000,
            1010010000,
            302020000,
            500000000
        ],
        "contexts": [
            "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
            " (d) the batch number of the medicine preceded by the batch number prefix; and",
            " (a) Subject to paragraph (b), if: (i) a medicine is contained in a plastic ampoule; and (ii) the capacity of the container of the medicine in the plastic ampoule is 8 millilitres or less; and (iii) two or more ampoules are attached to a connecting strip; and (iv) the ampoules and their connecting strip are enclosed in a primary pack that complies with the requirements of this Order, then the information required by this Order to appear on the label of the container of the medicine may be divided between the ampoule and the connecting strip.",
            "(b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order.",
            "5 Exemptions \u2013 Medicines to which this Order does not apply "
        ],
        "result_dict": {},
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assume a herbal material is a plant or part of a plant, defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part, whether fresh or dried, that is whole, fragmented, cut or ground. A medicine containing this herbal material is exempt from listing and registration requirements, other than those specified in section 5 of this Order. The medicine is contained in plastic ampoules with a capacity of 5 millilitres each, and 3 ampoules are attached to a connecting strip. The ampoules and connecting strip are enclosed in a primary pack that complies with the requirements of this Order. Where can the required information appear on the medicine label?\", \"Answer\": \"The required information may be divided between the ampoule and the connecting strip.\", \"Answer Explanation\": \"The medicine contains a 'herbal material' as defined in the given context. It is exempt from listing and registration requirements other than section 5 as per context (b). The ampoules meet the criteria in context (a) - plastic ampoules 8mL or less capacity, multiple ampoules on a connecting strip, enclosed in a compliant primary pack. Therefore, according to (a), the required label information may be divided between the ampoule and connecting strip.\"}, {\"Question\": \"Assume a medicine is exempt from listing and registration requirements, except those in section 5 of this Order, which this question does not relate to. The medicine contains a herbal material, defined as a fresh or dried plant or plant part that is whole, fragmented, cut or ground, identified by its botanical binomial nomenclature and the plant part. The medicine is in 10mL glass ampoules, with 4 ampoules attached to a connecting strip, and enclosed in a fully compliant primary pack. Can the required label information be split between the ampoule and connecting strip?\", \"Answer\": \"No, the required label information cannot be split between the ampoule and connecting strip in this case.\", \"Answer Explanation\": \"Although the medicine contains a 'herbal material' and is exempt except for section 5 as outlined in contexts (b), it does not meet all the criteria in (a) to allow splitting the label information. The ampoules are glass, not plastic, and have a 10mL capacity which exceeds the 8mL limit specified in (a)(ii). Therefore the label information cannot be divided between the ampoule and strip, and must appear in full on the container label.\"}, {\"Question\": \"Assume a non-prescription medicine is exempt from listing and registration requirements except section 5 of this Order. It contains a dried, ground part of a plant, defined by its botanical name according to the binomial nomenclature system, including author. The medicine is contained in 6mL plastic ampoules, 2 of which are connected by a strip and packaged in a primary pack meeting all requirements of this Order. The batch number on the label is not preceded by the batch number prefix. Does this meet labelling requirements?\", \"Answer\": \"No, this does not fully meet the labelling requirements as specified in the given contexts.\", \"Answer Explanation\": \"The substance is a 'herbal material' according to the definition provided. The medicine meets exemption criteria in (b). The packaging meets all criteria in (a) to allow label information to be split between ampoule and connecting strip. However, context (d) requires the batch number to be preceded by the batch number prefix, which is not the case here. So while most labelling requirements are satisfied, the batch number format is non-compliant.\"}, {\"Question\": \"Suppose a medicine contains a whole, fresh part of a plant, botanically identified only by its genus name. It is exempt from listing and registration requirements completely, including section 5 of this Order. The medicine is in 5mL plastic ampoules, 4 of which are attached to a connecting strip and enclosed in a primary pack meeting this Order's requirements. Assuming all required information appears on the label, can it be divided between the ampoule and connecting strip?\", \"Answer\": \"No, the label information cannot be split between the ampoule and connecting strip in this case.\", \"Answer Explanation\": \"The substance does not fully meet the definition of 'herbal material', as it is only identified by genus, not the complete binomial nomenclature specified. The medicine packaging satisfies the criteria in (a) for splitting label information. However, (a) only provides an exception for the location of information 'required by this Order'. Since this medicine is fully exempt, including section 5, no labelling is"
    },
    {
        "path": [
            601570000,
            300000000,
            601460003,
            1102080000,
            1102030000
        ],
        "contexts": [
            "\"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;",
            "3 Application - Therapeutic goods to which this Order applies",
            "(c) where the medicine is a medicine of any of the kinds referred to in paragraph (b) and the medicine consists of a number of identical containers within the primary pack \u2013 the number of containers (e.g. 5 x 10 mL vials);",
            " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a liquid oral medicine consists of 5 identical 10 mL containers within the primary pack, what information must be included on the label according to the regulation?",
                    "Answer": "The label must include the number of containers, which is 5 in this case.",
                    "Answer Explanation": "According to section 3(c), where the medicine consists of a number of identical containers within the primary pack, the number of containers must be included on the label, with the example given of '5 x 10 mL vials'."
                },
                {
                    "Question": "For a liquid oral preparation containing an active ingredient for mineral supplementation, and assuming the stated dose volume is 5 mL with strengths of 2 mg\/mL and 10 mg\/mL, how should the quantity of active ingredient be expressed on the label as per the regulation?",
                    "Answer": "The label should express the quantity of active ingredient as 10 mg in 5 mL and 50 mg in 5 mL for the 2 mg\/mL and 10 mg\/mL strengths respectively.",
                    "Answer Explanation": "Section 11(2)(c)(ii) states that for a series of strengths of a liquid for ingestion containing the same active ingredient, the quantity of active ingredient must be expressed consistently across the series in terms of the same stated dose volume. Section 11(2)(h) allows the quantity to be expressed as the name and quantity of the element intended for mineral supplementation. With a dose volume of 5 mL, the 2 mg\/mL and 10 mg\/mL strengths must be labelled as 10 mg in 5 mL and 50 mg in 5 mL respectively, as per the example given in 11(2)(c)(ii)."
                },
                {
                    "Question": "According to the regulation, what is meant by the term 'stated volume of fill', and how does this relate to the labelling requirements for oral liquid preparations containing mineral supplementation ingredients?",
                    "Answer": "The 'stated volume of fill' is defined as the volume of medicine that the container is specified by the sponsor to contain. For oral liquid preparations with mineral supplementation ingredients, the quantity of the active ingredient can be expressed as the name and quantity of the element per the stated dose volume, rather than per the stated volume of fill.",
                    "Answer Explanation": "The definition of 'stated volume of fill' is provided in the first context statement. Section 11(2)(c) specifies labelling the quantity of active ingredient per stated dose volume for oral liquid preparations. However, 11(2)(h) provides an exception, allowing mineral supplementation ingredients to be expressed as the name and quantity of the element, without reference to the stated volume of fill."
                },
                {
                    "Question": "Assuming an oral liquid medicine comes in a series of strengths of 1 mg\/mL, 2 mg\/mL and 4 mg\/mL with a 5 mL stated dose volume, and the active ingredient is not for mineral supplementation, how should the quantity of active ingredient be expressed on the labels as per the regulation?",
                    "Answer": "The labels should express the quantity of active ingredient as 5 mg in 5 mL, 10 mg in 5 mL, and 20 mg in 5 mL for the 1 mg\/mL, 2 mg\/mL and 4 mg\/mL strengths respectively.",
                    "Answer Explanation": "Section 11(2)(c)(ii) requires that for a series of strengths of an oral liquid with the same active ingredient, the quantity of active ingredient must be expressed consistently across the series in terms of the same stated dose volume. With a 5 mL dose volume, the labels must state 5 mg in 5 mL for 1 mg\/mL, 10 mg in 5 mL for 2 mg\/mL, and 20 mg in 5 mL for 4 mg\/mL, as per the example in 11(2)(c)(ii). The exception in 11(2)(h) for expressing mineral supplementation ingredients differently does not apply here, since the active ingredient is stated to not be for mineral supplementation."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a liquid oral medicine consists of 5 identical 10 mL containers within the primary pack, what information must be included on the label according to the regulation?\",\n      \"Answer\": \"The label must include the number of containers, which is 5 in this case.\",\n      \"Answer Explanation\": \"According to section 3(c), where the medicine consists of a number of identical containers within the primary pack, the number of containers must be included on the label, with the example given of '5 x 10 mL vials'.\"\n    },\n    {\n      \"Question\": \"For a liquid oral preparation containing an active ingredient for mineral supplementation, and assuming the stated dose volume is 5 mL with strengths of 2 mg\/mL and 10 mg\/mL, how should the quantity of active ingredient be expressed on the label as per the regulation?\",\n      \"Answer\": \"The label should express the quantity of active ingredient as 10 mg in 5 mL and 50 mg in 5 mL for the 2 mg\/mL and 10 mg\/mL strengths respectively.\",\n      \"Answer Explanation\": \"Section 11(2)(c)(ii) states that for a series of strengths of a liquid for ingestion containing the same active ingredient, the quantity of active ingredient must be expressed consistently across the series in terms of the same stated dose volume. Section 11(2)(h) allows the quantity to be expressed as the name and quantity of the element intended for mineral supplementation. With a dose volume of 5 mL, the 2 mg\/mL and 10 mg\/mL strengths must be labelled as 10 mg in 5 mL and 50 mg in 5 mL respectively, as per the example given in 11(2)(c)(ii).\"\n    },\n    {\n      \"Question\": \"According to the regulation, what is meant by the term 'stated volume of fill', and how does this relate to the labelling requirements for oral liquid preparations containing mineral supplementation ingredients?\",\n      \"Answer\": \"The 'stated volume of fill' is defined as the volume of medicine that the container is specified by the sponsor to contain. For oral liquid preparations with mineral supplementation ingredients, the quantity of the active ingredient can be expressed as the name and quantity of the element per the stated dose volume, rather than per the stated volume of fill.\",\n      \"Answer Explanation\": \"The definition of 'stated volume of fill' is provided in the first context statement. Section 11(2)(c) specifies labelling the quantity of active ingredient per stated dose volume for oral liquid preparations. However, 11(2)(h) provides an exception, allowing mineral supplementation ingredients to be expressed as the name and quantity of the element, without reference to the stated volume of fill.\"\n    },\n    {\n      \"Question\": \"Assuming an oral liquid medicine comes in a series of strengths of 1 mg\/mL, 2 mg\/mL and 4 mg\/mL with a 5 mL stated dose volume, and the active ingredient is not for mineral supplementation, how should the quantity of active ingredient be expressed on the labels as per the regulation?\",\n      \"Answer\": \"The labels should express the quantity of active ingredient as 5 mg in 5 mL, 10 mg in 5 mL, and 20 mg in 5 mL for the 1 mg\/mL, 2 mg\/mL and 4 mg\/mL strengths respectively.\",\n      \"Answer Explanation\": \"Section 11(2)(c)(ii) requires that for a series of strengths of an oral liquid with the same active ingredient, the quantity of active ingredient must be expressed consistently across the series in terms of the same stated dose volume. With a 5 mL dose volume, the labels must state 5 mg in 5 mL for 1 mg\/mL, 10 mg in 5 mL for 2 mg\/mL, and 20 mg in 5 mL for 4 mg\/mL, as per the example in 11(2)(c)(ii). The exception in 11(2)(h) for expressing mineral supplementation ingredients differently does not apply here, since the active ingredient is stated to not be for mineral supplementation.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            914000000,
            501150000,
            601460002,
            907030000,
            802000000
        ],
        "contexts": [
            " (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028.",
            "(o) a medical gas; or",
            "(b) where the medicine is: (i) a solid or semi-solid - the stated weight in the container; (ii) a liquid - the stated volume of fill in the container; (iii) a pressurised metered-dose preparation or dry powder inhaler - the stated number of deliverable doses in the container; (iv) a non-pressurised metered dose preparation - the minimum number of deliverable doses in the container;",
            " (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " (2)"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a solid or semi-solid and contains more than four active ingredients, what labeling requirements apply regarding the weight or volume of the medicine?",
                    "Answer": "The medicine is not required to include the stated weight in the container on the label.",
                    "Answer Explanation": "According to context (b), for a solid or semi-solid medicine, the stated weight in the container must be included on the label. However, context (c) states that if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Therefore, the specific weight is not required on the label in this case."
                },
                {
                    "Question": "Assuming a medicine is released for supply on or after May 1, 2028 and contains an active ingredient specified in Part 2 of Schedule 2, where must the active ingredient name be included according to the regulation?",
                    "Answer": "The active ingredient must be included on the main label of the medicine in accordance with the Australian Approved Names List.",
                    "Answer Explanation": "Context (14) states that an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028."
                },
                {
                    "Question": "Assuming a medicine is a liquid and contains three active ingredients, what information must be included on the label regarding the quantity of the medicine?",
                    "Answer": "The stated volume of fill in the container must be included on the label.",
                    "Answer Explanation": "According to context (b), for a liquid medicine, the stated volume of fill in the container must be included on the label. Context (c) does not apply since the medicine contains only three active ingredients, so the labeling requirement in (b) must be followed."
                },
                {
                    "Question": "Assuming a medicine is a medical gas, what labeling requirements apply regarding the weight, volume, or number of doses in the container?",
                    "Answer": "The contexts provided do not specify any labeling requirements for the weight, volume, or number of doses for a medicine that is a medical gas.",
                    "Answer Explanation": "Context (o) mentions that a medicine may be a medical gas, but none of the other provided contexts specify labeling requirements related to weight, volume, or number of doses for medical gases. The labeling requirements in context (b) apply to solids, semi-solids, liquids, pressurized metered-dose preparations, dry powder inhalers, and non-pressurized metered-dose preparations, but not specifically to medical gases."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a solid or semi-solid and contains more than four active ingredients, what labeling requirements apply regarding the weight or volume of the medicine?\", \"Answer\": \"The medicine is not required to include the stated weight in the container on the label.\", \"Answer Explanation\": \"According to context (b), for a solid or semi-solid medicine, the stated weight in the container must be included on the label. However, context (c) states that if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Therefore, the specific weight is not required on the label in this case.\"}, {\"Question\": \"Assuming a medicine is released for supply on or after May 1, 2028 and contains an active ingredient specified in Part 2 of Schedule 2, where must the active ingredient name be included according to the regulation?\", \"Answer\": \"The active ingredient must be included on the main label of the medicine in accordance with the Australian Approved Names List.\", \"Answer Explanation\": \"Context (14) states that an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028.\"}, {\"Question\": \"Assuming a medicine is a liquid and contains three active ingredients, what information must be included on the label regarding the quantity of the medicine?\", \"Answer\": \"The stated volume of fill in the container must be included on the label.\", \"Answer Explanation\": \"According to context (b), for a liquid medicine, the stated volume of fill in the container must be included on the label. Context (c) does not apply since the medicine contains only three active ingredients, so the labeling requirement in (b) must be followed.\"}, {\"Question\": \"Assuming a medicine is a medical gas, what labeling requirements apply regarding the weight, volume, or number of doses in the container?\", \"Answer\": \"The contexts provided do not specify any labeling requirements for the weight, volume, or number of doses for a medicine that is a medical gas.\", \"Answer Explanation\": \"Context (o) mentions that a medicine may be a medical gas, but none of the other provided contexts specify labeling requirements related to weight, volume, or number of doses for medical gases. The labeling requirements in context (b) apply to solids, semi-solids, liquids, pressurized metered-dose preparations, dry powder inhalers, and non-pressurized metered-dose preparations, but not specifically to medical gases.\"}]}"
    },
    {
        "path": [
            907040000,
            801150000,
            601270000,
            601150000,
            801100000
        ],
        "contexts": [
            " (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine.",
            " (o) if the medicine is contained in an ampoule, a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.",
            "\"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;",
            "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " (j) where: (i) a substance or substance within the group of substances referred to in Column 1 of Schedule 1 to this Order is present in the medicine; (ii) the circumstances as set out in Column 2 of Schedule 1 exist in relation to such a substance or no circumstances are set out in Column 2; and (iii) the medicine is intended to be administered via any one or more of the route(s) of administration referred to in Column 3 of Schedule 1, then: (iv) a statement: (A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1; and (B) where any of the circumstances and requirements set out in Column 2 of Schedule 1 exist in relation to the substance \u2013 a statement of the kind referred to as a \u2018requirement\u2019 in that Column (if any); and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains only one active ingredient named 'magnesium aspartate dihydrate' and the quantity is displayed in accordance with subsection 8(2), can the therapeutically active moiety 'magnesium' be displayed on the main label of the primary pack instead of the full ingredient name if the text size is at least 3.0 mm and no quantity information is shown?",
                    "Answer": "Yes",
                    "Answer Explanation": "Based on the information provided in context (d), if a medicine contains an active ingredient with a name that includes therapeutically irrelevant descriptors (like 'aspartate dihydrate' in 'magnesium aspartate dihydrate'), and the name and quantity are displayed per subsection 8(2), then the therapeutically active moiety name ('magnesium') can be displayed on the main label instead of the full ingredient name, provided the text size is at least 3.0 mm and no quantity information is displayed for any active ingredients."
                },
                {
                    "Question": "Assuming a medicine is contained in an ampoule and is administered via inhalation, which is an approved route, does the main label need to include a statement indicating the route of administration?",
                    "Answer": "Yes",
                    "Answer Explanation": "Context (o) states that if a medicine is in an ampoule, the main label must include a statement of the approved route of administration, such as 'inhalation' or another phrase, word or abbreviation denoting the approved route(s). Since the question states the medicine is in an ampoule and inhalation is an approved route, a statement indicating this route must be on the main label."
                },
                {
                    "Question": "Assuming a herbal preparation is an active ingredient in a medicine, and the medicine contains a substance listed in Column 1 of Schedule 1 under the circumstances in Column 2 and is administered via a route in Column 3, does the main label need to include the name of the substance as stated in Column 4 and any required statements from Column 2?",
                    "Answer": "Yes",
                    "Answer Explanation": "Context (j) outlines that if a medicine contains a substance from Column 1 of Schedule 1, under any circumstances in Column 2 (or no specified circumstances), and is administered via a route in Column 3, then the main label must state that the medicine contains the substance using the name in Column 4. It must also include any statements listed as a 'requirement' in Column 2. The definition of 'herbal preparation' in context (c) confirms it is an ingredient, so these label requirements would apply even if the substance is a herbal preparation."
                },
                {
                    "Question": "Assuming a medicine's main label is required to display critical health information under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), and the medicine contains an ampoule with a herbal preparation, do the statements required by (j) and (o) need to be included in this critical health information?",
                    "Answer": "Yes",
                    "Answer Explanation": "The definition of 'critical health information' in context (d) specifies that it includes the information required under paragraphs 8(1)(j) and 8(1)(n). Context (j) requires certain statements for substances in Schedule 1, and context (o) requires a statement of the route of administration for medicines in an ampoule. Therefore, both the Schedule 1 substance statements from (j) and the route of administration statement from (o) must be included in the critical health information on the main label, even if the substance is a herbal preparation as defined in context (c)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains only one active ingredient named 'magnesium aspartate dihydrate' and the quantity is displayed in accordance with subsection 8(2), can the therapeutically active moiety 'magnesium' be displayed on the main label of the primary pack instead of the full ingredient name if the text size is at least 3.0 mm and no quantity information is shown?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Based on the information provided in context (d), if a medicine contains an active ingredient with a name that includes therapeutically irrelevant descriptors (like 'aspartate dihydrate' in 'magnesium aspartate dihydrate'), and the name and quantity are displayed per subsection 8(2), then the therapeutically active moiety name ('magnesium') can be displayed on the main label instead of the full ingredient name, provided the text size is at least 3.0 mm and no quantity information is displayed for any active ingredients.\"}, {\"Question\": \"Assuming a medicine is contained in an ampoule and is administered via inhalation, which is an approved route, does the main label need to include a statement indicating the route of administration?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Context (o) states that if a medicine is in an ampoule, the main label must include a statement of the approved route of administration, such as 'inhalation' or another phrase, word or abbreviation denoting the approved route(s). Since the question states the medicine is in an ampoule and inhalation is an approved route, a statement indicating this route must be on the main label.\"}, {\"Question\": \"Assuming a herbal preparation is an active ingredient in a medicine, and the medicine contains a substance listed in Column 1 of Schedule 1 under the circumstances in Column 2 and is administered via a route in Column 3, does the main label need to include the name of the substance as stated in Column 4 and any required statements from Column 2?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Context (j) outlines that if a medicine contains a substance from Column 1 of Schedule 1, under any circumstances in Column 2 (or no specified circumstances), and is administered via a route in Column 3, then the main label must state that the medicine contains the substance using the name in Column 4. It must also include any statements listed as a 'requirement' in Column 2. The definition of 'herbal preparation' in context (c) confirms it is an ingredient, so these label requirements would apply even if the substance is a herbal preparation.\"}, {\"Question\": \"Assuming a medicine's main label is required to display critical health information under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), and the medicine contains an ampoule with a herbal preparation, do the statements required by (j) and (o) need to be included in this critical health information?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"The definition of 'critical health information' in context (d) specifies that it includes the information required under paragraphs 8(1)(j) and 8(1)(n). Context (j) requires certain statements for substances in Schedule 1, and context (o) requires a statement of the route of administration for medicines in an ampoule. Therefore, both the Schedule 1 substance statements from (j) and the route of administration statement from (o) must be included in the critical health information on the main label, even if the substance is a herbal preparation as defined in context (c).\"}]}"
    },
    {
        "path": [
            1008030000,
            601410000,
            905030000,
            802050000,
            802030000
        ],
        "contexts": [
            " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            "\"name of an excipient\" means the name of the excipient that is accepted for inclusion in the Australian Approved Names List;",
            " (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
            " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming an individual bag of dry herbs is contained within a compliant primary pack, what labeling requirements must the individual bag meet according to section (c) under the 'Where:' heading?",
                    "Answer": "The individual bag does not need to be labelled with the information referred to in sections 8 and 9.",
                    "Answer Explanation": "Section (c) under the 'Where:' heading states that if a medicine consists of dry herbs in individual bags retained during preparation, and these bags are in a primary pack with a compliant label, then the individual bags do not need to be labelled with the information from sections 8 and 9."
                },
                {
                    "Question": "If a non-prescription medicine is registered goods and subsection 8(2) does not apply, what are the minimum text size requirements for displaying the names and quantities or proportions of active ingredients, and where must this information be displayed?",
                    "Answer": "The names and quantities or proportions of active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.",
                    "Answer Explanation": "Section (c) under the assumptions states that for registered goods where subsection 8(2) does not apply, the names and quantities or proportions of active ingredients must be displayed on the side or rear panel or label with a minimum text size of 2.5 millimetres, per subclause (i)."
                },
                {
                    "Question": "Assuming subsection 8(2) applies to a medicine that is registered goods, what impact does this have on the labeling requirements specified in paragraphs 9(1)(b) and 9(1)(c)?",
                    "Answer": "Compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
                    "Answer Explanation": "Section (c) states that if a medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required, as per subclause (ii)."
                },
                {
                    "Question": "Under the 'Other information' heading or other appropriate headings immediately below those mentioned in 8(2)(b), what specific information may be included according to section (e), assuming the information is not critical health information or of a kind mentioned in subsections 8(2)(c) or 8(2)(d)?",
                    "Answer": "The information under these headings must be limited to: A. storage condition requirements, B. package tamper-prevention features, C. names of all excipients (as defined in the 'name of an excipient' context), and D. sponsor or distributor contact details.",
                    "Answer Explanation": "Section (e) specifies that under the 'Other information' heading or other appropriate headings immediately following those in 8(2)(b), only information related to storage conditions, tamper-prevention features, excipient names (per the 'name of an excipient' definition), and sponsor\/distributor contact details may be included, provided it is not critical health information or information mentioned in 8(2)(c) or 8(2)(d). Section (c) allows the information under 8(2)(b)(i) to include words describing the active ingredients' purpose or actions that are not required by the Order."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming an individual bag of dry herbs is contained within a compliant primary pack, what labeling requirements must the individual bag meet according to section (c) under the 'Where:' heading?\",\n      \"Answer\": \"The individual bag does not need to be labelled with the information referred to in sections 8 and 9.\",\n      \"Answer Explanation\": \"Section (c) under the 'Where:' heading states that if a medicine consists of dry herbs in individual bags retained during preparation, and these bags are in a primary pack with a compliant label, then the individual bags do not need to be labelled with the information from sections 8 and 9.\"\n    },\n    {\n      \"Question\": \"If a non-prescription medicine is registered goods and subsection 8(2) does not apply, what are the minimum text size requirements for displaying the names and quantities or proportions of active ingredients, and where must this information be displayed?\",\n      \"Answer\": \"The names and quantities or proportions of active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\",\n      \"Answer Explanation\": \"Section (c) under the assumptions states that for registered goods where subsection 8(2) does not apply, the names and quantities or proportions of active ingredients must be displayed on the side or rear panel or label with a minimum text size of 2.5 millimetres, per subclause (i).\"\n    },\n    {\n      \"Question\": \"Assuming subsection 8(2) applies to a medicine that is registered goods, what impact does this have on the labeling requirements specified in paragraphs 9(1)(b) and 9(1)(c)?\",\n      \"Answer\": \"Compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\",\n      \"Answer Explanation\": \"Section (c) states that if a medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required, as per subclause (ii).\"\n    },\n    {\n      \"Question\": \"Under the 'Other information' heading or other appropriate headings immediately below those mentioned in 8(2)(b), what specific information may be included according to section (e), assuming the information is not critical health information or of a kind mentioned in subsections 8(2)(c) or 8(2)(d)?\",\n      \"Answer\": \"The information under these headings must be limited to: A. storage condition requirements, B. package tamper-prevention features, C. names of all excipients (as defined in the 'name of an excipient' context), and D. sponsor or distributor contact details.\",\n      \"Answer Explanation\": \"Section (e) specifies that under the 'Other information' heading or other appropriate headings immediately following those in 8(2)(b), only information related to storage conditions, tamper-prevention features, excipient names (per the 'name of an excipient' definition), and sponsor\/distributor contact details may be included, provided it is not critical health information or information mentioned in 8(2)(c) or 8(2)(d). Section (c) allows the information under 8(2)(b)(i) to include words describing the active ingredients' purpose or actions that are not required by the Order.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            1007030000,
            901050000,
            1007120000,
            1009010000,
            900000000
        ],
        "contexts": [
            " (c) the name of the medicine; and",
            " (e) the quantity of the medicine; and",
            " (l) if the medicine is contained in an ampoule - a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine; and",
            " (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 9 Information to be included on the main label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is contained in ampoules and is administered via inhalation, what information must be included on the main label of the medicine according to the given regulation sections?",
                    "Answer": "The main label must include a statement indicating the approved route of administration, such as 'inhalation'.",
                    "Answer Explanation": "Section (l) states that if the medicine is contained in an ampoule, the label must include a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only', or another phrase, word, or abbreviation denoting the approved route(s) of administration."
                },
                {
                    "Question": "Given a non-prescription medicine consisting of individually enclosed tablets in a strip pack, which is then enclosed in a primary pack with a label complying with sections 8 and 9, what specific information is required on the label of the strip pack?",
                    "Answer": "The label on the strip pack must include the name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number with prefix, the expiry date with prefix, and the name of the sponsor\/distributor or their registered trademark.",
                    "Answer Explanation": "Section (a) lists the required information for the label on a strip, blister, or dial dispenser pack containing individual dosage units, when enclosed in a primary pack with a compliant label. This includes: (iv) name of the medicine, (v) name(s) of active ingredients, (vi) quantity\/proportion of active ingredients, (vii) batch number with prefix, (viii) expiry date with prefix, (ix) name of sponsor\/distributor or identifying trademark."
                },
                {
                    "Question": "What information related to the quantity of a non-prescription medicine must be included on the main label as per the given regulation sections?",
                    "Answer": "The main label must include the quantity of the medicine.",
                    "Answer Explanation": "Section (e) clearly states that the quantity of the medicine must be included on the main label."
                },
                {
                    "Question": "Based on the provided regulation sections, is the name of the non-prescription medicine required to be displayed on both the main label and the label of any strip, blister, or dial dispenser pack containing individual dosage units?",
                    "Answer": "Yes, the name of the medicine is required on both the main label and on the label of any strip, blister, or dial dispenser pack containing individual dosage units.",
                    "Answer Explanation": "Section (c) specifies that the name of the medicine must be included on the main label. Additionally, section (a) states that for a medicine consisting of individually enclosed dosage units in a strip, blister, or dial dispenser pack, the label on such packaging must also include (iv) the name of the medicine."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine is contained in ampoules and is administered via inhalation, what information must be included on the main label of the medicine according to the given regulation sections?\",\n    \"Answer\": \"The main label must include a statement indicating the approved route of administration, such as 'inhalation'.\",\n    \"Answer Explanation\": \"Section (l) states that if the medicine is contained in an ampoule, the label must include a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only', or another phrase, word, or abbreviation denoting the approved route(s) of administration.\"\n  },\n  {\n    \"Question\": \"Given a non-prescription medicine consisting of individually enclosed tablets in a strip pack, which is then enclosed in a primary pack with a label complying with sections 8 and 9, what specific information is required on the label of the strip pack?\", \n    \"Answer\": \"The label on the strip pack must include the name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number with prefix, the expiry date with prefix, and the name of the sponsor\/distributor or their registered trademark.\",\n    \"Answer Explanation\": \"Section (a) lists the required information for the label on a strip, blister, or dial dispenser pack containing individual dosage units, when enclosed in a primary pack with a compliant label. This includes: (iv) name of the medicine, (v) name(s) of active ingredients, (vi) quantity\/proportion of active ingredients, (vii) batch number with prefix, (viii) expiry date with prefix, (ix) name of sponsor\/distributor or identifying trademark.\"\n  },\n  {\n    \"Question\": \"What information related to the quantity of a non-prescription medicine must be included on the main label as per the given regulation sections?\",\n    \"Answer\": \"The main label must include the quantity of the medicine.\",\n    \"Answer Explanation\": \"Section (e) clearly states that the quantity of the medicine must be included on the main label.\"\n  },\n  {\n    \"Question\": \"Based on the provided regulation sections, is the name of the non-prescription medicine required to be displayed on both the main label and the label of any strip, blister, or dial dispenser pack containing individual dosage units?\",\n    \"Answer\": \"Yes, the name of the medicine is required on both the main label and on the label of any strip, blister, or dial dispenser pack containing individual dosage units.\",\n    \"Answer Explanation\": \"Section (c) specifies that the name of the medicine must be included on the main label. Additionally, section (a) states that for a medicine consisting of individually enclosed dosage units in a strip, blister, or dial dispenser pack, the label on such packaging must also include (iv) the name of the medicine.\"\n  }\n]}"
    },
    {
        "path": [
            802030000,
            601260000,
            1008020000,
            601150000,
            801120000
        ],
        "contexts": [
            " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
            "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
            " (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.",
            "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming that a non-prescription medicine consists of only pastilles or lozenges, and each dosage unit is enclosed in an unsealed individual wrapper, then enclosed in a primary pack complying with sections 8 and 9, what information must be displayed on the label for each individual wrapper to comply with sections 8 and 9?",
                    "Answer": "The name of the medicine.",
                    "Answer Explanation": "According to section (b), if a non-prescription medicine consists only of pastilles or lozenges, each dosage unit is enclosed in an unsealed individual wrapper, and each dosage unit is then enclosed in a primary pack complying with sections 8 and 9, then to comply with sections 8 and 9, it is sufficient if the name of the medicine is displayed on the label for each individual wrapper."
                },
                {
                    "Question": "Assuming a non-prescription medicine label does not have sufficient space to include directions for use on either the container or primary pack, what two conditions must be met to comply with the regulation?",
                    "Answer": "The directions for use must be set out in a package insert provided in the primary pack, and a statement must be included on the label that the directions are in the package insert.",
                    "Answer Explanation": "Section (l) states that if there is insufficient space on the label of either the container or primary pack to include directions for use, it is acceptable if: (A) the directions are set out in a package insert in the primary pack, and (B) a statement is included on whichever label (container or primary pack) that does not have the directions, indicating the directions are in the package insert."
                },
                {
                    "Question": "Assuming an herbal material is used as an active ingredient in a non-prescription medicine, how must the herbal material be defined on the label according to the regulation?",
                    "Answer": "The herbal material must be defined by its botanical scientific name according to the binomial nomenclature system, including author, and the plant part.",
                    "Answer Explanation": "The definition of 'herbal material' specifies that a plant or plant part used as an herbal material, whether fresh or dried, whole, fragmented, cut or ground, must be defined by its botanical scientific name using the binomial nomenclature system, including the author name, and the plant part."
                },
                {
                    "Question": "What specific paragraphs in section 8 are considered 'critical health information' that is required for safe use of self-selected non-prescription medicines?",
                    "Answer": "Paragraphs 8(1)(b), (c), (j), (k), (l) and (n) contain information that is considered 'critical health information' required for safe use of self-selected medicines.",
                    "Answer Explanation": "The definition of 'critical health information' directly specifies that the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) is considered critical for safe use of non-prescription medicines that are self-selected by consumers."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming that a non-prescription medicine consists of only pastilles or lozenges, and each dosage unit is enclosed in an unsealed individual wrapper, then enclosed in a primary pack complying with sections 8 and 9, what information must be displayed on the label for each individual wrapper to comply with sections 8 and 9?\",\n      \"Answer\": \"The name of the medicine.\",\n      \"Answer Explanation\": \"According to section (b), if a non-prescription medicine consists only of pastilles or lozenges, each dosage unit is enclosed in an unsealed individual wrapper, and each dosage unit is then enclosed in a primary pack complying with sections 8 and 9, then to comply with sections 8 and 9, it is sufficient if the name of the medicine is displayed on the label for each individual wrapper.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine label does not have sufficient space to include directions for use on either the container or primary pack, what two conditions must be met to comply with the regulation?\",\n      \"Answer\": \"The directions for use must be set out in a package insert provided in the primary pack, and a statement must be included on the label that the directions are in the package insert.\",\n      \"Answer Explanation\": \"Section (l) states that if there is insufficient space on the label of either the container or primary pack to include directions for use, it is acceptable if: (A) the directions are set out in a package insert in the primary pack, and (B) a statement is included on whichever label (container or primary pack) that does not have the directions, indicating the directions are in the package insert.\"\n    },\n    {\n      \"Question\": \"Assuming an herbal material is used as an active ingredient in a non-prescription medicine, how must the herbal material be defined on the label according to the regulation?\",\n      \"Answer\": \"The herbal material must be defined by its botanical scientific name according to the binomial nomenclature system, including author, and the plant part.\",\n      \"Answer Explanation\": \"The definition of 'herbal material' specifies that a plant or plant part used as an herbal material, whether fresh or dried, whole, fragmented, cut or ground, must be defined by its botanical scientific name using the binomial nomenclature system, including the author name, and the plant part.\"\n    },\n    {\n      \"Question\": \"What specific paragraphs in section 8 are considered 'critical health information' that is required for safe use of self-selected non-prescription medicines?\",\n      \"Answer\": \"Paragraphs 8(1)(b), (c), (j), (k), (l) and (n) contain information that is considered 'critical health information' required for safe use of self-selected medicines.\",\n      \"Answer Explanation\": \"The definition of 'critical health information' directly specifies that the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) is considered critical for safe use of non-prescription medicines that are self-selected by consumers.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            1104000000,
            904000000,
            802050000,
            903020000,
            1102090000
        ],
        "contexts": [
            " (4) Permitted statements of storage temperature conditions For the purposes of this Order, the following statements of storage temperature conditions are permitted: (i) \u2018Store below \u201318oC (Deep freeze)\u2019; (ii) \u2018Store below \u20135oC (Freeze)\u2019; (iii) \u2018Store at 2oC to 8oC (Refrigerate. Do not freeze)\u2019; (iv) \u2018Store below 25oC\u2019; (v) \u2018Store below 30oC\u2019; (vi) for a medicine that is, or is intended to be, registered goods, any other storage temperature conditions as specified in the approved product details in relation to the medicine.",
            " (4) All text required by this Order to be on the main label must be oriented in the same direction.",
            " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh weight of herbal material and also the quantity of standardised constituents(s) in the herbal material; (ii) where the active ingredient is a herbal preparation, as the dry or fresh weight of the herbal material from which the preparation was derived except: (A) where standardisation of the herbal preparation is claimed on the label, then, the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituents(s) in the herbal preparation; or (B) where the active ingredient is a herbal preparation that is an essential oil; (iii) where the active ingredient is an enzyme \u2013the activity unit as specified in Column 1 of Schedule 3 to this Order in relation to a particular enzyme set out in Column 3 of that Schedule; (iv) for preparations containing Vitamin A or a derivative of Vitamin A - as the quantity or proportion of Vitamin A expressed in terms of microgram retinol equivalents; (v) for preparations containing biological organisms - as the number of organisms present per metric unit for liquids and powders and as the number of organisms present per dosage unit for other dosage forms;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is intended to be registered goods and its approved product details specify storing it below 20\u00b0C, is the label allowed to state 'Store below 20\u00b0C' for the storage temperature conditions?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to section (4)(vi), for a medicine that is intended to be registered goods, the label can state any storage temperature conditions specified in the approved product details. Since the approved product details specify storing below 20\u00b0C in this case, the label is permitted to state 'Store below 20\u00b0C'."
                },
                {
                    "Question": "For a non-prescription medicine label that includes excipients and sponsor contact details under the 'Other information' heading, assuming no other optional information is included, does the text stating the excipients and contact details need to be oriented in the same direction as the rest of the mandatory label text?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section (4) requires that all text required by the Order to be on the main label must be oriented in the same direction. Section (e) allows including excipient names and sponsor contact details under the 'Other information' heading. Therefore, the excipient and contact detail text must be oriented the same way as the rest of the mandatory label text."
                },
                {
                    "Question": "On a non-prescription medicine label, is it permitted for any text or graphics to appear between the quantity and proportion statements for multiple active ingredients that are herbal preparations derived from herbal material, assuming no standardization is claimed and they are not essential oils?",
                    "Answer": "No",
                    "Answer Explanation": "Section (b) states that quantity and proportion statements must not be separated by any text or graphics, with some exceptions. Section (i)(ii) specifies that for active ingredients that are herbal preparations, the quantity should be stated as the dry or fresh weight of the source herbal material, unless standardization is claimed or it is an essential oil. None of the exceptions in (b) apply for this case, so no text or graphics can separate the herbal preparation quantity statements."
                },
                {
                    "Question": "For a liquid non-prescription medicine containing live bacteria as the active ingredient, is it required to state the quantity of the bacteria on the label per dosage unit or per metric volume unit?",
                    "Answer": "Per metric volume unit",
                    "Answer Explanation": "Section (i)(v) requires that for preparations containing biological organisms, the quantity must be stated as the number of organisms present per metric unit for liquids and powders, and as the number per dosage unit for other forms. Since this is a liquid medicine with live bacteria, the bacteria quantity must be given per metric volume unit, not per dosage unit."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine is intended to be registered goods and its approved product details specify storing it below 20\u00b0C, is the label allowed to state 'Store below 20\u00b0C' for the storage temperature conditions?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"According to section (4)(vi), for a medicine that is intended to be registered goods, the label can state any storage temperature conditions specified in the approved product details. Since the approved product details specify storing below 20\u00b0C in this case, the label is permitted to state 'Store below 20\u00b0C'.\"\n  },\n  {\n    \"Question\": \"For a non-prescription medicine label that includes excipients and sponsor contact details under the 'Other information' heading, assuming no other optional information is included, does the text stating the excipients and contact details need to be oriented in the same direction as the rest of the mandatory label text?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section (4) requires that all text required by the Order to be on the main label must be oriented in the same direction. Section (e) allows including excipient names and sponsor contact details under the 'Other information' heading. Therefore, the excipient and contact detail text must be oriented the same way as the rest of the mandatory label text.\"\n  },\n  {\n    \"Question\": \"On a non-prescription medicine label, is it permitted for any text or graphics to appear between the quantity and proportion statements for multiple active ingredients that are herbal preparations derived from herbal material, assuming no standardization is claimed and they are not essential oils?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section (b) states that quantity and proportion statements must not be separated by any text or graphics, with some exceptions. Section (i)(ii) specifies that for active ingredients that are herbal preparations, the quantity should be stated as the dry or fresh weight of the source herbal material, unless standardization is claimed or it is an essential oil. None of the exceptions in (b) apply for this case, so no text or graphics can separate the herbal preparation quantity statements.\"\n  },\n  {\n    \"Question\": \"For a liquid non-prescription medicine containing live bacteria as the active ingredient, is it required to state the quantity of the bacteria on the label per dosage unit or per metric volume unit?\",\n    \"Answer\": \"Per metric volume unit\",\n    \"Answer Explanation\": \"Section (i)(v) requires that for preparations containing biological organisms, the quantity must be stated as the number of organisms present per metric unit for liquids and powders, and as the number per dosage unit for other forms. Since this is a liquid medicine with live bacteria, the bacteria quantity must be given per metric volume unit, not per dosage unit.\"\n  }\n]}"
    },
    {
        "path": [
            1105010000,
            801130000,
            1102100000,
            903020000,
            1102080000
        ],
        "contexts": [
            " (a) on the same line of text - between the approved name of the active ingredient that is a vitamin and the quantity of that active ingredient; or",
            " (m) if the medicine requires some preparation, such as dissolving, suspending, diluting or reconstituting before use - instructions for its preparation and, where relevant, a statement of the conditions of storage and the maximum period of storage between preparation and use, except where: (i) there is insufficient space on the label of either the container or the primary pack, or both, to include this information; and (ii) this information is set out in a package insert provided in the primary pack of the medicine; and (iii) a statement is included on whichever label on the container or the primary pack, or both, that does not set out the information itself, that this information is set out in the package insert; and",
            " (j) for any other medicines: (i) where the medicine is a liquid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated volume of the medicine; (ii) where the medicine is a liquid and includes an active ingredient which is a solid - as the weight of active ingredient in a stated volume of the medicine; (iii) where the medicine is a liquid and includes an active ingredient which is a gas - as the weight of the active ingredient in a stated volume of the medicine; (iv) where the medicine is a solid or semi-solid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the medicine; (v) where the medicine is a solid or semi-solid and includes an active ingredient which is a solid - as the weight of the active ingredient in a stated weight of the medicine.",
            " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a liquid that includes an active ingredient which is also a liquid, how should the quantity of the active ingredient be expressed on the label as per the regulation?",
                    "Answer": "As the appropriate amount of the active ingredient, either by weight or volume, in a stated volume of the medicine.",
                    "Answer Explanation": "According to subparagraph 11(2)(j)(i), where the medicine is a liquid and includes an active ingredient which is a liquid, the quantity should be expressed as the appropriate amount of the active ingredient, either by weight or volume, in a stated volume of the medicine."
                },
                {
                    "Question": "For an oral preparation that contains active ingredients intended for mineral supplementation, what information is sufficient to include on the label to express the quantity or proportion of that active ingredient, as per the exceptions outlined in the regulation?",
                    "Answer": "The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "Paragraph 11(2)(h) provides an exception for oral preparations that contain active ingredients intended for mineral supplementation. It states that it is sufficient for the label to include the name of the active ingredient and the name and quantity of the element intended for mineral supplementation, rather than following the standard quantity expression requirements outlined in paragraphs 11(2)(a) - 11(2)(d)."
                },
                {
                    "Question": "Assuming a medicine requires preparation before use and there is insufficient space on the label to include the preparation instructions, what are the conditions that must be met to provide this information in a package insert instead, according to the regulation?",
                    "Answer": "The preparation instructions must be set out in a package insert provided in the primary pack of the medicine, and a statement must be included on the label indicating that this information is set out in the package insert.",
                    "Answer Explanation": "Paragraph 11(2)(m) allows preparation instructions to be provided in a package insert if there is insufficient space on the label, provided that: (i) the information is set out in a package insert in the primary pack, (ii) a statement is included on the label indicating that the information is in the package insert."
                },
                {
                    "Question": "According to the regulation, what is the only text or graphics allowed to separate the approved name of an active ingredient that is a vitamin from its quantity on the same line of text?",
                    "Answer": "The only text or graphics allowed to separate the approved name and quantity are: additional information required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), subsection 11(5), or information related to identifying different formulations in a composite pack or medicine kit.",
                    "Answer Explanation": "Paragraph 11(2)(b) states that the approved name and quantity of an active ingredient that is a vitamin on the same line of text must not be separated by any text or graphics, with the only exceptions being the additional information outlined in (i) paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), subsection 11(5), or (ii) information related to identifying different formulations in a composite pack or medicine kit."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is a liquid that includes an active ingredient which is also a liquid, how should the quantity of the active ingredient be expressed on the label as per the regulation?\",\n      \"Answer\": \"As the appropriate amount of the active ingredient, either by weight or volume, in a stated volume of the medicine.\",\n      \"Answer Explanation\": \"According to subparagraph 11(2)(j)(i), where the medicine is a liquid and includes an active ingredient which is a liquid, the quantity should be expressed as the appropriate amount of the active ingredient, either by weight or volume, in a stated volume of the medicine.\"\n    },\n    {\n      \"Question\": \"For an oral preparation that contains active ingredients intended for mineral supplementation, what information is sufficient to include on the label to express the quantity or proportion of that active ingredient, as per the exceptions outlined in the regulation?\",\n      \"Answer\": \"The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\",\n      \"Answer Explanation\": \"Paragraph 11(2)(h) provides an exception for oral preparations that contain active ingredients intended for mineral supplementation. It states that it is sufficient for the label to include the name of the active ingredient and the name and quantity of the element intended for mineral supplementation, rather than following the standard quantity expression requirements outlined in paragraphs 11(2)(a) - 11(2)(d).\"\n    },\n    {\n      \"Question\": \"Assuming a medicine requires preparation before use and there is insufficient space on the label to include the preparation instructions, what are the conditions that must be met to provide this information in a package insert instead, according to the regulation?\",\n      \"Answer\": \"The preparation instructions must be set out in a package insert provided in the primary pack of the medicine, and a statement must be included on the label indicating that this information is set out in the package insert.\",\n      \"Answer Explanation\": \"Paragraph 11(2)(m) allows preparation instructions to be provided in a package insert if there is insufficient space on the label, provided that: (i) the information is set out in a package insert in the primary pack, (ii) a statement is included on the label indicating that the information is in the package insert.\"\n    },\n    {\n      \"Question\": \"According to the regulation, what is the only text or graphics allowed to separate the approved name of an active ingredient that is a vitamin from its quantity on the same line of text?\",\n      \"Answer\": \"The only text or graphics allowed to separate the approved name and quantity are: additional information required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), subsection 11(5), or information related to identifying different formulations in a composite pack or medicine kit.\",\n      \"Answer Explanation\": \"Paragraph 11(2)(b) states that the approved name and quantity of an active ingredient that is a vitamin on the same line of text must not be separated by any text or graphics, with the only exceptions being the additional information outlined in (i) paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), subsection 11(5), or (ii) information related to identifying different formulations in a composite pack or medicine kit.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            601100000,
            601270000,
            1102000000,
            1009010000,
            800000000
        ],
        "contexts": [
            "\"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;",
            "\"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;",
            " (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed:",
            " (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 8 Information to be included on the label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assume a herbal medicine contains a single herbal preparation as the only active ingredient. What information must be on the label regarding the quantity of this active ingredient, according to the regulation?",
                    "Answer": "The quantity or proportion of the herbal preparation must be expressed on the label.",
                    "Answer Explanation": "According to the regulation sections provided, the quantity or proportion of an active ingredient must be expressed on the label, subject to certain exceptions in paragraph 11(2)(i) and subsection 11(3) (section (2)). A 'herbal preparation' is defined as an ingredient that is the result of processing a herbal material (section 'herbal preparation'). Therefore, a herbal preparation is an active ingredient, and its quantity or proportion must be expressed on the label."
                },
                {
                    "Question": "Assume a non-prescription medicine is in tablet form, with multiple tablets sealed in a blister pack. This blister pack is then enclosed in an outer box. The outer box label fully complies with sections 8 and 9 of the regulation. What is the minimum information required on the blister pack label to comply with the regulation?",
                    "Answer": "The blister pack label must contain at minimum the name of the medicine, the name(s) and quantity\/proportion of all active ingredients, the batch number with prefix, the expiry date with prefix, and the name of the sponsor\/distributor or their registered trademark.",
                    "Answer Explanation": "Section (a) states that if a medicine consists of individual dosage units like tablets that are individually enclosed in a blister pack such that they can only be extracted individually, and this blister pack is further enclosed in a primary pack with a label complying with sections 8 and 9, then the blister pack label needs to display at minimum: (iv) the medicine name, (v) the name(s) of all active ingredients, (vi) the quantity\/proportion of all active ingredients, (vii) the batch number with prefix, (viii) the expiry date with prefix, and (ix) the name of the sponsor\/distributor or their registered trademark that readily identifies them."
                },
                {
                    "Question": "Suppose a medicine consists of capsules individually enclosed in a blister pack, and this blister pack is not enclosed in any other packaging. Assuming the blister pack is the primary pack, what information must be on the blister pack label to comply with the labelling standard?",
                    "Answer": "The blister pack label must include all the information required by sections 8 and 9 of the labelling standard regulation.",
                    "Answer Explanation": "Section (a) provides an exception for reduced labelling requirements only if the individual dosage units like capsules in a blister pack are further enclosed in a primary pack that has a label complying with sections 8 and 9. Since in this case the blister pack is not enclosed in any other packaging and is the primary pack itself, this exception does not apply. Therefore, the blister pack label must comply with all the labelling requirements specified in section 8 ('Information to be included on the label') and section 9 of the regulation."
                },
                {
                    "Question": "Under what specific circumstances does a non-prescription medicine receive a 'Certificate of Listing', based on the information provided in the regulation?",
                    "Answer": "A non-prescription medicine receives a 'Certificate of Listing' when it is given to the applicant under subsection 26(4) or subsection 26A(9) of the Act in relation to the listing of that medicine.",
                    "Answer Explanation": "The regulation section 'Certificate of Listing' directly states that a 'Certificate of Listing' in relation to a medicine means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act. No other sections provide additional relevant information. Therefore, a non-prescription medicine receives this certificate specifically when it is given to the applicant under those two subsections of the Act during the medicine listing process."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assume a herbal medicine contains a single herbal preparation as the only active ingredient. What information must be on the label regarding the quantity of this active ingredient, according to the regulation?\",\n      \"Answer\": \"The quantity or proportion of the herbal preparation must be expressed on the label.\",\n      \"Answer Explanation\": \"According to the regulation sections provided, the quantity or proportion of an active ingredient must be expressed on the label, subject to certain exceptions in paragraph 11(2)(i) and subsection 11(3) (section (2)). A 'herbal preparation' is defined as an ingredient that is the result of processing a herbal material (section 'herbal preparation'). Therefore, a herbal preparation is an active ingredient, and its quantity or proportion must be expressed on the label.\"\n    },\n    {\n      \"Question\": \"Assume a non-prescription medicine is in tablet form, with multiple tablets sealed in a blister pack. This blister pack is then enclosed in an outer box. The outer box label fully complies with sections 8 and 9 of the regulation. What is the minimum information required on the blister pack label to comply with the regulation?\",\n      \"Answer\": \"The blister pack label must contain at minimum the name of the medicine, the name(s) and quantity\/proportion of all active ingredients, the batch number with prefix, the expiry date with prefix, and the name of the sponsor\/distributor or their registered trademark.\",\n      \"Answer Explanation\": \"Section (a) states that if a medicine consists of individual dosage units like tablets that are individually enclosed in a blister pack such that they can only be extracted individually, and this blister pack is further enclosed in a primary pack with a label complying with sections 8 and 9, then the blister pack label needs to display at minimum: (iv) the medicine name, (v) the name(s) of all active ingredients, (vi) the quantity\/proportion of all active ingredients, (vii) the batch number with prefix, (viii) the expiry date with prefix, and (ix) the name of the sponsor\/distributor or their registered trademark that readily identifies them.\"\n    },\n    {\n      \"Question\": \"Suppose a medicine consists of capsules individually enclosed in a blister pack, and this blister pack is not enclosed in any other packaging. Assuming the blister pack is the primary pack, what information must be on the blister pack label to comply with the labelling standard?\",\n      \"Answer\": \"The blister pack label must include all the information required by sections 8 and 9 of the labelling standard regulation.\",\n      \"Answer Explanation\": \"Section (a) provides an exception for reduced labelling requirements only if the individual dosage units like capsules in a blister pack are further enclosed in a primary pack that has a label complying with sections 8 and 9. Since in this case the blister pack is not enclosed in any other packaging and is the primary pack itself, this exception does not apply. Therefore, the blister pack label must comply with all the labelling requirements specified in section 8 ('Information to be included on the label') and section 9 of the regulation.\"\n    },\n    {\n      \"Question\": \"Under what specific circumstances does a non-prescription medicine receive a 'Certificate of Listing', based on the information provided in the regulation?\",\n      \"Answer\": \"A non-prescription medicine receives a 'Certificate of Listing' when it is given to the applicant under subsection 26(4) or subsection 26A(9) of the Act in relation to the listing of that medicine.\",\n      \"Answer Explanation\": \"The regulation section 'Certificate of Listing' directly states that a 'Certificate of Listing' in relation to a medicine means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act. No other sections provide additional relevant information. Therefore, a non-prescription medicine receives this certificate specifically when it is given to the applicant under those two subsections of the Act during the medicine listing process.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            1006080000,
            100000000,
            1006070000,
            907020000,
            802000000
        ],
        "contexts": [
            " (h) any warning statements that relate to any of the medicines within the kit;",
            "About this compilation ",
            " (g) an expiry date for the kit, being the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix;",
            " (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or",
            " (2)"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a first aid kit contains four medicines, each with different expiry dates, and the kit label lists the names and quantities of the active ingredients on the side panel in a text size of 2.5 millimeters, what expiry date must be printed on the kit label?",
                    "Answer": "The expiry date printed on the kit label must be the earliest expiry date out of the four medicines contained in the kit.",
                    "Answer Explanation": "According to context (g), the expiry date for the kit must be the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix. Context (b) allows the names and quantities of active ingredients to be printed on the side panel in a 2.5mm text size when the kit contains four or more medicines, so this does not affect the expiry date requirement from (g)."
                },
                {
                    "Question": "Given a kit that contains multiple non-prescription medicines, where should the warning statements relating to the medicines within the kit be displayed on the kit label?",
                    "Answer": "The warning statements that relate to any of the medicines within the kit should be displayed on the kit label itself.",
                    "Answer Explanation": "Context (h) directly states that any warning statements that relate to any of the medicines within the kit must be included on the kit label."
                },
                {
                    "Question": "Assuming a medicine kit contains five different medicines, and section 8(2) does not apply, what is the minimum allowed text size for printing the active ingredient names and quantities on either a side or rear panel of the kit label?",
                    "Answer": "When a medicine kit contains four or more active ingredients and section 8(2) does not apply, the minimum allowed text size for printing the active ingredient names and quantities on a side panel, side label, rear panel or rear label is 2.5 millimeters.",
                    "Answer Explanation": "Context (b) specifies that where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimeters."
                },
                {
                    "Question": "If a medicine kit includes both prescription and non-prescription medicines, which expiry date should be printed on the main kit label, assuming the contexts provided form a complete set of relevant regulations?",
                    "Answer": "There is not enough information provided in the given contexts to determine the expiry date labeling requirements for a kit that contains both prescription and non-prescription medicines. The contexts appear to be part of a broader regulation that is specific to labeling of non-prescription medicine kits only.",
                    "Answer Explanation": "The \"About this compilation\" context suggests the given contexts are part of a more extensive regulation specifically about non-prescription medicine labeling. Context (g) refers to an expiry date requirement for the kit based on the earliest expiry of the medicines within the kit, but does not specify whether this applies to kits with both prescription and non-prescription medicines. More context from the full regulation would be needed to definitively answer the question for a mixed prescription and non-prescription medicine kit."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a first aid kit contains four medicines, each with different expiry dates, and the kit label lists the names and quantities of the active ingredients on the side panel in a text size of 2.5 millimeters, what expiry date must be printed on the kit label?\", \"Answer\": \"The expiry date printed on the kit label must be the earliest expiry date out of the four medicines contained in the kit.\", \"Answer Explanation\": \"According to context (g), the expiry date for the kit must be the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix. Context (b) allows the names and quantities of active ingredients to be printed on the side panel in a 2.5mm text size when the kit contains four or more medicines, so this does not affect the expiry date requirement from (g).\"}, {\"Question\": \"Given a kit that contains multiple non-prescription medicines, where should the warning statements relating to the medicines within the kit be displayed on the kit label?\", \"Answer\": \"The warning statements that relate to any of the medicines within the kit should be displayed on the kit label itself.\", \"Answer Explanation\": \"Context (h) directly states that any warning statements that relate to any of the medicines within the kit must be included on the kit label.\"}, {\"Question\": \"Assuming a medicine kit contains five different medicines, and section 8(2) does not apply, what is the minimum allowed text size for printing the active ingredient names and quantities on either a side or rear panel of the kit label?\", \"Answer\": \"When a medicine kit contains four or more active ingredients and section 8(2) does not apply, the minimum allowed text size for printing the active ingredient names and quantities on a side panel, side label, rear panel or rear label is 2.5 millimeters.\", \"Answer Explanation\": \"Context (b) specifies that where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimeters.\"}, {\"Question\": \"If a medicine kit includes both prescription and non-prescription medicines, which expiry date should be printed on the main kit label, assuming the contexts provided form a complete set of relevant regulations?\", \"Answer\": \"There is not enough information provided in the given contexts to determine the expiry date labeling requirements for a kit that contains both prescription and non-prescription medicines. The contexts appear to be part of a broader regulation that is specific to labeling of non-prescription medicine kits only.\", \"Answer Explanation\": \"The \\\"About this compilation\\\" context suggests the given contexts are part of a more extensive regulation specifically about non-prescription medicine labeling. Context (g) refers to an expiry date requirement for the kit based on the earliest expiry of the medicines within the kit, but does not specify whether this applies to kits with both prescription and non-prescription medicines. More context from the full regulation would be needed to definitively answer the question for a mixed prescription and non-prescription medicine kit.\"}]}"
    },
    {
        "path": [
            914000000,
            601070000,
            601400000,
            908040000,
            907000000
        ],
        "contexts": [
            " (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028.",
            "\"batch number prefix\" means the prefix which precedes the batch number and has the following characteristics: (a) clearly indicates that the information following the prefix is the batch number; and (b) is in the following form: \\\"BATCH NUMBER\\\", \\\"BATCH NO.\\\", \\\"BATCH\\\", \\\"B\\\", \\\"(B)\\\", \\\"B\/N\\\", \\\"LOT NUMBER\\\", \\\"LOT NO.\\\", or \\\"LOT\\\", or words or symbols to this effect, including a mixture of lower and upper case letters;",
            "\"name of an active ingredient\" means: (a) the name of the active ingredient that is accepted for inclusion in the Australian Approved Names List; or (b) where the ingredient is a homoeopathic preparation: (i) either the name of the active ingredient, or the substance from which the dilution was prepared, that is accepted for inclusion in the Australian Approved Names List, together with a statement of the homoeopathic potency; or (ii) until such time as a name is accepted for inclusion in the Australian Approved Names List, a traditional homoeopathic name in full or as traditionally abbreviated with a statement of the homoeopathic potency;",
            " (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
            " (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains an active ingredient listed in Part 2 of Schedule 2 and is released for supply on or after 1 May 2028, what name must be used for the active ingredient on the main label of the medicine?",
                    "Answer": "The name specified in the Australian Approved Names List must be used for the active ingredient on the main label.",
                    "Answer Explanation": "According to context (14), for a medicine containing an active ingredient specified in Part 2 of Schedule 2 that is released for supply on or after 1 May 2028, the name of the active ingredient included on the main label must be in accordance with the Australian Approved Names List."
                },
                {
                    "Question": "For a registered medicine in a composite pack with multiple formulations, how must the batch number prefix information be provided according to subsections 9(6)(b), 9(7), and 9(9)?",
                    "Answer": "The batch number prefix information must be provided separately for each formulation of medicine in the composite pack.",
                    "Answer Explanation": "Context (d) states that for a composite pack with multiple medicine formulations, the information required under 9(6)(b) or 9(7) must be provided separately for each formulation. The definition of 'batch number prefix' is given in another context. Subsection 9(7) applies specifically to registered goods, subject to 9(9). Putting these pieces together, for a registered composite pack medicine, the batch number prefix must be listed separately for each formulation in the pack."
                },
                {
                    "Question": "Assuming a homeopathic medicine's active ingredient does not yet have a name accepted in the Australian Approved Names List, what name can be used for the active ingredient according to the provided definition of 'name of an active ingredient'?",
                    "Answer": "A traditional homeopathic name, either in full or as traditionally abbreviated, along with a statement of the homeopathic potency can be used for the active ingredient name.",
                    "Answer Explanation": "The definition of 'name of an active ingredient' states that for a homeopathic preparation, if the active ingredient name is not yet accepted in the Australian Approved Names List, a traditional homeopathic name in full or as traditionally abbreviated with a statement of the homeopathic potency can be used."
                },
                {
                    "Question": "Consider a registered homeopathic medicine in a composite pack with multiple formulations released for supply after 1 May 2028. The homeopathic preparations contain active ingredients listed in Part 2 of Schedule 2, but the ingredient names are not yet in the Australian Approved Names List. How should the active ingredient names and batch number information be listed on the main label?",
                    "Answer": "For each formulation in the composite pack, the active ingredient should be listed on the main label using either the full traditional homeopathic name or traditional abbreviation, along with a statement of homeopathic potency. The batch number prefix information must be provided separately for each formulation in the pack.",
                    "Answer Explanation": "Context (14) requires active ingredients in Part 2 Schedule 2 to use the name in the Australian Approved Names List on the main label for medicines released after 1 May 2028. However, the definition of 'name of an active ingredient' allows using a traditional homeopathic name with potency if the name is not yet in the Australian Approved Names List. Context (d) requires listing the batch number prefix separately for each formulation in a composite pack medicine, which context (7) notes applies to registered goods like this example, subject to 9(9). Combining the relevant portions of all the contexts provided leads to this answer."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains an active ingredient listed in Part 2 of Schedule 2 and is released for supply on or after 1 May 2028, what name must be used for the active ingredient on the main label of the medicine?\",\n    \"Answer\": \"The name specified in the Australian Approved Names List must be used for the active ingredient on the main label.\",\n    \"Answer Explanation\": \"According to context (14), for a medicine containing an active ingredient specified in Part 2 of Schedule 2 that is released for supply on or after 1 May 2028, the name of the active ingredient included on the main label must be in accordance with the Australian Approved Names List.\"\n  },\n  {\n    \"Question\": \"For a registered medicine in a composite pack with multiple formulations, how must the batch number prefix information be provided according to subsections 9(6)(b), 9(7), and 9(9)?\",\n    \"Answer\": \"The batch number prefix information must be provided separately for each formulation of medicine in the composite pack.\",\n    \"Answer Explanation\": \"Context (d) states that for a composite pack with multiple medicine formulations, the information required under 9(6)(b) or 9(7) must be provided separately for each formulation. The definition of 'batch number prefix' is given in another context. Subsection 9(7) applies specifically to registered goods, subject to 9(9). Putting these pieces together, for a registered composite pack medicine, the batch number prefix must be listed separately for each formulation in the pack.\"\n  },\n  {\n    \"Question\": \"Assuming a homeopathic medicine's active ingredient does not yet have a name accepted in the Australian Approved Names List, what name can be used for the active ingredient according to the provided definition of 'name of an active ingredient'?\",\n    \"Answer\": \"A traditional homeopathic name, either in full or as traditionally abbreviated, along with a statement of the homeopathic potency can be used for the active ingredient name.\",\n    \"Answer Explanation\": \"The definition of 'name of an active ingredient' states that for a homeopathic preparation, if the active ingredient name is not yet accepted in the Australian Approved Names List, a traditional homeopathic name in full or as traditionally abbreviated with a statement of the homeopathic potency can be used.\"\n  },\n  {\n    \"Question\": \"Consider a registered homeopathic medicine in a composite pack with multiple formulations released for supply after 1 May 2028. The homeopathic preparations contain active ingredients listed in Part 2 of Schedule 2, but the ingredient names are not yet in the Australian Approved Names List. How should the active ingredient names and batch number information be listed on the main label?\",\n    \"Answer\": \"For each formulation in the composite pack, the active ingredient should be listed on the main label using either the full traditional homeopathic name or traditional abbreviation, along with a statement of homeopathic potency. The batch number prefix information must be provided separately for each formulation in the pack.\",\n    \"Answer Explanation\": \"Context (14) requires active ingredients in Part 2 Schedule 2 to use the name in the Australian Approved Names List on the main label for medicines released after 1 May 2028. However, the definition of 'name of an active ingredient' allows using a traditional homeopathic name with potency if the name is not yet in the Australian Approved Names List. Context (d) requires listing the batch number prefix separately for each formulation in a composite pack medicine, which context (7) notes applies to registered goods like this example, subject to 9(9). Combining the relevant portions of all the contexts provided leads to this answer.\"\n  }\n]}"
    },
    {
        "path": [
            903030000,
            901020000,
            501120000,
            903020000,
            1105000000
        ],
        "contexts": [
            " (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
            " (b) the name(s) of all active ingredients in the medicine; and",
            "(l) supplied, in the course of treating a patient, by a health professional in the lawful practice of his or her profession; or",
            " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either:"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assume a non-prescription medicine is supplied in a small container and contains multiple active ingredients. How should the names and quantities of the active ingredients be presented on the label to comply with the regulations?",
                    "Answer": "The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text.",
                    "Answer Explanation": "According to context (c), if a medicine is supplied in a small or medium container and contains multiple active ingredients, the names and quantities of the active ingredients may be presented together on a continuous line or lines of text to comply with paragraph 9(3)(a) of the regulations."
                },
                {
                    "Question": "Assume a non-prescription medicine label must include the names of all active ingredients. How should this information be presented in relation to other required or permitted information on the label?",
                    "Answer": "The names of all active ingredients must not be separated by any text or graphics, with some specific exceptions.",
                    "Answer Explanation": "Context (b) states that the label must include the names of all active ingredients. Context (b) under a different section specifies that the names of active ingredients must not be separated by any text or graphics, except where additional information is required or permitted by specific paragraphs and subsections, or in relation to identifying different formulations in composite packs or medicine kits."
                },
                {
                    "Question": "Assume a non-prescription medicine contains an active ingredient that is a vitamin. How may the common name of the vitamin be presented on the main label?",
                    "Answer": "The word 'vitamin' or a suitable unambiguous abbreviation, together with the common name of the vitamin, may appear on the main label either before or after the name of the active ingredient.",
                    "Answer Explanation": "According to context (5), where a non-prescription medicine contains an active ingredient that is a vitamin, the word 'vitamin' or a suitable abbreviation, along with the vitamin's common name, may appear on the main label either before or after the name of the active ingredient, as stated in context (b)."
                },
                {
                    "Question": "Assume a health professional is treating a patient and supplies them with a non-prescription medicine in the lawful practice of their profession. Do the label requirements regarding the names and quantities of active ingredients still apply in this case?",
                    "Answer": "No, the label requirements do not apply in this case.",
                    "Answer Explanation": "Context (l) states that the regulations do not apply if the medicine is supplied by a health professional in the course of treating a patient, in the lawful practice of their profession. Therefore, the requirements in context (b) about including the names of all active ingredients and in context (c) about presenting the names and quantities of multiple active ingredients do not apply in this situation."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assume a non-prescription medicine is supplied in a small container and contains multiple active ingredients. How should the names and quantities of the active ingredients be presented on the label to comply with the regulations?\",\n    \"Answer\": \"The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text.\",\n    \"Answer Explanation\": \"According to context (c), if a medicine is supplied in a small or medium container and contains multiple active ingredients, the names and quantities of the active ingredients may be presented together on a continuous line or lines of text to comply with paragraph 9(3)(a) of the regulations.\"\n  },\n  {\n    \"Question\": \"Assume a non-prescription medicine label must include the names of all active ingredients. How should this information be presented in relation to other required or permitted information on the label?\",\n    \"Answer\": \"The names of all active ingredients must not be separated by any text or graphics, with some specific exceptions.\",\n    \"Answer Explanation\": \"Context (b) states that the label must include the names of all active ingredients. Context (b) under a different section specifies that the names of active ingredients must not be separated by any text or graphics, except where additional information is required or permitted by specific paragraphs and subsections, or in relation to identifying different formulations in composite packs or medicine kits.\"\n  },\n  {\n    \"Question\": \"Assume a non-prescription medicine contains an active ingredient that is a vitamin. How may the common name of the vitamin be presented on the main label?\",\n    \"Answer\": \"The word 'vitamin' or a suitable unambiguous abbreviation, together with the common name of the vitamin, may appear on the main label either before or after the name of the active ingredient.\",\n    \"Answer Explanation\": \"According to context (5), where a non-prescription medicine contains an active ingredient that is a vitamin, the word 'vitamin' or a suitable abbreviation, along with the vitamin's common name, may appear on the main label either before or after the name of the active ingredient, as stated in context (b).\"\n  },\n  {\n    \"Question\": \"Assume a health professional is treating a patient and supplies them with a non-prescription medicine in the lawful practice of their profession. Do the label requirements regarding the names and quantities of active ingredients still apply in this case?\",\n    \"Answer\": \"No, the label requirements do not apply in this case.\",\n    \"Answer Explanation\": \"Context (l) states that the regulations do not apply if the medicine is supplied by a health professional in the course of treating a patient, in the lawful practice of their profession. Therefore, the requirements in context (b) about including the names of all active ingredients and in context (c) about presenting the names and quantities of multiple active ingredients do not apply in this situation.\"\n  }\n]}"
    },
    {
        "path": [
            1102060000,
            601430103,
            401020010,
            1102070000,
            1102060000
        ],
        "contexts": [
            " (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;",
            "(iii) the dosage form (except where this is integral to differentiate medicines from other medicines);",
            "(i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or",
            " (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;",
            " (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming that Therapeutic Goods Order No. 69 is currently in effect, what are the general requirements for medicine labels according to the given regulation sections?",
                    "Answer": "Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69) specifies the general requirements for medicine labels until 30 June 2017 (inclusive), according to regulation section (i).",
                    "Answer Explanation": "The answer is directly stated in regulation section (i), which indicates that TGO 69 defines the general label requirements for medicines up until the specified date of 30 June 2017. No other regulation sections are needed to answer the question, given the stated assumption that TGO 69 is currently in effect."
                },
                {
                    "Question": "For a nasal spray product where the Secretary has accepted the clinically established dose as the metered dose during registration, how should the quantity of active ingredient be expressed on the label, based only on the provided regulation sections?",
                    "Answer": "For a nasal spray product where the Secretary has accepted the clinically established dose as the metered dose during registration, the quantity of the active ingredient should be expressed as the quantity metered per actuation, according to regulation section (f)(ii).",
                    "Answer Explanation": "Regulation section (f) specifies labeling requirements for pressurized metered dose inhalers, dry powder inhalers, and other metered dose products such as nasal sprays. Subsection (ii) states that if the Secretary has accepted the clinically established dose as the metered dose during registration, then the quantity of active ingredient should be expressed as the quantity metered per actuation. No other regulation sections are required to answer the question for the specific case of a nasal spray meeting the stated condition."
                },
                {
                    "Question": "Assuming a topical cream product does not meet the conditions in paragraph (f), how should the quantity of active ingredient be expressed on the label according to the given regulation sections?",
                    "Answer": "For a topical cream product that does not meet the conditions in paragraph (f), the quantity of active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate, according to regulation section (g).",
                    "Answer Explanation": "Regulation section (g) specifies that for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f), the quantity of active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine. Paragraph (f) does not apply to topical creams, so section (g) provides the relevant labeling requirement for the stated product type."
                },
                {
                    "Question": "Based only on the given regulation sections, is the dosage form required to be included on the label for differentiating between medicines?",
                    "Answer": "No, according to regulation section (iii), the dosage form is not required on the label when it is integral to differentiate medicines from other medicines.",
                    "Answer Explanation": "Regulation section (iii) directly states that the dosage form is not required on the label in cases where the dosage form itself serves to differentiate the medicine from other medicines. No other regulation sections contradict or expand upon this requirement, so section (iii) alone is sufficient to answer the question."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming that Therapeutic Goods Order No. 69 is currently in effect, what are the general requirements for medicine labels according to the given regulation sections?\",\n    \"Answer\": \"Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69) specifies the general requirements for medicine labels until 30 June 2017 (inclusive), according to regulation section (i).\",\n    \"Answer Explanation\": \"The answer is directly stated in regulation section (i), which indicates that TGO 69 defines the general label requirements for medicines up until the specified date of 30 June 2017. No other regulation sections are needed to answer the question, given the stated assumption that TGO 69 is currently in effect.\"\n  },\n  {\n    \"Question\": \"For a nasal spray product where the Secretary has accepted the clinically established dose as the metered dose during registration, how should the quantity of active ingredient be expressed on the label, based only on the provided regulation sections?\",\n    \"Answer\": \"For a nasal spray product where the Secretary has accepted the clinically established dose as the metered dose during registration, the quantity of the active ingredient should be expressed as the quantity metered per actuation, according to regulation section (f)(ii).\",\n    \"Answer Explanation\": \"Regulation section (f) specifies labeling requirements for pressurized metered dose inhalers, dry powder inhalers, and other metered dose products such as nasal sprays. Subsection (ii) states that if the Secretary has accepted the clinically established dose as the metered dose during registration, then the quantity of active ingredient should be expressed as the quantity metered per actuation. No other regulation sections are required to answer the question for the specific case of a nasal spray meeting the stated condition.\"\n  },\n  {\n    \"Question\": \"Assuming a topical cream product does not meet the conditions in paragraph (f), how should the quantity of active ingredient be expressed on the label according to the given regulation sections?\",\n    \"Answer\": \"For a topical cream product that does not meet the conditions in paragraph (f), the quantity of active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate, according to regulation section (g).\",\n    \"Answer Explanation\": \"Regulation section (g) specifies that for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f), the quantity of active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine. Paragraph (f) does not apply to topical creams, so section (g) provides the relevant labeling requirement for the stated product type.\"\n  },\n  {\n    \"Question\": \"Based only on the given regulation sections, is the dosage form required to be included on the label for differentiating between medicines?\",\n    \"Answer\": \"No, according to regulation section (iii), the dosage form is not required on the label when it is integral to differentiate medicines from other medicines.\",\n    \"Answer Explanation\": \"Regulation section (iii) directly states that the dosage form is not required on the label in cases where the dosage form itself serves to differentiate the medicine from other medicines. No other regulation sections contradict or expand upon this requirement, so section (iii) alone is sufficient to answer the question.\"\n  }\n]}"
    },
    {
        "path": [
            501000000,
            903000000,
            1006030000,
            301000000,
            500000000
        ],
        "contexts": [
            " This Order does not apply to a medicine that is:",
            " (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:",
            " (c) the name of each of the medicines within the kit and its dosage form;",
            "(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
            "5 Exemptions \u2013 Medicines to which this Order does not apply "
        ],
        "result_dict": {},
        "result_str": "Here is my attempt at generating 4 multi-hop questions and answers based on the given regulation sections:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine kit contains multiple medicines with different dosage forms, what information must be included on the label for each medicine in the kit according to section (c)?\",\n      \"Answer\": \"The name and dosage form of each medicine within the kit.\",\n      \"Answer Explanation\": \"Section (c) states 'the name of each of the medicines within the kit and its dosage form;' must be included on the label for medicine kits containing multiple medicines.\"\n    },\n    {\n      \"Question\": \"For a non-prescription medicine supplied in Australia, what two key pieces of information must be included on the main label according to section (3), assuming no exceptions apply?\", \n      \"Answer\": \"The name of the medicine and the name(s) of active ingredient(s).\",\n      \"Answer Explanation\": \"Section (3) states that 'Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:' be included, indicating these are required label elements for medicines this Order applies to, which section (1) defines as medicines supplied in Australia unless exempted under section 3 of Therapeutic Goods Order No. 91.\"\n    },\n    {\n      \"Question\": \"If a medicine is subject to Therapeutic Goods Order No. 91 section 3, does this Therapeutic Goods Order apply to it when the medicine is supplied in Australia?\",\n      \"Answer\": \"No, this Order does not apply to medicines specified under section 3 of Therapeutic Goods Order No. 91, even if the medicine is supplied in Australia.\",\n      \"Answer Explanation\": \"Section (1) states this Order applies to medicines supplied in Australia, but provides an exception, stating it does not apply to 'those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.' Section 5 further clarifies that this Order does not apply to medicines outlined in section 3.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is not mentioned in any of the contexts provided, can we conclusively determine whether this Order applies to the medicine?\",\n      \"Answer\": \"No, it cannot be conclusively determined from the given contexts alone whether this Order would apply to a medicine not explicitly mentioned.\",\n      \"Answer Explanation\": \"The contexts provide some conditions for when this Order does or does not apply, but do not give an exhaustive list. Section 5 refers to exemptions in section 3, and section (1) refers to section 3 of Therapeutic Goods Order No. 91, but the full text of those sections is not provided. Therefore, a medicine not mentioned could still potentially be exempt based on the full criteria outlined in those sections.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            903020000,
            601440000,
            601450000,
            1007000000,
            1001000000
        ],
        "contexts": [
            " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            "\"Poisons Standard\" means the current Poisons Standard as defined in section 52A of the Act;",
            "\"primary pack\" has the same meaning as in the Act;",
            " (7) Small containers If:",
            " (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a preparation for ophthalmic use and is in a small container, what label requirements apply according to the given regulation sections?",
                    "Answer": "The label must meet the requirements in sections 8, 9, 10(7), and 11(1).",
                    "Answer Explanation": "Since the medicine is for ophthalmic use, section 11(1) states the label requirements in sections 8 and 9 apply, in addition to specifying the medicine is for ophthalmic use. As it is in a small container, section 10(7) also applies. So the label must meet all the requirements laid out in 8, 9, 10(7) and 11(1)."
                },
                {
                    "Question": "Based on the provided regulation sections, how must the required statements on a label be separated if additional permitted information is included from paragraph 11(2)(h)?",
                    "Answer": "The required statements must not be separated by any text or graphics, except the additional permitted information from 11(2)(h).",
                    "Answer Explanation": "Section 11(3)(b) states that required statements must not be separated by any text or graphics, with a few exceptions. One exception listed in 11(3)(b)(i)(A) is additional information permitted by paragraph 11(2)(h). So 11(2)(h) information is allowed to separate required label statements."
                },
                {
                    "Question": "Under the definitions provided in the given regulation sections, what is the meaning of 'primary pack' and how does it relate to the term's usage in the Act?",
                    "Answer": "The term 'primary pack' has the same meaning in these regulations as it does in the Act.",
                    "Answer Explanation": "One of the provided definitions states that 'primary pack' has the same meaning as in the Act. So for the purposes of these regulations, the meaning of 'primary pack' is explicitly linked to and matches the definition provided in the referenced Act."
                },
                {
                    "Question": "Assuming a medicine label must include additional information to identify different formulations in a composite pack, can this information separate the required statements on the label?",
                    "Answer": "Yes, information to identify different formulations in a composite pack is permitted to separate required label statements.",
                    "Answer Explanation": "Section 11(3)(b) generally prohibits required label statements from being separated. However, 11(3)(b)(ii) provides an exception that allows separating statements with information to identify different formulations of medicines in a composite pack. So this identifying information may separate required statements on the label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a preparation for ophthalmic use and is in a small container, what label requirements apply according to the given regulation sections?\", \"Answer\": \"The label must meet the requirements in sections 8, 9, 10(7), and 11(1).\", \"Answer Explanation\": \"Since the medicine is for ophthalmic use, section 11(1) states the label requirements in sections 8 and 9 apply, in addition to specifying the medicine is for ophthalmic use. As it is in a small container, section 10(7) also applies. So the label must meet all the requirements laid out in 8, 9, 10(7) and 11(1).\"}, {\"Question\": \"Based on the provided regulation sections, how must the required statements on a label be separated if additional permitted information is included from paragraph 11(2)(h)?\", \"Answer\": \"The required statements must not be separated by any text or graphics, except the additional permitted information from 11(2)(h).\", \"Answer Explanation\": \"Section 11(3)(b) states that required statements must not be separated by any text or graphics, with a few exceptions. One exception listed in 11(3)(b)(i)(A) is additional information permitted by paragraph 11(2)(h). So 11(2)(h) information is allowed to separate required label statements.\"}, {\"Question\": \"Under the definitions provided in the given regulation sections, what is the meaning of 'primary pack' and how does it relate to the term's usage in the Act?\", \"Answer\": \"The term 'primary pack' has the same meaning in these regulations as it does in the Act.\", \"Answer Explanation\": \"One of the provided definitions states that 'primary pack' has the same meaning as in the Act. So for the purposes of these regulations, the meaning of 'primary pack' is explicitly linked to and matches the definition provided in the referenced Act.\"}, {\"Question\": \"Assuming a medicine label must include additional information to identify different formulations in a composite pack, can this information separate the required statements on the label?\", \"Answer\": \"Yes, information to identify different formulations in a composite pack is permitted to separate required label statements.\", \"Answer Explanation\": \"Section 11(3)(b) generally prohibits required label statements from being separated. However, 11(3)(b)(ii) provides an exception that allows separating statements with information to identify different formulations of medicines in a composite pack. So this identifying information may separate required statements on the label.\"}]}"
    },
    {
        "path": [
            801070000,
            401020010,
            101000006,
            403000000,
            402000000
        ],
        "contexts": [
            " (g) the expiry date of the medicine, preceded by the expiry date prefix; and",
            "(i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or",
            "(6) Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au).",
            "(3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017).",
            "(2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine was imported into Australia on 1 August 2020 and supplied by someone other than the sponsor on 1 October 2020, which Therapeutic Goods Order must the medicine comply with?",
                    "Answer": "The medicine must comply with TGO 69 (2017).",
                    "Answer Explanation": "According to context (3), medicines imported into Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine was imported on 1 August 2020 (before 1 September 2020) and supplied on 1 October 2020 (after 1 September 2020) by someone other than the sponsor, it must comply with TGO 69 (2017)."
                },
                {
                    "Question": "Assuming a medicine is manufactured in Australia on 1 September 2020, which requirements specified in the Order must the medicine comply with?",
                    "Answer": "The medicine must comply with the requirements specified in this Order.",
                    "Answer Explanation": "According to context (2), on and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. Since the medicine is manufactured in Australia on 1 September 2020, it must comply with the requirements specified in this Order."
                },
                {
                    "Question": "What information must be included on the label of a medicine, and where can guidelines to assist in the design of medicine labels be found?",
                    "Answer": "The label of a medicine must include the expiry date of the medicine, preceded by the expiry date prefix. Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au).",
                    "Answer Explanation": "According to context (g), the expiry date of the medicine, preceded by the expiry date prefix, must be included on the label of a medicine. Context (6) states that guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au)."
                },
                {
                    "Question": "Assuming a medicine was manufactured in Australia on 1 July 2017, which Therapeutic Goods Order was in effect at that time?",
                    "Answer": "Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69) was in effect until 30 June 2017 (inclusive).",
                    "Answer Explanation": "According to context (i), Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69) was in effect up until 30 June 2017 (inclusive). Since the medicine was manufactured on 1 July 2017, TGO 69 was no longer in effect at that time."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine was imported into Australia on 1 August 2020 and supplied by someone other than the sponsor on 1 October 2020, which Therapeutic Goods Order must the medicine comply with?\", \"Answer\": \"The medicine must comply with TGO 69 (2017).\", \"Answer Explanation\": \"According to context (3), medicines imported into Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine was imported on 1 August 2020 (before 1 September 2020) and supplied on 1 October 2020 (after 1 September 2020) by someone other than the sponsor, it must comply with TGO 69 (2017).\"}, {\"Question\": \"Assuming a medicine is manufactured in Australia on 1 September 2020, which requirements specified in the Order must the medicine comply with?\", \"Answer\": \"The medicine must comply with the requirements specified in this Order.\", \"Answer Explanation\": \"According to context (2), on and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. Since the medicine is manufactured in Australia on 1 September 2020, it must comply with the requirements specified in this Order.\"}, {\"Question\": \"What information must be included on the label of a medicine, and where can guidelines to assist in the design of medicine labels be found?\", \"Answer\": \"The label of a medicine must include the expiry date of the medicine, preceded by the expiry date prefix. Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au).\", \"Answer Explanation\": \"According to context (g), the expiry date of the medicine, preceded by the expiry date prefix, must be included on the label of a medicine. Context (6) states that guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au).\"}, {\"Question\": \"Assuming a medicine was manufactured in Australia on 1 July 2017, which Therapeutic Goods Order was in effect at that time?\", \"Answer\": \"Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69) was in effect until 30 June 2017 (inclusive).\", \"Answer Explanation\": \"According to context (i), Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69) was in effect up until 30 June 2017 (inclusive). Since the medicine was manufactured on 1 July 2017, TGO 69 was no longer in effect at that time.\"}]}"
    },
    {
        "path": [
            1006070000,
            914000000,
            801150000,
            1008030000,
            900000000
        ],
        "contexts": [
            " (g) an expiry date for the kit, being the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix;",
            " (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028.",
            " (o) if the medicine is contained in an ampoule, a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.",
            " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " 9 Information to be included on the main label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine kit contains multiple medicines with different expiry dates, and the kit itself must display an expiry date, what expiry date should be shown on the kit label?",
                    "Answer": "The expiry date displayed on the kit label should be the earliest expiry date of the medicines within the kit.",
                    "Answer Explanation": "According to section (g), the expiry date for the kit must be the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix."
                },
                {
                    "Question": "Assuming a medicine contains an active ingredient specified in Part 2 of Schedule 2 and is released for supply on or after 1 May 2028, where must the active ingredient name be included according to the Australian Approved Names List?",
                    "Answer": "The active ingredient must be included on the main label of the medicine.",
                    "Answer Explanation": "Section (14) states that an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028. Section 9 further specifies that this information is to be included on the main label."
                },
                {
                    "Question": "Assuming a medicine is contained in an ampoule, what statement must be included on the label regarding the route of administration?",
                    "Answer": "The label must include a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only' or other phrase, word or abbreviation denoting the approved route(s) of administration.",
                    "Answer Explanation": "Section (o) requires that if the medicine is contained in an ampoule, the label must include a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only' or other phrase, word or abbreviation denoting the approved route(s) of administration."
                },
                {
                    "Question": "Assuming a medicine consists of dry herbs contained in individual bags that are retained around the herbs during preparation, and the bags are contained in a primary pack with a label that complies with sections 8 and 9, what labelling requirements apply to the individual herb bags?",
                    "Answer": "The individual bags containing the dry herbs do not need to be labelled with the information referred to in sections 8 and 9.",
                    "Answer Explanation": "Section (c) states that where a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and the bags are in a primary pack with a label complying with sections 8 and 9, then the individual bags need not be labelled with the information from sections 8 and 9."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine kit contains multiple medicines with different expiry dates, and the kit itself must display an expiry date, what expiry date should be shown on the kit label?\",\n    \"Answer\": \"The expiry date displayed on the kit label should be the earliest expiry date of the medicines within the kit.\",\n    \"Answer Explanation\": \"According to section (g), the expiry date for the kit must be the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine contains an active ingredient specified in Part 2 of Schedule 2 and is released for supply on or after 1 May 2028, where must the active ingredient name be included according to the Australian Approved Names List?\",\n    \"Answer\": \"The active ingredient must be included on the main label of the medicine.\",\n    \"Answer Explanation\": \"Section (14) states that an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028. Section 9 further specifies that this information is to be included on the main label.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is contained in an ampoule, what statement must be included on the label regarding the route of administration?\",\n    \"Answer\": \"The label must include a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only' or other phrase, word or abbreviation denoting the approved route(s) of administration.\",\n    \"Answer Explanation\": \"Section (o) requires that if the medicine is contained in an ampoule, the label must include a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only' or other phrase, word or abbreviation denoting the approved route(s) of administration.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine consists of dry herbs contained in individual bags that are retained around the herbs during preparation, and the bags are contained in a primary pack with a label that complies with sections 8 and 9, what labelling requirements apply to the individual herb bags?\",\n    \"Answer\": \"The individual bags containing the dry herbs do not need to be labelled with the information referred to in sections 8 and 9.\",\n    \"Answer Explanation\": \"Section (c) states that where a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and the bags are in a primary pack with a label complying with sections 8 and 9, then the individual bags need not be labelled with the information from sections 8 and 9.\"\n  }\n]}"
    },
    {
        "path": [
            1100000000,
            1008010000,
            601360000,
            1103030000,
            1103020000
        ],
        "contexts": [
            " 11 How information is to be expressed",
            " (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories, single doses of a powder, single doses of a liquid, or a transdermal patch; and (ii) each dosage unit is enclosed in an individual wrapper or blister, whether sealed or unsealed; and (iii) one or more dosage units are enclosed in a primary pack; and (iv) the label on the primary pack complies with sections 8 and 9, then, in relation to compliance of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            "\"medicine\" has the same meaning as in the Act;",
            " (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
            " (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine consists of individual dosage units enclosed in a primary pack whose label complies with sections 8 and 9, what information must be displayed on the label of each individual wrapper or blister of the dosage units to be sufficient for compliance with sections 8 and 9?",
                    "Answer": "The name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies them.",
                    "Answer Explanation": "Section 11(a) states that if a medicine consists of individual dosage units enclosed in individual wrappers or blisters, and one or more dosage units are in a primary pack whose label complies with sections 8 and 9, then for the individual wrappers\/blisters to comply with sections 8 and 9 it is sufficient to display the information listed in 11(a)(v)-(x), which is the name of the medicine, names and quantity\/proportion of active ingredients, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark."
                },
                {
                    "Question": "Assuming a medicine has multiple active ingredients that are all homeopathic preparations included in the same proportion, how should the quantity or proportion of the active ingredients be expressed on the label according to the given regulation sections?",
                    "Answer": "The quantity or proportion should be expressed as 'Contains equal parts of ...' followed by the name of each active ingredient.",
                    "Answer Explanation": "Section 11(b) specifies that where all active ingredients of a medicine are homeopathic preparations and are all included in the same proportion, the quantity or proportion should be expressed as 'Contains equal parts of ...' followed by the name of each active ingredient. This is an exception to the general requirement in 11(c) to express the quantity of the preparation in one millilitre or one gram of the medicine."
                },
                {
                    "Question": "In the context of section 11, what is the meaning of the term 'medicine' as used throughout the regulation sections?",
                    "Answer": "The term 'medicine' has the same meaning as in the Act that the regulation sections are based on.",
                    "Answer Explanation": "The 'context' section stating ''medicine' has the same meaning as in the Act' clarifies that wherever the term 'medicine' is used in section 11 or the other regulation sections, it carries the same meaning as defined in the governing Act that the regulations are created under."
                },
                {
                    "Question": "Assuming a medicine consists of tablets in a blister pack inside a primary pack, and the active ingredients are not all homeopathic preparations in equal proportion, what information must be on the blister pack label for it to be compliant if the primary pack label is compliant?",
                    "Answer": "The blister pack label must display the name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies them.",
                    "Answer Explanation": "Section 11(a) lists the information that must be on individual wrappers\/blisters for them to comply with sections 8 and 9 if the primary pack label complies. This applies when the medicine has individual dosage units like tablets in wrappers\/blisters inside a primary pack. Section 11(b) provides an exception for expressing the quantity of actives if they are all homeopathic and in equal proportion, but that is not the case here, so 11(a)(v)-(x) and 11(c) apply, requiring the listed information including the quantity of active ingredients per 11(c)."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine consists of individual dosage units enclosed in a primary pack whose label complies with sections 8 and 9, what information must be displayed on the label of each individual wrapper or blister of the dosage units to be sufficient for compliance with sections 8 and 9?\",\n      \"Answer\": \"The name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies them.\",\n      \"Answer Explanation\": \"Section 11(a) states that if a medicine consists of individual dosage units enclosed in individual wrappers or blisters, and one or more dosage units are in a primary pack whose label complies with sections 8 and 9, then for the individual wrappers\/blisters to comply with sections 8 and 9 it is sufficient to display the information listed in 11(a)(v)-(x), which is the name of the medicine, names and quantity\/proportion of active ingredients, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine has multiple active ingredients that are all homeopathic preparations included in the same proportion, how should the quantity or proportion of the active ingredients be expressed on the label according to the given regulation sections?\",\n      \"Answer\": \"The quantity or proportion should be expressed as 'Contains equal parts of ...' followed by the name of each active ingredient.\",\n      \"Answer Explanation\": \"Section 11(b) specifies that where all active ingredients of a medicine are homeopathic preparations and are all included in the same proportion, the quantity or proportion should be expressed as 'Contains equal parts of ...' followed by the name of each active ingredient. This is an exception to the general requirement in 11(c) to express the quantity of the preparation in one millilitre or one gram of the medicine.\"\n    },\n    {\n      \"Question\": \"In the context of section 11, what is the meaning of the term 'medicine' as used throughout the regulation sections?\",\n      \"Answer\": \"The term 'medicine' has the same meaning as in the Act that the regulation sections are based on.\",\n      \"Answer Explanation\": \"The 'context' section stating ''medicine' has the same meaning as in the Act' clarifies that wherever the term 'medicine' is used in section 11 or the other regulation sections, it carries the same meaning as defined in the governing Act that the regulations are created under.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine consists of tablets in a blister pack inside a primary pack, and the active ingredients are not all homeopathic preparations in equal proportion, what information must be on the blister pack label for it to be compliant if the primary pack label is compliant?\",\n      \"Answer\": \"The blister pack label must display the name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies them.\",\n      \"Answer Explanation\": \"Section 11(a) lists the information that must be on individual wrappers\/blisters for them to comply with sections 8 and 9 if the primary pack label complies. This applies when the medicine has individual dosage units like tablets in wrappers\/blisters inside a primary pack. Section 11(b) provides an exception for expressing the quantity of actives if they are all homeopathic and in equal proportion, but that is not the case here, so 11(a)(v)-(x) and 11(c) apply, requiring the listed information including the quantity of active ingredients per 11(c).\"\n    }\n  ]\n}"
    },
    {
        "path": [
            1008030000,
            1102030000,
            401010000,
            601150000,
            801020000
        ],
        "contexts": [
            " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.",
            "(a) the requirements specified in this Order; or",
            "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {},
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a liquid medicine for ingestion comes in a series of strengths containing the same active ingredient, and the stated dose volume is 10 mL with strengths of 2 mg\/mL and 10 mg\/mL, how should the quantity of active ingredient be expressed on the label to comply with the requirements specified in this Order?\", \"Answer\": \"The liquid medicine strengths should be labelled as 20 mg in 10 mL and 100 mg in 10 mL, respectively.\", \"Answer Explanation\": \"According to section (c)(ii), if a liquid medicine for ingestion is one of a series of strengths containing the same active ingredient, the quantity of active ingredient must be expressed consistently across the series in terms of the same stated dose volume. The example given shows that for a dose volume of 5 mL with strengths of 1 mg\/mL and 5 mg\/mL, the labels should read 5 mg in 5 mL and 25 mg in 5 mL, respectively. Applying this to the question where the dose volume is 10 mL and strengths are 2 mg\/mL and 10 mg\/mL, the labels should express the quantities as 20 mg in 10 mL and 100 mg in 10 mL to comply with the requirements specified in section (a).\"}, {\"Question\": \"Assuming a medicine consists of dry herbs in individual bags that are retained during preparation, and these bags are inside a primary pack with a fully compliant label, is it required for the name(s) of all active ingredients to be included on the individual bag labels to meet the critical health information requirements?\", \"Answer\": \"No, the individual bags do not need to include the name(s) of active ingredients on their labels in this case.\", \"Answer Explanation\": \"Section (c) states that where a medicine consists of dry herbs in individual bags that are kept around the herbs during preparation, and these bags are contained in a primary pack with a label that complies with the requirements of this Order, then the individual bags do not need to be labelled with the information referred to in sections 8 and 9. Paragraph 8(1)(b) specifies that the name(s) of all active ingredients in the medicine is required information. However, this is part of the 'critical health information' defined in the Order which falls under section 8. Therefore, since section (c) exempts the individual bags from needing the section 8 information when the conditions are met, the active ingredient names are not required on those labels.\"}, {\"Question\": \"Assuming the name of the active ingredient in a medicine is required to be on the label as per section 8(1)(b), but the primary pack label is missing this information, would having the active ingredient name on the label of the individual dry herb bags inside the primary pack be sufficient to meet the requirements of this Order?\", \"Answer\": \"No, having the active ingredient name only on the individual dry herb bag labels would not be sufficient to meet the requirements in this case.\", \"Answer Explanation\": \"Paragraph 8(1)(b) states that the name(s) of all active ingredients in the medicine is required information on the label. This is part of the 'critical health information' defined in the Order. Section (c) provides an exemption to labelling individual dry herb bags with the section 8 and 9 information only if those bags are contained in a primary pack that has a label complying with all the requirements of this Order. Therefore, if the primary pack label is missing the active ingredient name required by 8(1)(b), the medicine would not comply with the Order requirements per section (a), regardless of that information being on the individual bag labels. The exemption in (c) only applies when the outer primary pack is fully compliant.\"}, {\"Question\": \"Assuming a liquid medicine for ingestion is available in a single strength of 0.5 mg\/mL with a stated dose volume of 10 mL, is expressing the quantity of active ingredient on the label as 0.5 mg\/mL sufficient to meet the requirements of this Order?\", \"Answer\": \"No, expressing the quantity of active ingredient as 0.5 mg\/mL would not be sufficient in this case to meet the requirements.\", \"Answer Explanation\": \"Section (c)(i) specifies that for a liquid medicine for ingestion, the quantity of the active ingredient must be expressed on the label as the amount contained in the stated volume of a suitable dose of the liquid. Here, the stated dose volume is 10 mL,"
    },
    {
        "path": [
            1009030000,
            401010000,
            601570000,
            802060000,
            802050000
        ],
        "contexts": [
            " (c) In addition to the requirements referred to in paragraphs 10(9)(a) and (b) as relevant, if each dosage unit is enclosed in the strip or blister such that an individual segment containing the dosage unit can be readily detached, then the following information must appear on the label of the strip or blister at least once in relation to every two dosage units: (i) for a medicine to which paragraph 10(9)(a) applies \u2013 the name of the medicine, the name(s) of all active ingredients in the medicine and the quantity or proportion of all active ingredients in the medicine; and (ii) for a medicine to which paragraph 10(9)(b) applies \u2013 the name of the medicine.",
            "(a) the requirements specified in this Order; or",
            "\"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;",
            " (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
            " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a bottle of liquid medicine contains 10 individual dosage units, and the sponsor specifies the volume to be 100 mL, what information must appear on the label if each dosage unit is enclosed in a detachable segment of a strip or blister pack?",
                    "Answer": "The name of the medicine must appear on the label at least once in relation to every two dosage units.",
                    "Answer Explanation": "According to context (c), if each dosage unit is enclosed in a strip or blister such that an individual segment containing the dosage unit can be readily detached, the name of the medicine must appear on the label at least once in relation to every two dosage units for a medicine to which paragraph 10(9)(b) applies. The stated volume of fill of 100 mL for 10 dosage units indicates this is a medicine to which paragraph 10(9)(b) applies, based on the definition in context 'stated volume of fill'."
                },
                {
                    "Question": "Assuming a medicine label includes the critical health information and all required information, can additional information about package features to prevent tampering be included on the label? If so, where must it be placed?",
                    "Answer": "Yes, information about package features to prevent tampering can be included on the label. It must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the required headings.",
                    "Answer Explanation": "Context (e) states that if information other than the critical health information or required information is included, it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the required headings. Context (e) specifically allows information about package features to prevent tampering to be included under this 'Other information' section."
                },
                {
                    "Question": "Assuming a medicine label includes the critical health information and some additional information allowed under paragraphs 8(2)(c) and 8(2)(e), what color text and background must be used for presenting this information?",
                    "Answer": "The critical health information and any additional information included under paragraphs 8(2)(c) and 8(2)(e) must be presented in black or other dark colored text, using only one color, on a white or other contrasting background.",
                    "Answer Explanation": "Context (f) specifies that the presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c) or 8(2)(e) that is included, must be presented in black or other dark colored texts, using only one color, on a white or other contrasting background."
                },
                {
                    "Question": "Assuming a medicine label fully complies with all the requirements specified in this Order, is it required to also comply with the requirements referred to in paragraphs 10(9)(a) and (b)?",
                    "Answer": "Yes, in addition to complying with the requirements specified in this Order, the medicine label must also comply with the relevant requirements referred to in paragraphs 10(9)(a) and (b).",
                    "Answer Explanation": "Context (a) indicates that the requirements specified in 'this Order' and the requirements referred to in paragraphs 10(9)(a) and (b) are separate sets of requirements. Context (c) further clarifies that the requirements in paragraphs 10(9)(a) and (b) are 'in addition to' the requirements referred to in the Order. Therefore, full compliance requires meeting both the Order requirements and the relevant paragraph 10(9)(a) or (b) requirements."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a bottle of liquid medicine contains 10 individual dosage units, and the sponsor specifies the volume to be 100 mL, what information must appear on the label if each dosage unit is enclosed in a detachable segment of a strip or blister pack?\", \"Answer\": \"The name of the medicine must appear on the label at least once in relation to every two dosage units.\", \"Answer Explanation\": \"According to context (c), if each dosage unit is enclosed in a strip or blister such that an individual segment containing the dosage unit can be readily detached, the name of the medicine must appear on the label at least once in relation to every two dosage units for a medicine to which paragraph 10(9)(b) applies. The stated volume of fill of 100 mL for 10 dosage units indicates this is a medicine to which paragraph 10(9)(b) applies, based on the definition in context 'stated volume of fill'.\"}, {\"Question\": \"Assuming a medicine label includes the critical health information and all required information, can additional information about package features to prevent tampering be included on the label? If so, where must it be placed?\", \"Answer\": \"Yes, information about package features to prevent tampering can be included on the label. It must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the required headings.\", \"Answer Explanation\": \"Context (e) states that if information other than the critical health information or required information is included, it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the required headings. Context (e) specifically allows information about package features to prevent tampering to be included under this 'Other information' section.\"}, {\"Question\": \"Assuming a medicine label includes the critical health information and some additional information allowed under paragraphs 8(2)(c) and 8(2)(e), what color text and background must be used for presenting this information?\", \"Answer\": \"The critical health information and any additional information included under paragraphs 8(2)(c) and 8(2)(e) must be presented in black or other dark colored text, using only one color, on a white or other contrasting background.\", \"Answer Explanation\": \"Context (f) specifies that the presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c) or 8(2)(e) that is included, must be presented in black or other dark colored texts, using only one color, on a white or other contrasting background.\"}, {\"Question\": \"Assuming a medicine label fully complies with all the requirements specified in this Order, is it required to also comply with the requirements referred to in paragraphs 10(9)(a) and (b)?\", \"Answer\": \"Yes, in addition to complying with the requirements specified in this Order, the medicine label must also comply with the relevant requirements referred to in paragraphs 10(9)(a) and (b).\", \"Answer Explanation\": \"Context (a) indicates that the requirements specified in 'this Order' and the requirements referred to in paragraphs 10(9)(a) and (b) are separate sets of requirements. Context (c) further clarifies that the requirements in paragraphs 10(9)(a) and (b) are 'in addition to' the requirements referred to in the Order. Therefore, full compliance requires meeting both the Order requirements and the relevant paragraph 10(9)(a) or (b) requirements.\"}]}"
    },
    {
        "path": [
            1007040000,
            601390000,
            102000001,
            1005000000,
            800000000
        ],
        "contexts": [
            " (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:",
            "\"name and contact details\" in respect of a sponsor or distributor, means (a) the name of the sponsor or distributor and sufficient information to allow the sponsor or distributor to be uniquely identified so as to facilitate public contact on matters of complaint, use or general enquiry. The contact details must include information such as the city or suburb of the sponsors distributors principal place of business in Australia (not being a post office, cable, telegraphic or code address). The Australian telephone number, website or email address may also be included; or (b) where there has been a change in the sponsors or distributors name or contact details in the previous twelve months, the name and contact details of the previous sponsor or distributor;",
            "This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines.",
            " (5) Sunscreen preparations If:",
            " 8 Information to be included on the label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine has 5 active ingredients, what information about the active ingredients must be included on the label, and what is the minimum text size for this information?",
                    "Answer": "The name of each active ingredient is not required to be listed on the label. No minimum text size is specified for the active ingredient information in this case.",
                    "Answer Explanation": "According to the regulation section (d), the names of all active ingredients are required on the label unless there are four or more active ingredients. Since the question states there are 5 active ingredients, their names are not required. Additionally, the minimum 1.5mm text size mentioned in (d) does not apply to the active ingredient information, only to the other label information listed after the text size requirement."
                },
                {
                    "Question": "If a sponsor of a non-prescription medicine changed their name 6 months ago, what name and contact information must be included on the label based on the definition of 'name and contact details' in the regulation?",
                    "Answer": "The label must include the current name of the sponsor and sufficient information to uniquely identify and contact them, such as the city or suburb of their principal place of business in Australia. The previous sponsor's name and contact details must also be included since the change occurred within the last 12 months.",
                    "Answer Explanation": "The 'name and contact details' definition (a) requires the current sponsor name and contact information sufficient to uniquely identify and contact them, including at minimum their city or suburb in Australia. Part (b) of the definition additionally requires the previous sponsor's name and contact details to be included if the sponsor changed within the last 12 months. Since the question states the change was 6 months ago, both the current and previous sponsor information must be on the label."
                },
                {
                    "Question": "What is the name of this Therapeutic Goods Order, and what products does it apply to based on the information provided?",
                    "Answer": "This is Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines. It applies to labels of non-prescription medicines, as stated in the order's title.",
                    "Answer Explanation": "The regulation context directly states 'This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines.' Therefore, Order 92 is the name, and it applies to labels of non-prescription medicines as specified in the title."
                },
                {
                    "Question": "Section 8 of the regulation refers to 'Information to be included on the label'. Assuming a sunscreen product is a non-prescription medicine, what specific information about that product is required to be on the label based only on the sections provided?",
                    "Answer": "There is insufficient information provided to determine any specific labeling requirements for sunscreen products. The regulation excerpts mention sunscreen preparations in section (5) but do not specify any particular information required on sunscreen labels.",
                    "Answer Explanation": "While section 8 generally refers to 'Information to be included on the label' and section (5) mentions 'Sunscreen preparations', neither section goes on to actually specify any required sunscreen label information. The information cannot be determined from only these excerpts of the regulation, as no labeling requirements for sunscreens are detailed in the limited sections provided."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine has 5 active ingredients, what information about the active ingredients must be included on the label, and what is the minimum text size for this information?\",\n      \"Answer\": \"The name of each active ingredient is not required to be listed on the label. No minimum text size is specified for the active ingredient information in this case.\",\n      \"Answer Explanation\": \"According to the regulation section (d), the names of all active ingredients are required on the label unless there are four or more active ingredients. Since the question states there are 5 active ingredients, their names are not required. Additionally, the minimum 1.5mm text size mentioned in (d) does not apply to the active ingredient information, only to the other label information listed after the text size requirement.\"\n    },\n    {\n      \"Question\": \"If a sponsor of a non-prescription medicine changed their name 6 months ago, what name and contact information must be included on the label based on the definition of 'name and contact details' in the regulation?\",\n      \"Answer\": \"The label must include the current name of the sponsor and sufficient information to uniquely identify and contact them, such as the city or suburb of their principal place of business in Australia. The previous sponsor's name and contact details must also be included since the change occurred within the last 12 months.\",\n      \"Answer Explanation\": \"The 'name and contact details' definition (a) requires the current sponsor name and contact information sufficient to uniquely identify and contact them, including at minimum their city or suburb in Australia. Part (b) of the definition additionally requires the previous sponsor's name and contact details to be included if the sponsor changed within the last 12 months. Since the question states the change was 6 months ago, both the current and previous sponsor information must be on the label.\"\n    },\n    {\n      \"Question\": \"What is the name of this Therapeutic Goods Order, and what products does it apply to based on the information provided?\",\n      \"Answer\": \"This is Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines. It applies to labels of non-prescription medicines, as stated in the order's title.\",\n      \"Answer Explanation\": \"The regulation context directly states 'This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines.' Therefore, Order 92 is the name, and it applies to labels of non-prescription medicines as specified in the title.\"\n    },\n    {\n      \"Question\": \"Section 8 of the regulation refers to 'Information to be included on the label'. Assuming a sunscreen product is a non-prescription medicine, what specific information about that product is required to be on the label based only on the sections provided?\",\n      \"Answer\": \"There is insufficient information provided to determine any specific labeling requirements for sunscreen products. The regulation excerpts mention sunscreen preparations in section (5) but do not specify any particular information required on sunscreen labels.\",\n      \"Answer Explanation\": \"While section 8 generally refers to 'Information to be included on the label' and section (5) mentions 'Sunscreen preparations', neither section goes on to actually specify any required sunscreen label information. The information cannot be determined from only these excerpts of the regulation, as no labeling requirements for sunscreens are detailed in the limited sections provided.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            101000001,
            601120000,
            801060000,
            907030000,
            901030000
        ],
        "contexts": [
            "(1) This Order sets out what kinds of information are required to be included on the label of medicines of the kind described in section 3, and in what circumstances.",
            "\"complementary healthcare practitioner\" means a person described in paragraph 42AA(1)(c) of the Act;",
            " (f) the batch number of the medicine preceded by the batch number prefix; and",
            " (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is being labeled in accordance with this Order, which of the following would not be required on the label: the name of the medicine, the quantity of all active ingredients, or the medicine's expiration date?",
                    "Answer": "The medicine's expiration date would not be required on the label.",
                    "Answer Explanation": "This Order sets out labeling requirements for certain non-prescription medicines (section 1). It mandates including the quantity or proportion of all active ingredients (section 1(c)). The name of the medicine is also required via the definition of 'label' in section 3. However, no part of the provided regulation sections mentions an expiration date requirement."
                },
                {
                    "Question": "For a non-prescription medicine with 5 active ingredients, is the label required to include both the quantity and proportion of each ingredient, assuming subsection 8(2) applies? Please state your assumptions.",
                    "Answer": "No, if the medicine has 4 or more active ingredients and subsection 8(2) applies, the label does not need to include both the quantity and proportion of each active ingredient.",
                    "Answer Explanation": "Section 1(c) generally requires the label to include the quantity or proportion of all active ingredients. However, section 1(c) provides an exception - if the medicine contains 4 or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. The question states the medicine has 5 active ingredients and that subsection 8(2) applies, so this exception is met and the label need not include both quantity and proportion of each ingredient."
                },
                {
                    "Question": "Assuming no exceptions apply, which of the following pieces of information are required on the label of a non-prescription medicine according to the provided regulation sections: a description of the medicine, the batch number, or the name of a complementary healthcare practitioner?",
                    "Answer": "The batch number of the medicine preceded by the batch number prefix is required on the label. A description of the medicine and the name of a complementary healthcare practitioner are not required.",
                    "Answer Explanation": "Section 1(f) states that the batch number of the medicine preceded by the batch number prefix must be included on the label. The provided sections do not mention that a general description of the medicine is required. While 'complementary healthcare practitioner' is defined in section 2, the sections do not state that their name must appear on medicine labels."
                },
                {
                    "Question": "Based on the given regulation sections, if a non-prescription medicine label omits the quantity of active ingredients, under what conditions would this be allowed? State any assumptions.",
                    "Answer": "Omitting the quantity of active ingredients on the label would only be allowed if the medicine contains 4 or more active ingredients and subsection 8(2) applies. This assumes no other exceptions are relevant.",
                    "Answer Explanation": "Section 1(c) requires medicine labels to include the quantity or proportion of all active ingredients. However, it also provides an exception in section 1(c) - if there are 4 or more active ingredients and subsection 8(2) applies, then paragraphs 9(1)(b) and 9(1)(c) (which presumably mandate quantity\/proportion labeling) do not need to be followed. No other exceptions to the quantity labeling requirement are mentioned in the provided sections."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine is being labeled in accordance with this Order, which of the following would not be required on the label: the name of the medicine, the quantity of all active ingredients, or the medicine's expiration date?\",\n    \"Answer\": \"The medicine's expiration date would not be required on the label.\",\n    \"Answer Explanation\": \"This Order sets out labeling requirements for certain non-prescription medicines (section 1). It mandates including the quantity or proportion of all active ingredients (section 1(c)). The name of the medicine is also required via the definition of 'label' in section 3. However, no part of the provided regulation sections mentions an expiration date requirement.\"\n  },\n  {\n    \"Question\": \"For a non-prescription medicine with 5 active ingredients, is the label required to include both the quantity and proportion of each ingredient, assuming subsection 8(2) applies? Please state your assumptions.\",\n    \"Answer\": \"No, if the medicine has 4 or more active ingredients and subsection 8(2) applies, the label does not need to include both the quantity and proportion of each active ingredient.\",\n    \"Answer Explanation\": \"Section 1(c) generally requires the label to include the quantity or proportion of all active ingredients. However, section 1(c) provides an exception - if the medicine contains 4 or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. The question states the medicine has 5 active ingredients and that subsection 8(2) applies, so this exception is met and the label need not include both quantity and proportion of each ingredient.\"\n  },\n  {\n    \"Question\": \"Assuming no exceptions apply, which of the following pieces of information are required on the label of a non-prescription medicine according to the provided regulation sections: a description of the medicine, the batch number, or the name of a complementary healthcare practitioner?\",\n    \"Answer\": \"The batch number of the medicine preceded by the batch number prefix is required on the label. A description of the medicine and the name of a complementary healthcare practitioner are not required.\",\n    \"Answer Explanation\": \"Section 1(f) states that the batch number of the medicine preceded by the batch number prefix must be included on the label. The provided sections do not mention that a general description of the medicine is required. While 'complementary healthcare practitioner' is defined in section 2, the sections do not state that their name must appear on medicine labels.\"\n  },\n  {\n    \"Question\": \"Based on the given regulation sections, if a non-prescription medicine label omits the quantity of active ingredients, under what conditions would this be allowed? State any assumptions.\",\n    \"Answer\": \"Omitting the quantity of active ingredients on the label would only be allowed if the medicine contains 4 or more active ingredients and subsection 8(2) applies. This assumes no other exceptions are relevant.\",\n    \"Answer Explanation\": \"Section 1(c) requires medicine labels to include the quantity or proportion of all active ingredients. However, it also provides an exception in section 1(c) - if there are 4 or more active ingredients and subsection 8(2) applies, then paragraphs 9(1)(b) and 9(1)(c) (which presumably mandate quantity\/proportion labeling) do not need to be followed. No other exceptions to the quantity labeling requirement are mentioned in the provided sections.\"\n  }\n]}"
    },
    {
        "path": [
            1004000000,
            802000000,
            1005020000,
            1007000000,
            900000000
        ],
        "contexts": [
            " (4) Formulations containing both homoeopathic preparations and non-homoeopathic ingredients Where a medicine contains active ingredients that are homoeopathic preparations, and other active ingredients that are not homoeopathic preparations, then, in addition to the requirements referred to in sections 8 and 9 above:",
            " (2)",
            " (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other information is displayed in a text size of not less than 1.0 millimetres.",
            " (7) Small containers If:",
            " 9 Information to be included on the main label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains both homoeopathic and non-homoeopathic active ingredients, and is enclosed in a 20 ml container, what are the minimum text size requirements for the sun protection factor and other information on the label?",
                    "Answer": "The sun protection factor must be displayed in a text size of at least 1.5 mm, and all other information must be displayed in a text size of at least 1.0 mm.",
                    "Answer Explanation": "The medicine contains both homoeopathic and non-homoeopathic ingredients, so sections 8 and 9 apply in addition to the homoeopathic requirements (context 4). Since the container capacity is not more than 25 ml (context 7b), the minimum text sizes specified in context 7bi (1.5 mm for SPF) and 7bii (1.0 mm for other info) are sufficient to comply with the labeling requirements in sections 8 and 9 (context 7)."
                },
                {
                    "Question": "For a 20 ml container of a medicine with both homoeopathic and non-homoeopathic active ingredients, which specific sections of the regulation define the labeling requirements that must be met?",
                    "Answer": "Sections 8 and 9 define the labeling requirements that must be met for this medicine, in addition to homoeopathic requirements.",
                    "Answer Explanation": "Context 4 states that for medicines containing both homoeopathic and non-homoeopathic active ingredients, the requirements in sections 8 and 9 apply in addition to the homoeopathic requirements. Context 7 then provides allowances for small containers (not more than 25 ml per 7b) in relation to complying with sections 8 and 9."
                },
                {
                    "Question": "Suppose a medicine with both homoeopathic and non-homoeopathic active ingredients is in a 30 ml container. What text size requirements from sections 8 and 9 would fully apply?",
                    "Answer": "The full text size requirements defined in sections 8 and 9 would apply, as the small container allowances in context 7 only apply to containers with a capacity of not more than 25 ml.",
                    "Answer Explanation": "Context 4 establishes that sections 8 and 9 apply to the mixed homoeopathic\/non-homoeopathic medicine in addition to homoeopathic requirements. Context 7 provides modified text size allowances for small containers to comply with sections 8 and 9, but only if the container capacity is not more than 25 ml (7b). Since this medicine is in a 30 ml container, the full unmodified requirements of sections 8 and 9 apply."
                },
                {
                    "Question": "For a medicine with only non-homoeopathic ingredients in a 20 ml container, which parts of the regulation specify the minimum text sizes required on the label?",
                    "Answer": "Context 7bi and 7bii specify the minimum required text sizes of 1.5 mm for sun protection factor and 1.0 mm for all other information in order to comply with the labeling requirements in sections 8 and 9.",
                    "Answer Explanation": "Context 7 states that for a medicine in a container with a capacity of not more than 25 ml (7b), the text sizes specified in 7bi (1.5 mm for SPF) and 7bii (1.0 mm for other information) are sufficient to comply with sections 8 and 9. Context 4 is not relevant since the medicine only contains non-homoeopathic ingredients."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains both homoeopathic and non-homoeopathic active ingredients, and is enclosed in a 20 ml container, what are the minimum text size requirements for the sun protection factor and other information on the label?\",\n    \"Answer\": \"The sun protection factor must be displayed in a text size of at least 1.5 mm, and all other information must be displayed in a text size of at least 1.0 mm.\",\n    \"Answer Explanation\": \"The medicine contains both homoeopathic and non-homoeopathic ingredients, so sections 8 and 9 apply in addition to the homoeopathic requirements (context 4). Since the container capacity is not more than 25 ml (context 7b), the minimum text sizes specified in context 7bi (1.5 mm for SPF) and 7bii (1.0 mm for other info) are sufficient to comply with the labeling requirements in sections 8 and 9 (context 7).\"\n  },\n  {\n    \"Question\": \"For a 20 ml container of a medicine with both homoeopathic and non-homoeopathic active ingredients, which specific sections of the regulation define the labeling requirements that must be met?\",\n    \"Answer\": \"Sections 8 and 9 define the labeling requirements that must be met for this medicine, in addition to homoeopathic requirements.\",\n    \"Answer Explanation\": \"Context 4 states that for medicines containing both homoeopathic and non-homoeopathic active ingredients, the requirements in sections 8 and 9 apply in addition to the homoeopathic requirements. Context 7 then provides allowances for small containers (not more than 25 ml per 7b) in relation to complying with sections 8 and 9.\"\n  },\n  {\n    \"Question\": \"Suppose a medicine with both homoeopathic and non-homoeopathic active ingredients is in a 30 ml container. What text size requirements from sections 8 and 9 would fully apply?\",\n    \"Answer\": \"The full text size requirements defined in sections 8 and 9 would apply, as the small container allowances in context 7 only apply to containers with a capacity of not more than 25 ml.\",\n    \"Answer Explanation\": \"Context 4 establishes that sections 8 and 9 apply to the mixed homoeopathic\/non-homoeopathic medicine in addition to homoeopathic requirements. Context 7 provides modified text size allowances for small containers to comply with sections 8 and 9, but only if the container capacity is not more than 25 ml (7b). Since this medicine is in a 30 ml container, the full unmodified requirements of sections 8 and 9 apply.\"\n  },\n  {\n    \"Question\": \"For a medicine with only non-homoeopathic ingredients in a 20 ml container, which parts of the regulation specify the minimum text sizes required on the label?\",\n    \"Answer\": \"Context 7bi and 7bii specify the minimum required text sizes of 1.5 mm for sun protection factor and 1.0 mm for all other information in order to comply with the labeling requirements in sections 8 and 9.\",\n    \"Answer Explanation\": \"Context 7 states that for a medicine in a container with a capacity of not more than 25 ml (7b), the text sizes specified in 7bi (1.5 mm for SPF) and 7bii (1.0 mm for other information) are sufficient to comply with sections 8 and 9. Context 4 is not relevant since the medicine only contains non-homoeopathic ingredients.\"\n  }\n]}"
    },
    {
        "path": [
            903030000,
            101000000,
            601290000,
            907040000,
            802000000
        ],
        "contexts": [
            " (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
            "Introduction ",
            "\"homoeopathic potency\" means the dilution factor of a homoeopathic preparation, expressed as: (a) (b) \\\"nX\\\" where each dilution is a decimal or ten-fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 10n; or \\\"nC\\\" where each dilution is a centesimal or hundred-fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 100n; or (c) \\\"nLM\\\" or \\\"LMn\\\" where, from a 3C starting dilution, each subsequent dilution is a fifty millesimal or fifty thousand fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 50,000^n. Note: Where 1000 centesimal dilutions are performed, the potency is expressed as nM; that is, 1M potency represents a 1,000C dilution, 2M a 2,000C dilution, etc",
            " (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine.",
            " (2)"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine in a medium container has multiple active ingredients, is it allowed to present the names and quantities of those ingredients together on continuous lines of text to comply with paragraph 9(3)(a) of the label regulations?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to the context provided in (c), if a medicine is supplied in either a small or medium container and contains multiple active ingredients, then the names of the active ingredients and their quantities may be presented together on a continuous line or lines of text in relation to compliance with paragraph 9(3)(a) of the label regulations."
                },
                {
                    "Question": "For a homoeopathic preparation that has undergone 5 dilutions, each being a centesimal or hundred-fold dilution, what would the homoeopathic potency be expressed as? Assume the standard notation conventions are followed.",
                    "Answer": "5C",
                    "Answer Explanation": "Based on the context provided in the \"homoeopathic potency\" definition, for a homoeopathic preparation where each dilution is a centesimal or hundred-fold dilution, the potency is expressed as \"nC\" where \"n\" is the number of dilutions. Since this preparation has undergone 5 centesimal dilutions, its potency would be expressed as \"5C\", meaning the total dilution is 100^5."
                },
                {
                    "Question": "Assume a non-prescription medicine includes an active ingredient with a name that has chemical salt descriptors not therapeutically relevant. If the ingredient name and quantity are displayed per subsection 8(2), can the therapeutically active moiety name be used on the main label instead, in a 2.5mm text size without showing ingredient quantities?",
                    "Answer": "No",
                    "Answer Explanation": "The context in (d) allows displaying the therapeutically active moiety name on the main label instead of the full active ingredient name only if: the ingredient name and quantity are displayed per subsection 8(2), the moiety name text size is not less than 3.0mm, and no quantities are displayed for any ingredients. Since the 2.5mm text size is less than the required minimum of 3.0mm, using just the moiety name on the main label would not be allowed in this case."
                },
                {
                    "Question": "Suppose a homoeopathic preparation starts from a 3C dilution, then undergoes 2 subsequent dilutions, each being a fifty millesimal dilution. Assuming standard notation, what is the expression for the homoeopathic potency of the final preparation?",
                    "Answer": "2LM",
                    "Answer Explanation": "The definition for \"homoeopathic potency\" states that starting from a 3C dilution, when each subsequent dilution is a fifty millesimal or fifty thousand fold dilution, the potency is expressed as \"nLM\" or \"LMn\", where \"n\" is the number of fifty millesimal dilutions. In this case, with 2 fifty millesimal dilutions, the potency expression would be \"2LM\", indicating a total dilution of 50,000^2 from the 3C starting point."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine in a medium container has multiple active ingredients, is it allowed to present the names and quantities of those ingredients together on continuous lines of text to comply with paragraph 9(3)(a) of the label regulations?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"According to the context provided in (c), if a medicine is supplied in either a small or medium container and contains multiple active ingredients, then the names of the active ingredients and their quantities may be presented together on a continuous line or lines of text in relation to compliance with paragraph 9(3)(a) of the label regulations.\"\n    },\n    {\n      \"Question\": \"For a homoeopathic preparation that has undergone 5 dilutions, each being a centesimal or hundred-fold dilution, what would the homoeopathic potency be expressed as? Assume the standard notation conventions are followed.\",\n      \"Answer\": \"5C\",\n      \"Answer Explanation\": \"Based on the context provided in the \\\"homoeopathic potency\\\" definition, for a homoeopathic preparation where each dilution is a centesimal or hundred-fold dilution, the potency is expressed as \\\"nC\\\" where \\\"n\\\" is the number of dilutions. Since this preparation has undergone 5 centesimal dilutions, its potency would be expressed as \\\"5C\\\", meaning the total dilution is 100^5.\"\n    },\n    {\n      \"Question\": \"Assume a non-prescription medicine includes an active ingredient with a name that has chemical salt descriptors not therapeutically relevant. If the ingredient name and quantity are displayed per subsection 8(2), can the therapeutically active moiety name be used on the main label instead, in a 2.5mm text size without showing ingredient quantities?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"The context in (d) allows displaying the therapeutically active moiety name on the main label instead of the full active ingredient name only if: the ingredient name and quantity are displayed per subsection 8(2), the moiety name text size is not less than 3.0mm, and no quantities are displayed for any ingredients. Since the 2.5mm text size is less than the required minimum of 3.0mm, using just the moiety name on the main label would not be allowed in this case.\"\n    },\n    {\n      \"Question\": \"Suppose a homoeopathic preparation starts from a 3C dilution, then undergoes 2 subsequent dilutions, each being a fifty millesimal dilution. Assuming standard notation, what is the expression for the homoeopathic potency of the final preparation?\",\n      \"Answer\": \"2LM\",\n      \"Answer Explanation\": \"The definition for \\\"homoeopathic potency\\\" states that starting from a 3C dilution, when each subsequent dilution is a fifty millesimal or fifty thousand fold dilution, the potency is expressed as \\\"nLM\\\" or \\\"LMn\\\", where \\\"n\\\" is the number of fifty millesimal dilutions. In this case, with 2 fifty millesimal dilutions, the potency expression would be \\\"2LM\\\", indicating a total dilution of 50,000^2 from the 3C starting point.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            700000000,
            1102050000,
            1008030000,
            1009020000,
            800000000
        ],
        "contexts": [
            " 7 General requirements, including label presentation",
            " (e) for a transdermal patch, as the total quantity of the active ingredient in each patch and the quantity of the active ingredient released in a stated time;",
            " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 8 Information to be included on the label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine has 5 active ingredients and is intended to be registered goods, what information must be displayed on the label of a blister pack containing the medicine in order to comply with sections 8 and 9?",
                    "Answer": "The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and name of the sponsor or distributor (or registered trademark if it readily identifies them).",
                    "Answer Explanation": "Section 7(b)(i) states that for a medicine with 4 or more active ingredients that is intended to be registered goods, the blister pack label must display the information listed in 7(b)(iii) through (vi) to comply with sections 8 and 9. This includes the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark."
                },
                {
                    "Question": "Assuming a transdermal patch medicine label states the total quantity of active ingredient per patch, what additional information about the active ingredient is required on the label as per section 7(e)?",
                    "Answer": "The label must also state the quantity of the active ingredient released in a stated time period.",
                    "Answer Explanation": "Section 7(e) specifies that for a transdermal patch, the label must state the total quantity of active ingredient in each patch as well as the quantity of the active ingredient released in a stated time period."
                },
                {
                    "Question": "Assuming a medicine consists of dry herbs in individual bags that are retained during preparation, and the bags are in a primary pack with a fully compliant label, what information is not required on the labels of the individual herb bags based on section 7(c)?",
                    "Answer": "The individual bags containing the herbs do not need to be labelled with the information referred to in sections 8 and 9.",
                    "Answer Explanation": "Section 7(c) states that if a medicine consists of dry herbs in individual bags that are kept around the herbs during preparation, and these bags are in a primary pack with a label fully complying with the Order's requirements, then the individual herb bags themselves do not need to be labelled with the information specified in sections 8 and 9."
                },
                {
                    "Question": "Assuming a listed medicine has 3 active ingredients, what information must be displayed on the label of a strip pack containing the medicine to comply with sections 8 and 9?",
                    "Answer": "The full set of information required by sections 8 and 9 must be displayed on the label of a strip pack for a listed medicine with 3 active ingredients.",
                    "Answer Explanation": "Section 7(b)(ii) specifies that the reduced labelling requirements only apply for listed medicines with 2 or more active ingredients. Since this is a listed medicine with 3 active ingredients, it exceeds that threshold, so the strip pack label must display the full set of information mandated by sections 8 and 9."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine has 5 active ingredients and is intended to be registered goods, what information must be displayed on the label of a blister pack containing the medicine in order to comply with sections 8 and 9?\", \"Answer\": \"The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and name of the sponsor or distributor (or registered trademark if it readily identifies them).\", \"Answer Explanation\": \"Section 7(b)(i) states that for a medicine with 4 or more active ingredients that is intended to be registered goods, the blister pack label must display the information listed in 7(b)(iii) through (vi) to comply with sections 8 and 9. This includes the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark.\"}, {\"Question\": \"Assuming a transdermal patch medicine label states the total quantity of active ingredient per patch, what additional information about the active ingredient is required on the label as per section 7(e)?\", \"Answer\": \"The label must also state the quantity of the active ingredient released in a stated time period.\", \"Answer Explanation\": \"Section 7(e) specifies that for a transdermal patch, the label must state the total quantity of active ingredient in each patch as well as the quantity of the active ingredient released in a stated time period.\"}, {\"Question\": \"Assuming a medicine consists of dry herbs in individual bags that are retained during preparation, and the bags are in a primary pack with a fully compliant label, what information is not required on the labels of the individual herb bags based on section 7(c)?\", \"Answer\": \"The individual bags containing the herbs do not need to be labelled with the information referred to in sections 8 and 9.\", \"Answer Explanation\": \"Section 7(c) states that if a medicine consists of dry herbs in individual bags that are kept around the herbs during preparation, and these bags are in a primary pack with a label fully complying with the Order's requirements, then the individual herb bags themselves do not need to be labelled with the information specified in sections 8 and 9.\"}, {\"Question\": \"Assuming a listed medicine has 3 active ingredients, what information must be displayed on the label of a strip pack containing the medicine to comply with sections 8 and 9?\", \"Answer\": \"The full set of information required by sections 8 and 9 must be displayed on the label of a strip pack for a listed medicine with 3 active ingredients.\", \"Answer Explanation\": \"Section 7(b)(ii) specifies that the reduced labelling requirements only apply for listed medicines with 2 or more active ingredients. Since this is a listed medicine with 3 active ingredients, it exceeds that threshold, so the strip pack label must display the full set of information mandated by sections 8 and 9.\"}]}"
    },
    {
        "path": [
            601570000,
            601100000,
            802000000,
            802050000,
            802020000
        ],
        "contexts": [
            "\"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;",
            "\"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;",
            " (2)",
            " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a sponsor has specified that a container of a medicine should contain a volume of 100mL, does the sponsor have to include the names of all excipients in the medicine on the label under the 'Other information' heading or another separate appropriate heading?",
                    "Answer": "Yes",
                    "Answer Explanation": "The 'stated volume of fill' is defined as the volume of medicine that the sponsor specifies the container to contain. Subsection 8(2)(e) states that if information other than the critical health information is included on the label, it must be placed under the 'Other information' heading or another separate appropriate heading, and must include the names of all excipients."
                },
                {
                    "Question": "Assuming a medicine has been listed and a Certificate of Listing has been given to the applicant, does the label for the medicine have to present the critical health information in a specific order under appropriate headings?",
                    "Answer": "Yes",
                    "Answer Explanation": "The 'Certificate of Listing' is defined as the certificate given to the applicant for listing of the medicine under the Act. Subsection 8(2)(b) specifies that the critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
                },
                {
                    "Question": "Assuming a sponsor wants to include the sponsor contact details on the medicine label, can this information be included under the 'Warnings' heading?",
                    "Answer": "No",
                    "Answer Explanation": "Subsection 8(2)(b) states that the critical health information, which includes Warnings, must be presented under appropriate headings and in a specific order. Subsection 8(2)(e) then states that if other information is to be included, such as sponsor contact details, it must be placed under the 'Other information' heading or another separate appropriate heading that follows below the headings mentioned in 8(2)(b). Therefore, the sponsor contact details cannot be included under the 'Warnings' heading."
                },
                {
                    "Question": "Assuming a medicine container is specified by the sponsor to contain 50mL, which is the stated volume of fill, can the medicine label include information about package features to prevent tampering under the 'Directions for use' heading?",
                    "Answer": "No",
                    "Answer Explanation": "The 'stated volume of fill' is defined as the volume of medicine that the sponsor specifies the container to contain, which is 50mL in this case. Subsection 8(2)(b) states that the 'Directions for use' heading is part of the critical health information that must be presented in a specific order. Subsection 8(2)(e) then specifies that information about package features to prevent tampering, if included, must be placed under the 'Other information' heading or another separate appropriate heading that follows below the critical health information headings mentioned in 8(2)(b). Therefore, the tamper evident feature information cannot be placed under the 'Directions for use' heading."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a sponsor has specified that a container of a medicine should contain a volume of 100mL, does the sponsor have to include the names of all excipients in the medicine on the label under the 'Other information' heading or another separate appropriate heading?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"The 'stated volume of fill' is defined as the volume of medicine that the sponsor specifies the container to contain. Subsection 8(2)(e) states that if information other than the critical health information is included on the label, it must be placed under the 'Other information' heading or another separate appropriate heading, and must include the names of all excipients.\"}, {\"Question\": \"Assuming a medicine has been listed and a Certificate of Listing has been given to the applicant, does the label for the medicine have to present the critical health information in a specific order under appropriate headings?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"The 'Certificate of Listing' is defined as the certificate given to the applicant for listing of the medicine under the Act. Subsection 8(2)(b) specifies that the critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.\"}, {\"Question\": \"Assuming a sponsor wants to include the sponsor contact details on the medicine label, can this information be included under the 'Warnings' heading?\", \"Answer\": \"No\", \"Answer Explanation\": \"Subsection 8(2)(b) states that the critical health information, which includes Warnings, must be presented under appropriate headings and in a specific order. Subsection 8(2)(e) then states that if other information is to be included, such as sponsor contact details, it must be placed under the 'Other information' heading or another separate appropriate heading that follows below the headings mentioned in 8(2)(b). Therefore, the sponsor contact details cannot be included under the 'Warnings' heading.\"}, {\"Question\": \"Assuming a medicine container is specified by the sponsor to contain 50mL, which is the stated volume of fill, can the medicine label include information about package features to prevent tampering under the 'Directions for use' heading?\", \"Answer\": \"No\", \"Answer Explanation\": \"The 'stated volume of fill' is defined as the volume of medicine that the sponsor specifies the container to contain, which is 50mL in this case. Subsection 8(2)(b) states that the 'Directions for use' heading is part of the critical health information that must be presented in a specific order. Subsection 8(2)(e) then specifies that information about package features to prevent tampering, if included, must be placed under the 'Other information' heading or another separate appropriate heading that follows below the critical health information headings mentioned in 8(2)(b). Therefore, the tamper evident feature information cannot be placed under the 'Directions for use' heading.\"}]}"
    },
    {
        "path": [
            904000000,
            501010000,
            601600001,
            910000000,
            909000000
        ],
        "contexts": [
            " (4) All text required by this Order to be on the main label must be oriented in the same direction.",
            "(a) intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act; or",
            "(a) any labelling requirements specified in the instrument made by the Minister under subsection 3(5A) of the Act, as in force from time to time; Note These requirements apply to all medicines other than those described in Part 1 of Schedule 10 to the Therapeutic Goods Regulations 1990",
            " (10) Subsection 9(9) does not apply:",
            " (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is intended to be registered goods and has an active ingredient name specified in Schedule 2 to this Order, what is the minimum required text size for displaying the names and quantities or proportions of all active ingredients on the main label, and in what direction must this text be oriented?",
                    "Answer": "The minimum required text size is 2.5 millimetres, and the text must be oriented in the same direction as all other text required on the main label.",
                    "Answer Explanation": "Subsection 9(9) states that if the medicine is intended to be registered goods and has an active ingredient name specified in Schedule 2, the names and quantities or proportions of all active ingredients must be displayed in a text size of not less than 2.5 millimetres. Subsection 4 requires that all text on the main label must be oriented in the same direction."
                },
                {
                    "Question": "Assuming a medicine is intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act, does subsection 9(9) apply to this medicine?",
                    "Answer": "No, subsection 9(9) does not apply to this medicine.",
                    "Answer Explanation": "Subsection 9(10)(a) states that subsection 9(9) does not apply to medicines intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act."
                },
                {
                    "Question": "Assuming a medicine is not described in Part 1 of Schedule 10 to the Therapeutic Goods Regulations 1990, what additional labelling requirements must be met beyond those specified in this Order?",
                    "Answer": "The medicine must meet any labelling requirements specified in the instrument made by the Minister under subsection 3(5A) of the Act, as in force from time to time.",
                    "Answer Explanation": "Subsection (a) states that any labelling requirements specified in the instrument made by the Minister under subsection 3(5A) of the Act apply to all medicines other than those described in Part 1 of Schedule 10 to the Therapeutic Goods Regulations 1990."
                },
                {
                    "Question": "Assuming a registered medicine has an active ingredient name specified in Schedule 2 to this Order, what is the minimum text size required for displaying the names and quantities or proportions of all active ingredients on the main label if the medicine is also intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act?",
                    "Answer": "There is no minimum text size requirement in this case, as subsection 9(9) does not apply to medicines intended for use under paragraph 19(1)(a) of the Act.",
                    "Answer Explanation": "While subsection 9(9) would normally require a minimum 2.5 millimetre text size for registered medicines with an active ingredient specified in Schedule 2, subsection 9(10)(a) exempts medicines intended for use under paragraph 19(1)(a) of the Act from this requirement."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is intended to be registered goods and has an active ingredient name specified in Schedule 2 to this Order, what is the minimum required text size for displaying the names and quantities or proportions of all active ingredients on the main label, and in what direction must this text be oriented?\", \"Answer\": \"The minimum required text size is 2.5 millimetres, and the text must be oriented in the same direction as all other text required on the main label.\", \"Answer Explanation\": \"Subsection 9(9) states that if the medicine is intended to be registered goods and has an active ingredient name specified in Schedule 2, the names and quantities or proportions of all active ingredients must be displayed in a text size of not less than 2.5 millimetres. Subsection 4 requires that all text on the main label must be oriented in the same direction.\"}, {\"Question\": \"Assuming a medicine is intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act, does subsection 9(9) apply to this medicine?\", \"Answer\": \"No, subsection 9(9) does not apply to this medicine.\", \"Answer Explanation\": \"Subsection 9(10)(a) states that subsection 9(9) does not apply to medicines intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act.\"}, {\"Question\": \"Assuming a medicine is not described in Part 1 of Schedule 10 to the Therapeutic Goods Regulations 1990, what additional labelling requirements must be met beyond those specified in this Order?\", \"Answer\": \"The medicine must meet any labelling requirements specified in the instrument made by the Minister under subsection 3(5A) of the Act, as in force from time to time.\", \"Answer Explanation\": \"Subsection (a) states that any labelling requirements specified in the instrument made by the Minister under subsection 3(5A) of the Act apply to all medicines other than those described in Part 1 of Schedule 10 to the Therapeutic Goods Regulations 1990.\"}, {\"Question\": \"Assuming a registered medicine has an active ingredient name specified in Schedule 2 to this Order, what is the minimum text size required for displaying the names and quantities or proportions of all active ingredients on the main label if the medicine is also intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act?\", \"Answer\": \"There is no minimum text size requirement in this case, as subsection 9(9) does not apply to medicines intended for use under paragraph 19(1)(a) of the Act.\", \"Answer Explanation\": \"While subsection 9(9) would normally require a minimum 2.5 millimetre text size for registered medicines with an active ingredient specified in Schedule 2, subsection 9(10)(a) exempts medicines intended for use under paragraph 19(1)(a) of the Act from this requirement.\"}]}"
    },
    {
        "path": [
            601260000,
            801040000,
            601010000,
            908040000,
            906020000
        ],
        "contexts": [
            "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
            " (d) the name of the dosage form; and",
            "\"Act\" means the Therapeutic Goods Act 1989;",
            " (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
            " (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains the herbal materials ginkgo biloba leaf, echinacea purpurea root, and panax ginseng root, and is in the form of a capsule, what information must be included on the label according to the given regulation sections?",
                    "Answer": "The label must include the botanical scientific name and plant part for each herbal material (ginkgo biloba leaf, echinacea purpurea root, panax ginseng root), and the name of the dosage form (capsule).",
                    "Answer Explanation": "The regulation states that 'herbal material' must be defined by its botanical scientific name and plant part, whether fresh or dried, whole, fragmented, cut or ground (paragraph 1). It also requires the name of the dosage form to be included (paragraph 2)."
                },
                {
                    "Question": "For a composite pack containing 3 different medicine formulations, and assuming the Therapeutic Goods Act 1989 applies, how must the information required under paragraph 9(6)(b) or subsection 9(7) be provided on the label?",
                    "Answer": "The information required under paragraph 9(6)(b) or subsection 9(7) of the Therapeutic Goods Act 1989 must be provided separately for each of the 3 medicine formulations in the composite pack.",
                    "Answer Explanation": "Paragraph 3 defines 'Act' as the Therapeutic Goods Act 1989. Paragraph 4 then states that for composite packs or medicine kits, the information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine in the pack or kit."
                },
                {
                    "Question": "Assuming a non-prescription medicine contains 5 active ingredients and is not in a composite pack or medicine kit, where on the label may the names and quantities\/proportions of the active ingredients be listed?",
                    "Answer": "For a medicine with 5 active ingredients that is not in a composite pack or kit, the names and quantities\/proportions of all the active ingredients may appear on a side panel, side label, rear panel or rear label.",
                    "Answer Explanation": "Paragraph 5 allows that if a medicine has 4 or more active ingredients, the name, quantity and proportion of every active ingredient may appear on a side panel, side label, rear panel or rear label. Since the medicine has 5 active ingredients and is not a composite pack or kit (paragraph 4), this provision applies."
                },
                {
                    "Question": "For a dried, cut herbal material consisting of multiple plant parts, packaged as a tablet and regulated under the Therapeutic Goods Act 1989, what key information must be on the label?",
                    "Answer": "The label must include: the botanical scientific names (with authors) of each plant; each specific plant part; that the herbal materials are dried and cut; and that the dosage form is a tablet. This is required by the Therapeutic Goods Act 1989.",
                    "Answer Explanation": "Per paragraph 1, 'herbal material' must be labelled with botanical scientific name and author, plant part, and whether fresh\/dried and whole\/cut\/fragmented\/ground. Paragraph 2 requires the dosage form (tablet). Paragraph 3 clarifies 'Act' means Therapeutic Goods Act 1989."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains the herbal materials ginkgo biloba leaf, echinacea purpurea root, and panax ginseng root, and is in the form of a capsule, what information must be included on the label according to the given regulation sections?\",\n    \"Answer\": \"The label must include the botanical scientific name and plant part for each herbal material (ginkgo biloba leaf, echinacea purpurea root, panax ginseng root), and the name of the dosage form (capsule).\",\n    \"Answer Explanation\": \"The regulation states that 'herbal material' must be defined by its botanical scientific name and plant part, whether fresh or dried, whole, fragmented, cut or ground (paragraph 1). It also requires the name of the dosage form to be included (paragraph 2).\"\n  },\n  {\n    \"Question\": \"For a composite pack containing 3 different medicine formulations, and assuming the Therapeutic Goods Act 1989 applies, how must the information required under paragraph 9(6)(b) or subsection 9(7) be provided on the label?\",\n    \"Answer\": \"The information required under paragraph 9(6)(b) or subsection 9(7) of the Therapeutic Goods Act 1989 must be provided separately for each of the 3 medicine formulations in the composite pack.\",\n    \"Answer Explanation\": \"Paragraph 3 defines 'Act' as the Therapeutic Goods Act 1989. Paragraph 4 then states that for composite packs or medicine kits, the information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine in the pack or kit.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine contains 5 active ingredients and is not in a composite pack or medicine kit, where on the label may the names and quantities\/proportions of the active ingredients be listed?\",\n    \"Answer\": \"For a medicine with 5 active ingredients that is not in a composite pack or kit, the names and quantities\/proportions of all the active ingredients may appear on a side panel, side label, rear panel or rear label.\",\n    \"Answer Explanation\": \"Paragraph 5 allows that if a medicine has 4 or more active ingredients, the name, quantity and proportion of every active ingredient may appear on a side panel, side label, rear panel or rear label. Since the medicine has 5 active ingredients and is not a composite pack or kit (paragraph 4), this provision applies.\"\n  },\n  {\n    \"Question\": \"For a dried, cut herbal material consisting of multiple plant parts, packaged as a tablet and regulated under the Therapeutic Goods Act 1989, what key information must be on the label?\",\n    \"Answer\": \"The label must include: the botanical scientific names (with authors) of each plant; each specific plant part; that the herbal materials are dried and cut; and that the dosage form is a tablet. This is required by the Therapeutic Goods Act 1989.\",\n    \"Answer Explanation\": \"Per paragraph 1, 'herbal material' must be labelled with botanical scientific name and author, plant part, and whether fresh\/dried and whole\/cut\/fragmented\/ground. Paragraph 2 requires the dosage form (tablet). Paragraph 3 clarifies 'Act' means Therapeutic Goods Act 1989.\"\n  }\n]}"
    },
    {
        "path": [
            601140000,
            1001000000,
            907020000,
            908030000,
            907000000
        ],
        "contexts": [
            "\"container\" has the same meaning as in the Act;",
            " (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:",
            " (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or",
            " (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
            " (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is registered goods and is a preparation for ophthalmic use containing 5 active ingredients, what text size must be used to include the names and quantities of the active ingredients on a side panel of the label on the container, and what subsections specify this requirement?",
                    "Answer": "2.5 millimetres",
                    "Answer Explanation": "Subsection (1) states additional labeling requirements for ophthalmic preparations. Paragraph (b) allows names and quantities of active ingredients to be on a side panel in minimum 2.5mm text size if the medicine contains 4 or more active ingredients and subsection 8(2) doesn't apply. Subsection (7) indicates this applies if the medicine is registered goods."
                },
                {
                    "Question": "For a composite pack medicine kit intended to be registered goods, how are the total number of active ingredients determined for the purposes of applying paragraph 9(6)(b) or subsection 9(7), if the same active ingredient is contained in multiple formulations in the kit?",
                    "Answer": "Each instance of the same active ingredient is counted separately.",
                    "Answer Explanation": "Paragraph (c) specifies that to determine if paragraph 9(6)(b) or which part of subsection 9(7) applies to a composite pack or medicine kit that is intended to be registered goods, (i) the total active ingredients across all formulations are counted, and (ii) if the same active ingredient is in multiple formulations, each instance is counted separately."
                },
                {
                    "Question": "What is the definition of 'container' as used in these regulations?",
                    "Answer": "The same meaning as in the Act.",
                    "Answer Explanation": "The context directly states that 'container' has the same meaning as in the Act. No other definition is provided in the given regulation sections."
                },
                {
                    "Question": "Assuming a registered composite pack medicine kit contains 3 formulations with active ingredients as follows: Formulation 1 (ingredients A,B), Formulation 2 (ingredient A), Formulation 3 (ingredients C,D). How many total active ingredients does the kit contain for the purpose of labeling requirements?",
                    "Answer": "5 active ingredients",
                    "Answer Explanation": "Based on paragraph (c), the total active ingredients are counted across all formulations, with repeats counted separately. So Formulation 1 contributes 2 (A,B), Formulation 2 contributes 1 (A, repeat counted separately), and Formulation 3 contributes 2 (C,D), for a total of 5 active ingredients for determining applicable labeling requirements in 9(6)(b) or 9(7), as stated in (7) for registered goods."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is registered goods and is a preparation for ophthalmic use containing 5 active ingredients, what text size must be used to include the names and quantities of the active ingredients on a side panel of the label on the container, and what subsections specify this requirement?\",\n      \"Answer\": \"2.5 millimetres\",\n      \"Answer Explanation\": \"Subsection (1) states additional labeling requirements for ophthalmic preparations. Paragraph (b) allows names and quantities of active ingredients to be on a side panel in minimum 2.5mm text size if the medicine contains 4 or more active ingredients and subsection 8(2) doesn't apply. Subsection (7) indicates this applies if the medicine is registered goods.\"\n    },\n    {\n      \"Question\": \"For a composite pack medicine kit intended to be registered goods, how are the total number of active ingredients determined for the purposes of applying paragraph 9(6)(b) or subsection 9(7), if the same active ingredient is contained in multiple formulations in the kit?\",\n      \"Answer\": \"Each instance of the same active ingredient is counted separately.\",\n      \"Answer Explanation\": \"Paragraph (c) specifies that to determine if paragraph 9(6)(b) or which part of subsection 9(7) applies to a composite pack or medicine kit that is intended to be registered goods, (i) the total active ingredients across all formulations are counted, and (ii) if the same active ingredient is in multiple formulations, each instance is counted separately.\"\n    },\n    {\n      \"Question\": \"What is the definition of 'container' as used in these regulations?\",\n      \"Answer\": \"The same meaning as in the Act.\",\n      \"Answer Explanation\": \"The context directly states that 'container' has the same meaning as in the Act. No other definition is provided in the given regulation sections.\"\n    },\n    {\n      \"Question\": \"Assuming a registered composite pack medicine kit contains 3 formulations with active ingredients as follows: Formulation 1 (ingredients A,B), Formulation 2 (ingredient A), Formulation 3 (ingredients C,D). How many total active ingredients does the kit contain for the purpose of labeling requirements?\",\n      \"Answer\": \"5 active ingredients\",\n      \"Answer Explanation\": \"Based on paragraph (c), the total active ingredients are counted across all formulations, with repeats counted separately. So Formulation 1 contributes 2 (A,B), Formulation 2 contributes 1 (A, repeat counted separately), and Formulation 3 contributes 2 (C,D), for a total of 5 active ingredients for determining applicable labeling requirements in 9(6)(b) or 9(7), as stated in (7) for registered goods.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            908000000,
            1007070000,
            1005010000,
            1102080000,
            1102040000
        ],
        "contexts": [
            " (8) Where a medicine is:",
            " (g) the name of the dosage form; and",
            " (a) the medicine is a sunscreen preparation; and",
            " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " (d) for a medicine required to be prepared before use, and: (i) where the process results in a medicine that is a liquid for ingestion: (A) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine; or (B) in the case where the medicine is one of a series of strengths containing the same active ingredient - as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively. (ii) for any other medicines - as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is a sunscreen preparation and is required to be prepared before use resulting in a liquid for ingestion, how should the quantity of active ingredient be expressed on the label if the medicine is part of a series of strengths containing the same active ingredient?",
                    "Answer": "The quantity of active ingredient should be expressed as the quantity contained in the stated volume of a suitable dose of the liquid after preparation, with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume.",
                    "Answer Explanation": "According to context (a), the medicine is assumed to be a sunscreen preparation. Context (d)(i) states that for a medicine required to be prepared before use resulting in a liquid for ingestion, if it is part of a series of strengths containing the same active ingredient, the quantity of active ingredient should be expressed as the quantity contained in the stated volume of a suitable dose of the liquid after preparation, with the quantity or proportion expressed consistently across the series in terms of the same stated dose volume."
                },
                {
                    "Question": "Assuming a non-prescription medicine contains active ingredients intended for mineral supplementation and is an oral preparation, what information is sufficient to include on the label regarding the quantity or proportion of the active ingredient, according to the regulations?",
                    "Answer": "For oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the label includes the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "Context (h) directly states that for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, the label can sufficiently express the quantity or proportion of the active ingredient by including the name of the active ingredient and the name and quantity of the element intended for mineral supplementation."
                },
                {
                    "Question": "Assuming a non-prescription medicine is required to be prepared before use but does not result in a liquid for ingestion, how should the quantity of active ingredient be expressed on the label according to the regulations?",
                    "Answer": "For medicines required to be prepared before use that do not result in a liquid for ingestion, the label should express the quantity of active ingredient as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included on the label.",
                    "Answer Explanation": "Context (d)(ii) specifies that for medicines required to be prepared before use that do not result in a liquid for ingestion, the quantity of active ingredient should be expressed as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation according to the label instructions."
                },
                {
                    "Question": "Assuming a non-prescription medicine label must include the name of the dosage form, is any other information regarding the dosage form required to be on the label based on the provided regulation sections?",
                    "Answer": "No, based on the provided regulation sections, no other information beyond the name of the dosage form is explicitly required on the label regarding the dosage form.",
                    "Answer Explanation": "Context (g) states that the name of the dosage form must be included on the label. However, none of the other provided regulation sections specify any additional dosage form information as required on the label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine is a sunscreen preparation and is required to be prepared before use resulting in a liquid for ingestion, how should the quantity of active ingredient be expressed on the label if the medicine is part of a series of strengths containing the same active ingredient?\", \"Answer\": \"The quantity of active ingredient should be expressed as the quantity contained in the stated volume of a suitable dose of the liquid after preparation, with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume.\", \"Answer Explanation\": \"According to context (a), the medicine is assumed to be a sunscreen preparation. Context (d)(i) states that for a medicine required to be prepared before use resulting in a liquid for ingestion, if it is part of a series of strengths containing the same active ingredient, the quantity of active ingredient should be expressed as the quantity contained in the stated volume of a suitable dose of the liquid after preparation, with the quantity or proportion expressed consistently across the series in terms of the same stated dose volume.\"}, {\"Question\": \"Assuming a non-prescription medicine contains active ingredients intended for mineral supplementation and is an oral preparation, what information is sufficient to include on the label regarding the quantity or proportion of the active ingredient, according to the regulations?\", \"Answer\": \"For oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the label includes the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\", \"Answer Explanation\": \"Context (h) directly states that for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, the label can sufficiently express the quantity or proportion of the active ingredient by including the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\"}, {\"Question\": \"Assuming a non-prescription medicine is required to be prepared before use but does not result in a liquid for ingestion, how should the quantity of active ingredient be expressed on the label according to the regulations?\", \"Answer\": \"For medicines required to be prepared before use that do not result in a liquid for ingestion, the label should express the quantity of active ingredient as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included on the label.\", \"Answer Explanation\": \"Context (d)(ii) specifies that for medicines required to be prepared before use that do not result in a liquid for ingestion, the quantity of active ingredient should be expressed as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation according to the label instructions.\"}, {\"Question\": \"Assuming a non-prescription medicine label must include the name of the dosage form, is any other information regarding the dosage form required to be on the label based on the provided regulation sections?\", \"Answer\": \"No, based on the provided regulation sections, no other information beyond the name of the dosage form is explicitly required on the label regarding the dosage form.\", \"Answer Explanation\": \"Context (g) states that the name of the dosage form must be included on the label. However, none of the other provided regulation sections specify any additional dosage form information as required on the label.\"}]}"
    },
    {
        "path": [
            101000000,
            601070000,
            905020000,
            1009020000,
            900000000
        ],
        "contexts": [
            "Introduction ",
            "\"batch number prefix\" means the prefix which precedes the batch number and has the following characteristics: (a) clearly indicates that the information following the prefix is the batch number; and (b) is in the following form: \\\"BATCH NUMBER\\\", \\\"BATCH NO.\\\", \\\"BATCH\\\", \\\"B\\\", \\\"(B)\\\", \\\"B\/N\\\", \\\"LOT NUMBER\\\", \\\"LOT NO.\\\", or \\\"LOT\\\", or words or symbols to this effect, including a mixture of lower and upper case letters;",
            " (b) at least two of those active ingredients belong to any of the following categories: (i) a vitamin that is identified by both: (A) the approved name of the active ingredient that is a vitamin; and (B) in accordance with subsection 11(5), the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin; or (ii) a mineral;  (iii) a herbal preparation that, under subparagraph 11(2)(i)(ii), is required to be quantified as either: (A) the dry or fresh weight of herbal material from which the preparation was derived; or (B) the minimum dry or fresh weight of herbal material from which the preparation was derived, then: the names, and quantities or proportions, of all active ingredients in the medicine may appear on a side panel or side label or on a rear panel or rear label instead of on the main label; and",
            " (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 9 Information to be included on the main label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains Vitamin A, Vitamin D, calcium and magnesium as active ingredients and is intended to be registered goods, can the names and quantities of the active ingredients be displayed on a side panel instead of the main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Based on the regulation sections provided, if a medicine contains at least two active ingredients that are either vitamins or minerals, and has four or more total active ingredients while being intended as registered goods, then the names and quantities of all active ingredients may appear on a side panel or side label instead of the main label, as per section (b)(i)."
                },
                {
                    "Question": "For a medicine packaged in a strip, blister or dial dispenser pack that is intended to be listed goods and contains three active ingredients, what information must be displayed on the label to comply with sections 8 and 9, assuming no other context is given?",
                    "Answer": "The name of the medicine, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor\/distributor or registered trademark if it identifies them.",
                    "Answer Explanation": "Section (b)(ii) states that for a medicine intended as listed goods with two or more active ingredients in a strip, blister or dial dispenser pack, the label must display the name of the medicine, batch number with prefix, expiry date with prefix, and name of sponsor\/distributor or identifying trademark to comply with sections 8 and 9."
                },
                {
                    "Question": "What are the possible formats for a valid batch number prefix according to the regulation, assuming no additional context is provided?",
                    "Answer": "\"BATCH NUMBER\", \"BATCH NO.\", \"BATCH\", \"B\", \"(B)\", \"B\/N\", \"LOT NUMBER\", \"LOT NO.\", \"LOT\", or words\/symbols to that effect, including mixed case.",
                    "Answer Explanation": "The section defining \"batch number prefix\" lists the valid formats as: \"BATCH NUMBER\", \"BATCH NO.\", \"BATCH\", \"B\", \"(B)\", \"B\/N\", \"LOT NUMBER\", \"LOT NO.\", or \"LOT\", or words or symbols to this effect, allowing a mix of lower and upper case letters. No other sections modify this definition."
                },
                {
                    "Question": "Assuming a medicine label must include the word 'vitamin' with the common name for any vitamin active ingredients, and one of the active ingredients is Vitamin B12, which of the following would be acceptable based only on the given regulation sections: (a) Vitamin B12, (b) vitamin B12, (c) Vit B12, (d) All of the above?",
                    "Answer": "(d) All of the above",
                    "Answer Explanation": "Section (b)(i)(B) states that vitamin active ingredients must be identified with the word 'vitamin' or any suitable unambiguous abbreviation, together with the vitamin's common name. Both 'Vitamin' and 'vitamin' would be acceptable, as would the abbreviation 'Vit', when accompanied by the common name 'B12'. The regulation excerpt does not prohibit mixing cases or using common abbreviations."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine contains Vitamin A, Vitamin D, calcium and magnesium as active ingredients and is intended to be registered goods, can the names and quantities of the active ingredients be displayed on a side panel instead of the main label?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Based on the regulation sections provided, if a medicine contains at least two active ingredients that are either vitamins or minerals, and has four or more total active ingredients while being intended as registered goods, then the names and quantities of all active ingredients may appear on a side panel or side label instead of the main label, as per section (b)(i).\"\n    },\n    {\n      \"Question\": \"For a medicine packaged in a strip, blister or dial dispenser pack that is intended to be listed goods and contains three active ingredients, what information must be displayed on the label to comply with sections 8 and 9, assuming no other context is given?\",\n      \"Answer\": \"The name of the medicine, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor\/distributor or registered trademark if it identifies them.\",\n      \"Answer Explanation\": \"Section (b)(ii) states that for a medicine intended as listed goods with two or more active ingredients in a strip, blister or dial dispenser pack, the label must display the name of the medicine, batch number with prefix, expiry date with prefix, and name of sponsor\/distributor or identifying trademark to comply with sections 8 and 9.\"\n    },\n    {\n      \"Question\": \"What are the possible formats for a valid batch number prefix according to the regulation, assuming no additional context is provided?\",\n      \"Answer\": \"\\\"BATCH NUMBER\\\", \\\"BATCH NO.\\\", \\\"BATCH\\\", \\\"B\\\", \\\"(B)\\\", \\\"B\/N\\\", \\\"LOT NUMBER\\\", \\\"LOT NO.\\\", \\\"LOT\\\", or words\/symbols to that effect, including mixed case.\",\n      \"Answer Explanation\": \"The section defining \\\"batch number prefix\\\" lists the valid formats as: \\\"BATCH NUMBER\\\", \\\"BATCH NO.\\\", \\\"BATCH\\\", \\\"B\\\", \\\"(B)\\\", \\\"B\/N\\\", \\\"LOT NUMBER\\\", \\\"LOT NO.\\\", or \\\"LOT\\\", or words or symbols to this effect, allowing a mix of lower and upper case letters. No other sections modify this definition.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine label must include the word 'vitamin' with the common name for any vitamin active ingredients, and one of the active ingredients is Vitamin B12, which of the following would be acceptable based only on the given regulation sections: (a) Vitamin B12, (b) vitamin B12, (c) Vit B12, (d) All of the above?\",\n      \"Answer\": \"(d) All of the above\",\n      \"Answer Explanation\": \"Section (b)(i)(B) states that vitamin active ingredients must be identified with the word 'vitamin' or any suitable unambiguous abbreviation, together with the vitamin's common name. Both 'Vitamin' and 'vitamin' would be acceptable, as would the abbreviation 'Vit', when accompanied by the common name 'B12'. The regulation excerpt does not prohibit mixing cases or using common abbreviations.\"\n    }\n  ]\n}"
    },
    {
        "path": [
            601150000,
            601330000,
            400000000,
            905030000,
            802000000
        ],
        "contexts": [
            "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            "\"listed goods\" has the same meaning as in the Act;",
            "4 Transition arrangements ",
            " (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
            " (2)"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Given a non-prescription medicine that is intended to be registered goods, and subsection 8(2) does not apply, what is the minimum text size required for displaying the names and quantities or proportions of the active ingredients on the side or rear panel or label, and which specific paragraph mandates this requirement?",
                    "Answer": "The minimum text size required is 2.5 millimetres.",
                    "Answer Explanation": "Paragraph 4(c)(i) specifies that if the medicine is intended to be, or is, registered goods, and subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres."
                },
                {
                    "Question": "Assuming a non-prescription medicine is intended to be registered goods and subsection 8(2) applies, which specific paragraphs state that compliance is not required for certain labelling provisions?",
                    "Answer": "Compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
                    "Answer Explanation": "Paragraph 4(c)(ii) states that if the medicine is intended to be, or is, registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
                },
                {
                    "Question": "What specific information is defined as 'critical health information' according to the provided context, and which paragraphs are referenced in this definition?",
                    "Answer": "Critical health information is defined as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer.",
                    "Answer Explanation": "The provided context directly states the definition of 'critical health information' and lists the specific paragraphs 8(1)(b), (c), (j), (k), (l) and (n) as part of this definition."
                },
                {
                    "Question": "How is the term 'listed goods' defined in the provided context?",
                    "Answer": "The term 'listed goods' has the same meaning as in the Act.",
                    "Answer Explanation": "The provided context directly states that 'listed goods' has the same meaning as in the Act, without providing further details on the specific definition within the Act itself."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Given a non-prescription medicine that is intended to be registered goods, and subsection 8(2) does not apply, what is the minimum text size required for displaying the names and quantities or proportions of the active ingredients on the side or rear panel or label, and which specific paragraph mandates this requirement?\", \"Answer\": \"The minimum text size required is 2.5 millimetres.\", \"Answer Explanation\": \"Paragraph 4(c)(i) specifies that if the medicine is intended to be, or is, registered goods, and subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\"}, {\"Question\": \"Assuming a non-prescription medicine is intended to be registered goods and subsection 8(2) applies, which specific paragraphs state that compliance is not required for certain labelling provisions?\", \"Answer\": \"Compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\", \"Answer Explanation\": \"Paragraph 4(c)(ii) states that if the medicine is intended to be, or is, registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"}, {\"Question\": \"What specific information is defined as 'critical health information' according to the provided context, and which paragraphs are referenced in this definition?\", \"Answer\": \"Critical health information is defined as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer.\", \"Answer Explanation\": \"The provided context directly states the definition of 'critical health information' and lists the specific paragraphs 8(1)(b), (c), (j), (k), (l) and (n) as part of this definition.\"}, {\"Question\": \"How is the term 'listed goods' defined in the provided context?\", \"Answer\": \"The term 'listed goods' has the same meaning as in the Act.\", \"Answer Explanation\": \"The provided context directly states that 'listed goods' has the same meaning as in the Act, without providing further details on the specific definition within the Act itself.\"}]}"
    },
    {
        "path": [
            601170000,
            402000000,
            601300000,
            907030000,
            901020000
        ],
        "contexts": [
            "\"dial dispenser pack\" means a container that has the following characteristics: (a) (b) (c) each of the dosage units is located in individual pockets preformed in a circular rigid tray; a close-fitting, rotatable, transparent lid which can only be rotated in one direction is located over the tray; and the individual dosage units can be dispensed by detaching a predefined portion of the lid or tray, and rotating the lid to the appropriate position;",
            "(2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order.",
            "\"homoeopathic preparation\" has the same meaning as in the Regulations.",
            " (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains five active ingredients and is required to comply with this Order as of September 1, 2020, is the medicine required to list the names of all active ingredients on the label?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to context (2), as of September 1, 2020, medicines must comply with the requirements in this Order. Context (b) states that the names of all active ingredients must be listed. Context (c) provides an exception to paragraphs 9(1)(b) and 9(1)(c) if the medicine has four or more active ingredients and subsection 8(2) applies, but since no information about subsection 8(2) is provided, we cannot assume this exception applies. Therefore, the medicine with five active ingredients must list all of their names to comply with the Order."
                },
                {
                    "Question": "Does the definition of 'dial dispenser pack' in this Order have the same meaning as the definition of 'homoeopathic preparation' in the Regulations?",
                    "Answer": "No",
                    "Answer Explanation": "The contexts provide distinct definitions for 'dial dispenser pack' and 'homoeopathic preparation'. The definition of 'dial dispenser pack' is given in context (a)(b)(c), specifying the characteristics of the container. Context (3) states that 'homoeopathic preparation' has the same meaning as in the Regulations, which are a separate document from this Order. Since the two terms are defined separately and in different regulatory documents, they do not have the same meaning in this Order."
                },
                {
                    "Question": "Assuming a medicine is required to comply with this Order as of September 1, 2020 and is packaged in a dial dispenser pack, is it required to list the names of all active ingredients on the label if it contains five active ingredients and subsection 8(2) does not apply?",
                    "Answer": "Yes",
                    "Answer Explanation": "Context (2) states that as of September 1, 2020, medicines must comply with the requirements in this Order. The medicine is packaged in a dial dispenser pack, which is defined in context (a)(b)(c), but this does not affect the labeling requirements. Context (b) requires the names of all active ingredients to be listed on the label. Context (c) provides an exception to this requirement in paragraphs 9(1)(b) and 9(1)(c) if the medicine has four or more active ingredients and subsection 8(2) applies. However, the question specifies that subsection 8(2) does not apply in this case. Therefore, the exception does not apply, and the medicine must list the names of all five active ingredients on the label to comply with the Order."
                },
                {
                    "Question": "Assuming a medicine is packaged in a container meeting the definition of 'dial dispenser pack', contains three active ingredients, and is a homoeopathic preparation as defined in the Regulations, is it required to comply with the requirements in this Order as of September 1, 2020?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to context (2), as of September 1, 2020, medicines must comply with the requirements specified in this Order. The medicine is packaged in a dial dispenser pack, which is defined in context (a)(b)(c), and is a homoeopathic preparation, which context (3) states has the same meaning as in the Regulations. However, neither of these facts exempts the medicine from the requirements of this Order. Context (c) provides an exemption from paragraphs 9(1)(b) and 9(1)(c) for medicines with four or more active ingredients if subsection 8(2) applies, but this medicine only has three active ingredients, so this exemption is not relevant. No other exemptions are mentioned in the provided contexts. Therefore, this homoeopathic preparation in a dial dispenser pack must comply with the requirements of this Order as of September 1, 2020."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains five active ingredients and is required to comply with this Order as of September 1, 2020, is the medicine required to list the names of all active ingredients on the label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to context (2), as of September 1, 2020, medicines must comply with the requirements in this Order. Context (b) states that the names of all active ingredients must be listed. Context (c) provides an exception to paragraphs 9(1)(b) and 9(1)(c) if the medicine has four or more active ingredients and subsection 8(2) applies, but since no information about subsection 8(2) is provided, we cannot assume this exception applies. Therefore, the medicine with five active ingredients must list all of their names to comply with the Order.\"}, {\"Question\": \"Does the definition of 'dial dispenser pack' in this Order have the same meaning as the definition of 'homoeopathic preparation' in the Regulations?\", \"Answer\": \"No\", \"Answer Explanation\": \"The contexts provide distinct definitions for 'dial dispenser pack' and 'homoeopathic preparation'. The definition of 'dial dispenser pack' is given in context (a)(b)(c), specifying the characteristics of the container. Context (3) states that 'homoeopathic preparation' has the same meaning as in the Regulations, which are a separate document from this Order. Since the two terms are defined separately and in different regulatory documents, they do not have the same meaning in this Order.\"}, {\"Question\": \"Assuming a medicine is required to comply with this Order as of September 1, 2020 and is packaged in a dial dispenser pack, is it required to list the names of all active ingredients on the label if it contains five active ingredients and subsection 8(2) does not apply?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Context (2) states that as of September 1, 2020, medicines must comply with the requirements in this Order. The medicine is packaged in a dial dispenser pack, which is defined in context (a)(b)(c), but this does not affect the labeling requirements. Context (b) requires the names of all active ingredients to be listed on the label. Context (c) provides an exception to this requirement in paragraphs 9(1)(b) and 9(1)(c) if the medicine has four or more active ingredients and subsection 8(2) applies. However, the question specifies that subsection 8(2) does not apply in this case. Therefore, the exception does not apply, and the medicine must list the names of all five active ingredients on the label to comply with the Order.\"}, {\"Question\": \"Assuming a medicine is packaged in a container meeting the definition of 'dial dispenser pack', contains three active ingredients, and is a homoeopathic preparation as defined in the Regulations, is it required to comply with the requirements in this Order as of September 1, 2020?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to context (2), as of September 1, 2020, medicines must comply with the requirements specified in this Order. The medicine is packaged in a dial dispenser pack, which is defined in context (a)(b)(c), and is a homoeopathic preparation, which context (3) states has the same meaning as in the Regulations. However, neither of these facts exempts the medicine from the requirements of this Order. Context (c) provides an exemption from paragraphs 9(1)(b) and 9(1)(c) for medicines with four or more active ingredients if subsection 8(2) applies, but this medicine only has three active ingredients, so this exemption is not relevant. No other exemptions are mentioned in the provided contexts. Therefore, this homoeopathic preparation in a dial dispenser pack must comply with the requirements of this Order as of September 1, 2020.\"}]}"
    },
    {
        "path": [
            908040000,
            601430105,
            501130000,
            601150000,
            801030000
        ],
        "contexts": [
            " (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
            "(v) the pack size;",
            "(m) made up or compounded extemporaneously, for a specific and individual case, by a complementary healthcare practitioner in the lawful practice of his or her profession; or",
            "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine kit contains multiple formulations, what information must be provided separately for each formulation according to paragraph 9(6)(b) or subsection 9(7)?",
                    "Answer": "The information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation in the medicine kit.",
                    "Answer Explanation": "Context (d) directly states that for composite packs or medicine kits, the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine included."
                },
                {
                    "Question": "According to the provided contexts, is the pack size considered 'critical health information' that is required for safe use of self-selected medicines?",
                    "Answer": "No, the pack size is not considered 'critical health information' based on the provided definition.",
                    "Answer Explanation": "Context (v) mentions 'pack size' as a piece of information, but context defining 'critical health information' does not include pack size. It lists only paragraphs 8(1)(b), (c), (j), (k), (l) and (n) as containing critical health information required for safe use of self-selected medicines."
                },
                {
                    "Question": "Assuming a complementary healthcare practitioner makes up or compounds a medicine extemporaneously for a specific individual case, does the medicine need to include the quantity or proportion of active ingredients?",
                    "Answer": "No, a medicine made up or compounded extemporaneously by a complementary healthcare practitioner for a specific individual case would not need to include the quantity or proportion of active ingredients.",
                    "Answer Explanation": "Context (m) provides an exception for medicines 'made up or compounded extemporaneously, for a specific and individual case, by a complementary healthcare practitioner in the lawful practice of his or her profession'. Context (c) states that normally the quantity or proportion of active ingredients is required. But (m) is an exception, so an extemporaneous formulation for an individual by a practitioner would not need to include this."
                },
                {
                    "Question": "Does 'critical health information' that must be included on self-selected medicines include the pack size or the quantity\/proportion of active ingredients?",
                    "Answer": "Critical health information does not include the pack size, but does require the quantity or proportion of all active ingredients.",
                    "Answer Explanation": "The definition of 'critical health information' lists specific paragraphs that are required for safe use of self-selected medicines. This list includes paragraph 8(1)(c), which context (c) shows is 'the quantity or proportion of all active ingredients in the medicine'. However, the pack size mentioned in context (v) is not part of the 'critical health information' definition."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine kit contains multiple formulations, what information must be provided separately for each formulation according to paragraph 9(6)(b) or subsection 9(7)?\",\n    \"Answer\": \"The information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation in the medicine kit.\",\n    \"Answer Explanation\": \"Context (d) directly states that for composite packs or medicine kits, the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine included.\"\n  },\n  {\n    \"Question\": \"According to the provided contexts, is the pack size considered 'critical health information' that is required for safe use of self-selected medicines?\",\n    \"Answer\": \"No, the pack size is not considered 'critical health information' based on the provided definition.\",\n    \"Answer Explanation\": \"Context (v) mentions 'pack size' as a piece of information, but context defining 'critical health information' does not include pack size. It lists only paragraphs 8(1)(b), (c), (j), (k), (l) and (n) as containing critical health information required for safe use of self-selected medicines.\"\n  },\n  {\n    \"Question\": \"Assuming a complementary healthcare practitioner makes up or compounds a medicine extemporaneously for a specific individual case, does the medicine need to include the quantity or proportion of active ingredients?\",\n    \"Answer\": \"No, a medicine made up or compounded extemporaneously by a complementary healthcare practitioner for a specific individual case would not need to include the quantity or proportion of active ingredients.\",\n    \"Answer Explanation\": \"Context (m) provides an exception for medicines 'made up or compounded extemporaneously, for a specific and individual case, by a complementary healthcare practitioner in the lawful practice of his or her profession'. Context (c) states that normally the quantity or proportion of active ingredients is required. But (m) is an exception, so an extemporaneous formulation for an individual by a practitioner would not need to include this.\"\n  },\n  {\n    \"Question\": \"Does 'critical health information' that must be included on self-selected medicines include the pack size or the quantity\/proportion of active ingredients?\",\n    \"Answer\": \"Critical health information does not include the pack size, but does require the quantity or proportion of all active ingredients.\",\n    \"Answer Explanation\": \"The definition of 'critical health information' lists specific paragraphs that are required for safe use of self-selected medicines. This list includes paragraph 8(1)(c), which context (c) shows is 'the quantity or proportion of all active ingredients in the medicine'. However, the pack size mentioned in context (v) is not part of the 'critical health information' definition.\"\n  }\n]}"
    },
    {
        "path": [
            1004010000,
            501050000,
            702050000,
            1103030000,
            1103010000
        ],
        "contexts": [
            " (a) the main label on the container and the main label on the primary pack (if any) must include a statement to the effect that the medicine contains homoeopathic preparations in text size that is not less than 50% of the text size of the name of the medicine and (in any event) not less than 2 millimetres;",
            "(e) the subject of an approval under section 19A of the Act; or",
            " (e) be in a colour or colours contrasting strongly with the background, except for:(i) the expiry date and expiry date prefix; and (ii) the batch number and batch number prefix when that information is embossed or debossed and not printed; and",
            " (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
            " (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains homoeopathic preparations and has a name printed in 4 millimeter text on the main labels, what is the minimum text size in millimeters required for the statement indicating the medicine contains homoeopathic preparations?",
                    "Answer": "2 millimeters",
                    "Answer Explanation": "According to context (a), the statement that the medicine contains homoeopathic preparations must be in text size that is not less than 50% of the text size of the name of the medicine and not less than 2 millimeters in any event. Since the medicine name is in 4 millimeter text, 50% of that would be 2 millimeters. However, 2 millimeters is also the absolute minimum size required regardless of the medicine name text size. Therefore, the minimum text size for the homoeopathic preparations statement is 2 millimeters."
                },
                {
                    "Question": "For a fully potentised, single ingredient, homoeopathic medicine where it is clear the single ingredient comprises 100% of the medicine, what information is required on the labels regarding the quantity of each active ingredient per dosage unit?",
                    "Answer": "The quantity of each active ingredient per dosage unit is not required",
                    "Answer Explanation": "According to context (a), for a fully potentised, single ingredient, homoeopathic medicine where it is clear the ingredient comprises 100% of the medicine, the name of the active ingredient is required on the labels. Contexts (b) and (c) cover cases where (a) does not apply. Since none of the provided contexts require specifying the quantity of each active ingredient per dosage unit in this case, that information is not required on the labels."
                },
                {
                    "Question": "Assuming a medicine is not covered under section 19A of the Act or in Schedules 4 or 8 of the Poisons Standard and is not for injection, what colour(s) must the batch number and expiry date be printed on the labels?",
                    "Answer": "The batch number and expiry date must be printed in a colour or colours contrasting strongly with the background, except the expiry date and batch number prefixes, and the batch number itself if embossed or debossed instead of printed.",
                    "Answer Explanation": "Context (e) indicates medicines covered under section 19A of the Act are excluded from this requirement. With no other contexts mentioning Schedules 4 or 8 of the Poisons Standard or injectable medicines, we can assume those are also not applicable here. Therefore, context (e) applies, requiring the expiry date and batch number to be printed in contrasting colours, with the listed exceptions."
                },
                {
                    "Question": "For a medicine containing multiple homoeopathic preparations, assuming the names of all the active ingredients are stated on the label, what additional information is required on the labels regarding the quantity of each active ingredient?",
                    "Answer": "The quantity of each active ingredient per dosage unit, or per mL or gram of the medicine",
                    "Answer Explanation": "Context (a) only applies to fully potentised, single ingredient medicines, so it does not apply here. Context (b) requires the quantity of each active ingredient per dosage unit, if the medicine is for oral, rectal or vaginal use. If (b) does not apply, context (c) requires the quantity of each active ingredient per mL or gram of the medicine. Since no other contexts negate (b) and (c), one of those two quantity formats must be stated on the labels for a medicine with multiple homoeopathic preparations."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains homoeopathic preparations and has a name printed in 4 millimeter text on the main labels, what is the minimum text size in millimeters required for the statement indicating the medicine contains homoeopathic preparations?\", \"Answer\": \"2 millimeters\", \"Answer Explanation\": \"According to context (a), the statement that the medicine contains homoeopathic preparations must be in text size that is not less than 50% of the text size of the name of the medicine and not less than 2 millimeters in any event. Since the medicine name is in 4 millimeter text, 50% of that would be 2 millimeters. However, 2 millimeters is also the absolute minimum size required regardless of the medicine name text size. Therefore, the minimum text size for the homoeopathic preparations statement is 2 millimeters.\"}, {\"Question\": \"For a fully potentised, single ingredient, homoeopathic medicine where it is clear the single ingredient comprises 100% of the medicine, what information is required on the labels regarding the quantity of each active ingredient per dosage unit?\", \"Answer\": \"The quantity of each active ingredient per dosage unit is not required\", \"Answer Explanation\": \"According to context (a), for a fully potentised, single ingredient, homoeopathic medicine where it is clear the ingredient comprises 100% of the medicine, the name of the active ingredient is required on the labels. Contexts (b) and (c) cover cases where (a) does not apply. Since none of the provided contexts require specifying the quantity of each active ingredient per dosage unit in this case, that information is not required on the labels.\"}, {\"Question\": \"Assuming a medicine is not covered under section 19A of the Act or in Schedules 4 or 8 of the Poisons Standard and is not for injection, what colour(s) must the batch number and expiry date be printed on the labels?\", \"Answer\": \"The batch number and expiry date must be printed in a colour or colours contrasting strongly with the background, except the expiry date and batch number prefixes, and the batch number itself if embossed or debossed instead of printed.\", \"Answer Explanation\": \"Context (e) indicates medicines covered under section 19A of the Act are excluded from this requirement. With no other contexts mentioning Schedules 4 or 8 of the Poisons Standard or injectable medicines, we can assume those are also not applicable here. Therefore, context (e) applies, requiring the expiry date and batch number to be printed in contrasting colours, with the listed exceptions.\"}, {\"Question\": \"For a medicine containing multiple homoeopathic preparations, assuming the names of all the active ingredients are stated on the label, what additional information is required on the labels regarding the quantity of each active ingredient?\", \"Answer\": \"The quantity of each active ingredient per dosage unit, or per mL or gram of the medicine\", \"Answer Explanation\": \"Context (a) only applies to fully potentised, single ingredient medicines, so it does not apply here. Context (b) requires the quantity of each active ingredient per dosage unit, if the medicine is for oral, rectal or vaginal use. If (b) does not apply, context (c) requires the quantity of each active ingredient per mL or gram of the medicine. Since no other contexts negate (b) and (c), one of those two quantity formats must be stated on the labels for a medicine with multiple homoeopathic preparations.\"}]}"
    },
    {
        "path": [
            1007120000,
            100000002,
            912000000,
            802030000,
            802020000
        ],
        "contexts": [
            " (l) if the medicine is contained in an ampoule - a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine; and",
            "Uncommenced amendments The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.",
            " (12) To avoid doubt, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2026.",
            " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
            " (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is contained in an ampoule and is intended for inhalation use only, what statement must be included on the label per the given regulations?",
                    "Answer": "A statement of the approved route of administration, such as 'inhalation', must be included on the label.",
                    "Answer Explanation": "Section (l) states that if a medicine is in an ampoule, the label must include 'a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only' or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine'."
                },
                {
                    "Question": "Per the regulations, in what order must the critical health information be presented on the main label under appropriate headings?",
                    "Answer": "The critical health information must be presented in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.",
                    "Answer Explanation": "Section (b) specifies 'The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.'"
                },
                {
                    "Question": "Assuming a medicine contains an active ingredient specified in Part 1 of Schedule 2 and is released for supply on or after 1 May 2026, what naming convention must be followed on the main label per the regulations?",
                    "Answer": "The active ingredient must be included on the main label in accordance with the Australian Approved Names List.",
                    "Answer Explanation": "Section (12) states 'To avoid doubt, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2026.'"
                },
                {
                    "Question": "Per the regulations, can the information provided about active ingredients include words describing the pharmacological category or principal intended actions that are not required by this Order?",
                    "Answer": "Yes, the information about active ingredients may include words describing the pharmacological category or principal intended actions that are not required by the Order.",
                    "Answer Explanation": "Section (c) allows that 'The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.'"
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is contained in an ampoule and is intended for inhalation use only, what statement must be included on the label per the given regulations?\", \"Answer\": \"A statement of the approved route of administration, such as 'inhalation', must be included on the label.\", \"Answer Explanation\": \"Section (l) states that if a medicine is in an ampoule, the label must include 'a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only' or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine'.\"}, {\"Question\": \"Per the regulations, in what order must the critical health information be presented on the main label under appropriate headings?\", \"Answer\": \"The critical health information must be presented in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.\", \"Answer Explanation\": \"Section (b) specifies 'The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.'\"}, {\"Question\": \"Assuming a medicine contains an active ingredient specified in Part 1 of Schedule 2 and is released for supply on or after 1 May 2026, what naming convention must be followed on the main label per the regulations?\", \"Answer\": \"The active ingredient must be included on the main label in accordance with the Australian Approved Names List.\", \"Answer Explanation\": \"Section (12) states 'To avoid doubt, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2026.'\"}, {\"Question\": \"Per the regulations, can the information provided about active ingredients include words describing the pharmacological category or principal intended actions that are not required by this Order?\", \"Answer\": \"Yes, the information about active ingredients may include words describing the pharmacological category or principal intended actions that are not required by the Order.\", \"Answer Explanation\": \"Section (c) allows that 'The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.'\"}]}"
    },
    {
        "path": [
            601500000,
            601130000,
            1105020000,
            802050000,
            802040000
        ],
        "contexts": [
            "\"Regulations\" means the Therapeutic Goods Regulations 1990;",
            "\"composite pack\" has the same meaning as in the Act;",
            " (b) on a separate line of text - immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient.",
            " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements)."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine label lists an active ingredient that is a vitamin, and also lists the quantity of that vitamin, where must the quantity be placed in relation to the name of the vitamin?",
                    "Answer": "The quantity must be placed on a separate line of text immediately below the name of the vitamin.",
                    "Answer Explanation": "According to the regulation section (b), the quantity of an active ingredient that is a vitamin must be placed 'on a separate line of text - immediately below the related name of the active ingredient that is a vitamin'."
                },
                {
                    "Question": "Assuming a medicine label includes information beyond the critical health information and certain other allowed information, under what heading must this additional information be placed?",
                    "Answer": "The additional information must be placed under the 'Other information' heading or under another separate appropriate heading that follows immediately below certain specified headings.",
                    "Answer Explanation": "Regulation section (e) states that if information other than critical health information or certain other allowed information is included, 'it must be placed under the 'Other information' heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b)'."
                },
                {
                    "Question": "Assuming a medicine label provides safety related information beyond what is required by the regulations, where can this additional safety information be included?",
                    "Answer": "The additional safety related information may be included under the information provided in accordance with paragraph 8(2)(b)(iii) of the regulations.",
                    "Answer Explanation": "According to regulation section (d), 'The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements)'."
                },
                {
                    "Question": "Assuming a medicine is packaged in a composite pack, what specific regulatory definition applies to the term 'composite pack' in this context?",
                    "Answer": "In the context of these regulations, the term 'composite pack' has the same meaning as defined in the Therapeutic Goods Act.",
                    "Answer Explanation": "The regulation section defining 'composite pack' states that it 'has the same meaning as in the Act', referring to the Therapeutic Goods Act which contains the applicable definition."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine label lists an active ingredient that is a vitamin, and also lists the quantity of that vitamin, where must the quantity be placed in relation to the name of the vitamin?\", \"Answer\": \"The quantity must be placed on a separate line of text immediately below the name of the vitamin.\", \"Answer Explanation\": \"According to the regulation section (b), the quantity of an active ingredient that is a vitamin must be placed 'on a separate line of text - immediately below the related name of the active ingredient that is a vitamin'.\"}, {\"Question\": \"Assuming a medicine label includes information beyond the critical health information and certain other allowed information, under what heading must this additional information be placed?\", \"Answer\": \"The additional information must be placed under the 'Other information' heading or under another separate appropriate heading that follows immediately below certain specified headings.\", \"Answer Explanation\": \"Regulation section (e) states that if information other than critical health information or certain other allowed information is included, 'it must be placed under the 'Other information' heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b)'.\"}, {\"Question\": \"Assuming a medicine label provides safety related information beyond what is required by the regulations, where can this additional safety information be included?\", \"Answer\": \"The additional safety related information may be included under the information provided in accordance with paragraph 8(2)(b)(iii) of the regulations.\", \"Answer Explanation\": \"According to regulation section (d), 'The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements)'.\"}, {\"Question\": \"Assuming a medicine is packaged in a composite pack, what specific regulatory definition applies to the term 'composite pack' in this context?\", \"Answer\": \"In the context of these regulations, the term 'composite pack' has the same meaning as defined in the Therapeutic Goods Act.\", \"Answer Explanation\": \"The regulation section defining 'composite pack' states that it 'has the same meaning as in the Act', referring to the Therapeutic Goods Act which contains the applicable definition.\"}]}"
    },
    {
        "path": [
            601270000,
            601100000,
            1102020000,
            1102080000,
            1102020000
        ],
        "contexts": [
            "\"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;",
            "\"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;",
            " (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;",
            " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a herbal preparation is an active ingredient in an oral preparation intended for mineral supplementation and is listed as 500mg of Magnesium per stated dose on the label, does this meet the labelling requirements specified in the given regulation sections?",
                    "Answer": "Yes",
                    "Answer Explanation": "Per context (h), for oral preparations containing active ingredients intended for mineral supplementation, the label can express the quantity of the active ingredient as the name of the active ingredient (which per context 'herbal preparation' is a type of active ingredient that results from processing herbal material) and the name and quantity of the mineral element. So listing '500mg of Magnesium' for a stated dose meets the labelling requirement for expressing the quantity of a herbal preparation active ingredient in this type of product."
                },
                {
                    "Question": "For a non-prescription medicine that is a solid for ingestion with no discrete dosage units, the label lists the active ingredient quantity as 50mg per 5g dose. Assuming this medicine was listed and a Certificate of Listing was issued, does the label comply with the active ingredient quantity labelling requirements?",
                    "Answer": "Yes",
                    "Answer Explanation": "Context (b) states that for a solid for ingestion with no discrete dosage unit, expressing the active ingredient quantity as the amount contained in the stated weight of a suitable dose is sufficient. The label listing '50mg per 5g dose' matches this. Context 'Certificate of Listing' indicates that a Certificate of Listing is issued when a medicine is listed, so this medicine having a Certificate means the labelling must have been compliant for it to be listed and the Certificate issued."
                },
                {
                    "Question": "If a herbal preparation is used as an active ingredient in a mineral supplement that is a solid for ingestion with no discrete dosage units, and the Certificate of Listing for this product shows the label expresses the quantity as '10mg Zinc per 1g', does this label align with the relevant labelling requirements?",
                    "Answer": "Yes",
                    "Answer Explanation": "A herbal preparation is a type of active ingredient per the 'herbal preparation' context. Context (b) allows expressing active quantity as the amount per stated weight of a suitable dose for solids for ingestion with no discrete units. Context (h) further allows expressing the active quantity for mineral supplements as just the mineral name and amount. The '10mg Zinc per 1g' matches both of these. The 'Certificate of Listing' context indicates that having this Certificate means the product is listed, which requires meeting applicable labelling requirements."
                },
                {
                    "Question": "Assuming an oral herbal preparation contains 250mcg of Chromium per 2g of the preparation with no discrete dose units, and this is an active ingredient for mineral supplementation, would stating the quantity on the label as '250mcg of Chromium per 2g' satisfy the requirements for a non-prescription medicine to obtain a Certificate of Listing?",
                    "Answer": "Yes",
                    "Answer Explanation": "Context (b) permits expressing the quantity of active ingredient as the amount contained in a stated weight of a suitable dose for solids for ingestion that have no discrete dosage units. '250mcg of Chromium per 2g' follows this format. Additionally, context (h) allows further expressing the quantity of mineral supplement actives as just the mineral name and amount, which '250mcg of Chromium' adheres to. Context 'herbal preparation' establishes that a herbal preparation is a type of active ingredient. Finally, context 'Certificate of Listing' conveys that obtaining this certificate requires the medicine labelling to meet applicable requirements, so satisfying the quantity labelling requirements means a Certificate of Listing could be issued."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a herbal preparation is an active ingredient in an oral preparation intended for mineral supplementation and is listed as 500mg of Magnesium per stated dose on the label, does this meet the labelling requirements specified in the given regulation sections?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Per context (h), for oral preparations containing active ingredients intended for mineral supplementation, the label can express the quantity of the active ingredient as the name of the active ingredient (which per context 'herbal preparation' is a type of active ingredient that results from processing herbal material) and the name and quantity of the mineral element. So listing '500mg of Magnesium' for a stated dose meets the labelling requirement for expressing the quantity of a herbal preparation active ingredient in this type of product.\"\n  },\n  {\n    \"Question\": \"For a non-prescription medicine that is a solid for ingestion with no discrete dosage units, the label lists the active ingredient quantity as 50mg per 5g dose. Assuming this medicine was listed and a Certificate of Listing was issued, does the label comply with the active ingredient quantity labelling requirements?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Context (b) states that for a solid for ingestion with no discrete dosage unit, expressing the active ingredient quantity as the amount contained in the stated weight of a suitable dose is sufficient. The label listing '50mg per 5g dose' matches this. Context 'Certificate of Listing' indicates that a Certificate of Listing is issued when a medicine is listed, so this medicine having a Certificate means the labelling must have been compliant for it to be listed and the Certificate issued.\"\n  },\n  {\n    \"Question\": \"If a herbal preparation is used as an active ingredient in a mineral supplement that is a solid for ingestion with no discrete dosage units, and the Certificate of Listing for this product shows the label expresses the quantity as '10mg Zinc per 1g', does this label align with the relevant labelling requirements?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"A herbal preparation is a type of active ingredient per the 'herbal preparation' context. Context (b) allows expressing active quantity as the amount per stated weight of a suitable dose for solids for ingestion with no discrete units. Context (h) further allows expressing the active quantity for mineral supplements as just the mineral name and amount. The '10mg Zinc per 1g' matches both of these. The 'Certificate of Listing' context indicates that having this Certificate means the product is listed, which requires meeting applicable labelling requirements.\"\n  },\n  {\n    \"Question\": \"Assuming an oral herbal preparation contains 250mcg of Chromium per 2g of the preparation with no discrete dose units, and this is an active ingredient for mineral supplementation, would stating the quantity on the label as '250mcg of Chromium per 2g' satisfy the requirements for a non-prescription medicine to obtain a Certificate of Listing?\",  \n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Context (b) permits expressing the quantity of active ingredient as the amount contained in a stated weight of a suitable dose for solids for ingestion that have no discrete dosage units. '250mcg of Chromium per 2g' follows this format. Additionally, context (h) allows further expressing the quantity of mineral supplement actives as just the mineral name and amount, which '250mcg of Chromium' adheres to. Context 'herbal preparation' establishes that a herbal preparation is a type of active ingredient. Finally, context 'Certificate of Listing' conveys that obtaining this certificate requires the medicine labelling to meet applicable requirements, so satisfying the quantity labelling requirements means a Certificate of Listing could be issued.\"\n  }\n]}"
    },
    {
        "path": [
            801130000,
            0,
            601430100,
            301000000,
            400000000
        ],
        "contexts": [
            " (m) if the medicine requires some preparation, such as dissolving, suspending, diluting or reconstituting before use - instructions for its preparation and, where relevant, a statement of the conditions of storage and the maximum period of storage between preparation and use, except where: (i) there is insufficient space on the label of either the container or the primary pack, or both, to include this information; and (ii) this information is set out in a package insert provided in the primary pack of the medicine; and (iii) a statement is included on whichever label on the container or the primary pack, or both, that does not set out the information itself, that this information is set out in the package insert; and",
            " Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines",
            "(a) where the medicine is intended to be, or is, entered in the Register - the name of the medicine intended to appear or appearing on the Certificate of Registration or Certificate of Listing in relation to the medicine, not including the following information:",
            "(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
            "4 Transition arrangements "
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is intended to be entered in the Register and requires preparation before use, what information must be included on the label regarding the preparation and storage of the medicine?",
                    "Answer": "The label must include instructions for preparation and, where relevant, the conditions of storage and maximum storage period between preparation and use.",
                    "Answer Explanation": "Section (m) requires that if a medicine requires preparation before use, the label must include instructions for preparation and any relevant storage conditions and maximum storage time after preparation. Section (a) establishes that this applies to non-prescription medicines intended to be entered in the Register, as specified in section (1)."
                },
                {
                    "Question": "In a situation where there is insufficient space on the label of a non-prescription medicine to include preparation instructions, storage conditions, and maximum storage time after preparation, under what conditions can this information be provided in a package insert instead?",
                    "Answer": "The preparation, storage condition, and maximum storage time information can be provided in a package insert if there is insufficient label space, the insert is in the primary pack, and the label references that the information is in the insert.",
                    "Answer Explanation": "Section (m) allows the preparation, storage condition, and maximum storage period information to be provided in a package insert instead of on the label if three conditions are met: (i) insufficient label space, (ii) the information is in an insert in the primary pack, and (iii) the label states that the information is in the insert. This applies to non-prescription medicines per sections (1) and (a)."
                },
                {
                    "Question": "Assuming a non-prescription medicine is intended to be entered in the Register, does the name of the medicine on the label need to exactly match the name that will appear on the Certificate of Registration or Listing?",
                    "Answer": "No, the label does not need to include all the information that appears with the medicine name on the Certificate of Registration or Listing.",
                    "Answer Explanation": "Section (a) states that for a medicine intended to be entered in the Register, the label must have the name of the medicine intended to appear on the Certificate of Registration or Listing, but not including all the information that appears with the name on the Certificate. Sections (1) and (m) establish the overall context that this applies to labels of non-prescription medicines."
                },
                {
                    "Question": "Do the labelling requirements in this Standard apply to both non-prescription medicines that are already entered in the Register and those intended to be entered?",
                    "Answer": "Yes, the labelling requirements in this Standard apply to both non-prescription medicines already entered and those intended to be entered in the Register.",
                    "Answer Explanation": "Section (1) states that this Standard applies to non-prescription medicines supplied or for supply in Australia. Section (a) further clarifies that for medicines intended to be entered in the Register, the label must have the name intended to appear on the Certificate of Registration or Listing. Together these sections indicate the Standard applies to both registered and unregistered non-prescription medicines that are supplied or will be supplied in Australia."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine is intended to be entered in the Register and requires preparation before use, what information must be included on the label regarding the preparation and storage of the medicine?\",\n    \"Answer\": \"The label must include instructions for preparation and, where relevant, the conditions of storage and maximum storage period between preparation and use.\",\n    \"Answer Explanation\": \"Section (m) requires that if a medicine requires preparation before use, the label must include instructions for preparation and any relevant storage conditions and maximum storage time after preparation. Section (a) establishes that this applies to non-prescription medicines intended to be entered in the Register, as specified in section (1).\"\n  },\n  {\n    \"Question\": \"In a situation where there is insufficient space on the label of a non-prescription medicine to include preparation instructions, storage conditions, and maximum storage time after preparation, under what conditions can this information be provided in a package insert instead?\",\n    \"Answer\": \"The preparation, storage condition, and maximum storage time information can be provided in a package insert if there is insufficient label space, the insert is in the primary pack, and the label references that the information is in the insert.\",\n    \"Answer Explanation\": \"Section (m) allows the preparation, storage condition, and maximum storage period information to be provided in a package insert instead of on the label if three conditions are met: (i) insufficient label space, (ii) the information is in an insert in the primary pack, and (iii) the label states that the information is in the insert. This applies to non-prescription medicines per sections (1) and (a).\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine is intended to be entered in the Register, does the name of the medicine on the label need to exactly match the name that will appear on the Certificate of Registration or Listing?\",\n    \"Answer\": \"No, the label does not need to include all the information that appears with the medicine name on the Certificate of Registration or Listing.\",\n    \"Answer Explanation\": \"Section (a) states that for a medicine intended to be entered in the Register, the label must have the name of the medicine intended to appear on the Certificate of Registration or Listing, but not including all the information that appears with the name on the Certificate. Sections (1) and (m) establish the overall context that this applies to labels of non-prescription medicines.\"\n  },\n  {\n    \"Question\": \"Do the labelling requirements in this Standard apply to both non-prescription medicines that are already entered in the Register and those intended to be entered?\",\n    \"Answer\": \"Yes, the labelling requirements in this Standard apply to both non-prescription medicines already entered and those intended to be entered in the Register.\",\n    \"Answer Explanation\": \"Section (1) states that this Standard applies to non-prescription medicines supplied or for supply in Australia. Section (a) further clarifies that for medicines intended to be entered in the Register, the label must have the name intended to appear on the Certificate of Registration or Listing. Together these sections indicate the Standard applies to both registered and unregistered non-prescription medicines that are supplied or will be supplied in Australia.\"\n  }\n]}"
    },
    {
        "path": [
            100000004,
            1101030000,
            1008030000,
            1008020000,
            900000000
        ],
        "contexts": [
            "Modifications If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.",
            " (c) Where the active ingredient is in liquid form, the equivalent metric units of volume must be expressed in the same manner. Example: A statement of volume for more than 1 millilitre up to 999 millilitres inclusive must be expressed in terms of millilitres, but a statement of volume for 1000 millilitres may be expressed as either 1000 millilitres or 1 litre. Note: The abbreviations mL and L can be used on all labels, but \\'microlitre\\' should be used in full unless the container is a small container. Then the abbreviation \\'\uf06d L\\' may be used.",
            " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.",
            " 9 Information to be included on the main label"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine contains an active ingredient in liquid form with a volume between 1 and 999 millilitres, what unit of measurement must be used to express the volume on the label?",
                    "Answer": "Millilitres",
                    "Answer Explanation": "According to section (c), for an active ingredient in liquid form, if the volume is more than 1 millilitre and up to 999 millilitres, it must be expressed in terms of millilitres on the label."
                },
                {
                    "Question": "Supposing a non-prescription medicine consists solely of dry herbs individually packaged in bags, and these bags are retained around the herbs during preparation, what labelling requirements apply to the individual bags if the primary pack containing them complies with sections 8 and 9?",
                    "Answer": "The individual bags do not need to be labelled with the information referred to in sections 8 and 9.",
                    "Answer Explanation": "Section (c) states that if a medicine consists of dry herbs in individual bags that are retained around the herbs during preparation, and these bags are in a primary pack that complies with the labelling requirements of sections 8 and 9, then the individual bags themselves do not need to include the information from sections 8 and 9."
                },
                {
                    "Question": "If a non-prescription medicine consists only of pastilles or lozenges, with each dosage unit wrapped individually in an unsealed wrapper and then enclosed in a primary pack compliant with sections 8 and 9, what is the minimum labelling requirement for the individual wrappers?",
                    "Answer": "The name of the medicine must be displayed on the label of each individual wrapper.",
                    "Answer Explanation": "According to section (b), if a medicine consists only of pastilles or lozenges, with each dosage unit in an unsealed individual wrapper, and these wrapped units are then enclosed in a primary pack compliant with sections 8 and 9, it is sufficient for the label on each individual wrapper to display just the name of the medicine in order to comply with sections 8 and 9."
                },
                {
                    "Question": "Assuming a compiled non-prescription medicines law is modified by another law, does the text of the compiled law itself get amended to reflect this modification?",
                    "Answer": "No",
                    "Answer Explanation": "The first section states that if a compiled law is modified by another law, the compiled law operates as modified, but the text of the compiled law itself is not amended to show this modification."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine contains an active ingredient in liquid form with a volume between 1 and 999 millilitres, what unit of measurement must be used to express the volume on the label?\",\n      \"Answer\": \"Millilitres\",\n      \"Answer Explanation\": \"According to section (c), for an active ingredient in liquid form, if the volume is more than 1 millilitre and up to 999 millilitres, it must be expressed in terms of millilitres on the label.\"\n    },\n    {\n      \"Question\": \"Supposing a non-prescription medicine consists solely of dry herbs individually packaged in bags, and these bags are retained around the herbs during preparation, what labelling requirements apply to the individual bags if the primary pack containing them complies with sections 8 and 9?\",\n      \"Answer\": \"The individual bags do not need to be labelled with the information referred to in sections 8 and 9.\",\n      \"Answer Explanation\": \"Section (c) states that if a medicine consists of dry herbs in individual bags that are retained around the herbs during preparation, and these bags are in a primary pack that complies with the labelling requirements of sections 8 and 9, then the individual bags themselves do not need to include the information from sections 8 and 9.\"\n    },\n    {\n      \"Question\": \"If a non-prescription medicine consists only of pastilles or lozenges, with each dosage unit wrapped individually in an unsealed wrapper and then enclosed in a primary pack compliant with sections 8 and 9, what is the minimum labelling requirement for the individual wrappers?\",\n      \"Answer\": \"The name of the medicine must be displayed on the label of each individual wrapper.\",\n      \"Answer Explanation\": \"According to section (b), if a medicine consists only of pastilles or lozenges, with each dosage unit in an unsealed individual wrapper, and these wrapped units are then enclosed in a primary pack compliant with sections 8 and 9, it is sufficient for the label on each individual wrapper to display just the name of the medicine in order to comply with sections 8 and 9.\"\n    },\n    {\n      \"Question\": \"Assuming a compiled non-prescription medicines law is modified by another law, does the text of the compiled law itself get amended to reflect this modification?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"The first section states that if a compiled law is modified by another law, the compiled law operates as modified, but the text of the compiled law itself is not amended to show this modification.\"\n    }\n  ]\n}"
    }
]